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The accumulation of the small peptide amyloid-β has been proposed as a major trigger for 
the development of Alzheimer’s disease. Within the brain, the concentration of amyloid-β is 
tightly controlled through production and clearance mechanisms. Studies have revealed 
that reduced levels of amyloid-β clearance are present in individuals living with Alzheimer’s 
disease which results in the observed accumulation of the peptide. This accumulation of 
amyloid-β can lead to the formation of large aggregated amyloid plaques - one of two 
detectable hallmarks of the disease. 
Amyloid degrading enzymes (ADEs) are a group of proteins with the ability to degrade 
amyloid-β and are major players in the clearance of amyloid-β. Stimulating ADE activity or 
expression, in order to compensate for the decreased clearance in the Alzheimer’s disease 
phenotype, provides a promising therapeutic target. It has been reported in mice that 
upregulation of ADEs can reduce the levels of amyloid-β peptide and amyloid plaques – in 
some cases this led to improved cognitive function. 
Among several known ADEs, neprilysin (NEP) and endothelin-converting enzyme I (ECE-1) 
have been identified to be two of the most potent. Both proteins have the capacity to digest 
soluble amyloid-β which, in turn, can form the toxic oligomeric species found within the 
brains of individuals living with Alzheimer’s disease. Whilst NEP and ECE-1 are known for 
their amyloid-degradation, they exhibit complexity through the additional substrates that 
they can degrade. Two such groups of substrates are the endothelins and natriuretic 
peptides. Both peptide groups are vasoactive and illustrate the strong link between NEP, 
ECE-1 and blood pressure regulation. The promiscuous nature of NEP and ECE-1 raises 
questions surrounding their specificity and how such a broad range of substrates can be 
degraded. 
This research builds upon current structural and functional understanding of both NEP and 
ECE-1, giving a detailed insight into the molecular interactions that leads to the hydrolysis 
of peptide substrates. This research has used a cross-disciplinary approach of X-ray structure 
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determination, mutagenesis and kinetic analysis in order to elucidate the crucial tasks 
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1.1 Dementia, Alzheimer’s disease and amyloid-β 
1.1.1 Dementia 
Dementia is a syndrome which encompasses a broad range of brain diseases. Whilst the 
first pathologies of dementia were reported in 1906, much of the past century has seen 
symptoms of dementia confused with the normal process of aging. However, an increasingly 
aging population combined with effective outreach work conducted by several UK and 
international charities have helped to bring dementia into the spotlight. Dementia has 
emerged as a prominent threat to the worlds aging populations and, while recent focus has 
drawn both funding and attention to the syndrome, much remains to be understood about 
the basics of this disease. 
According to the world health organisation “Dementia is a syndrome in which there is 
deterioration in memory, thinking, behaviour and the ability to perform everyday activities”. 
Improved awareness and diagnosis have begun reveal the impact of dementia within the 
UK, where dementia is now recognised as the leading cause of death (ONS, 2015). Current 
estimates predict over 1 million people will be living with dementia in the UK by 2025 (Prince 
et al., 2015). In addition to the social impact dementia has on individuals and families, the 
syndrome presents a substantial financial burden. In 2014 the cost of dementia in the UK 
was estimated at £26 billion with a large part of this money spent on the many years of 
social care required for individuals living with advanced forms of dementia. 
Clarity on the global impact of dementia is also becoming evident with estimates that 46.8 
million people worldwide were living with dementia in 2015. These figures are expected to 
rise greatly particularly in low to middle income countries as life expectancy increases. These 
lower income countries will be less well equipped to deal with the large amount of care 
required for individuals with dementia (Prince et al., 2015). The far-reaching implications of 
dementia means there can be no doubt that it represents one of the largest hurdles for 
science in the 21st century.  
1.1.2 Alzheimer’s disease 
By far the most prevalent form of dementia is Alzheimer’s disease, which accounts for some 
60-70% of global cases. Alzheimer’s disease can be separated into familial or sporadic forms. 




genetic predispositions to the disease (Campion et al., 1999). Typically, familial Alzheimer’s 
disease is early onset with the first symptoms appearing in individuals in their 30’s and 40’s. 
The sporadic form of Alzheimer’s disease accounts for all remaining cases of the disease 
and the first symptoms of the disease do not usually appear until over 65 years of age (Bird, 
1999).  
The symptoms of Alzheimer’s disease was first described by Alois Alzheimer in 1906 
following his investigation into the disease progression of a patient displaying memory loss, 
disturbed sleep, aggressiveness and confusion (Stelzma et al., 1995). Alzheimer recorded 
the presence of a distinct brain pathology to the disease, namely the presence of 
neurofibrillary tangles and senile plaques. These tangles and plaques remain identifiable 
hallmarks to the disease over 100 years later (Maurer et al., 1997).   
More recent research into the Alzheimer’s disease pathology has revealed the composition 
of both hallmarks. Senile plaques are composed of extracellular deposits of the small 
peptide fragment amyloid-β (Glenner and Wong, 1984), while neurofibrillary tangles are 
composed of hyperphosphorylated tau protein (Wood et al., 1986). These two hallmarks 
have shaped the field of Alzheimer’s disease research and represent core components in 
proposed hypotheses describing disease progression (Kumar et al., 2015).  
The most recognised Alzheimer’s disease hypothesis, the amyloid cascade hypothesis, was 
published in 1992 (Hardy et al., 1992). It proposed that the principle component in 
development of Alzheimer’s disease was amyloid-β peptide. An imbalance in production or 
degradation of amyloid-β led to its extracellular aggregation. This accumulation then leads 
to neuronal cell death directly or indirectly through downstream effects including 
neurofibrillary tangles. While the hypothesis has changed over the past two decades the 
core principle remains the same and the evidence linking amyloid-β to Alzheimer’s disease 
remains strong (Selkoe and Hardy, 2016).  
1.1.3 Evidence for the role of amyloid-β in Alzheimer’s disease 
Much of the research into Alzheimer’s disease has been conducted through investigations 
into individuals with familial Alzheimer’s disease (FAD). The inherited genetic mutations that 
cause FAD provide a means of investigating the cause of the disease. Missense mutations 




encoding the protein γ-secretase which is responsible for amyloid-β processing. Mutations 
in the PSEN genes can lead to elevated levels of higher molecular weight amyloid-β species 
which in turn have a higher propensity for aggregation (Hardy, 1997) -  amyloid-β lengths 
will be discussed in greater detail below. Other FAD causing mutations have also been 
identified in or directly flanking the amyloid precursor protein (APP) gene which encodes 
amyloid-β (Goate et al., 1991; Citron et al., 1992). Conversely, missense mutations in the APP 
gene can result in reduced amyloid-β expression and provide a protective function against 
Alzheimer’s disease (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006).  
Additional evidence for the role of amyloid-β in Alzheimer’s disease has been provided 
through research into individuals with trisomy of chromosome 21 (Down’s syndrome). These 
individuals possess a third copy of the APP gene and display symptoms similar to those 
observed in FAD at very early ages (Oyama et al., 1994; Head et al., 2012). Indeed, in rare 
cases where individuals without Down’s syndrome possess a duplication of just the APP 
gene, similar FAD symptoms are observed (Prasher et al., 1998). 
A large focus has been placed on studying the genetic factors of Alzheimer’s disease 
development in individuals with FAD or Down’s syndrome to understand the underlying 
mechanism of Alzheimer’s disease. While this is a good basis for research, the vast majority 
of Alzheimer’s disease cases are sporadic in nature, occurring in individuals above the age 
of 65. Analysis of individuals with sporadic Alzheimer’s disease has revealed one of the 
highest predictors of disease development is the possession of the APOE4 gene. Indeed, 
over 40% of individuals with Alzheimer’s disease possess this gene. The protein transcribed 
from APOE4, ApoE4, disrupts amyloid-β clearance across the blood-brain barrier to a greater 
extent than alternative isoforms ApoE3 and ApoE2 (Deane et al., 2008).   
Whilst the evidence for the role of amyloid-β in Alzheimer’s disease is strong, there is several 
pieces of conflicting evidence. Perhaps the most significant of these is the lack of 
Alzheimer’s disease associated cognitive decline in many elderly people that possess large 
quantities of amyloid-β plaques (Davis et al., 1999; Fagan et al., 2009). A commonly used 
counter argument to this evidence is that large amyloid-β plaques appear to be non-toxic, 




Another frequently used case against the role of amyloid-β in Alzheimer’s disease is the 
disappointing results from clinical trials aiming to reduce amyloid-β load. γ-secretase 
inhibitors have been unsuccessful in combatting the cognitive decline of Alzheimer’s disease 
(Doody et al., 2013; De Strooper, 2014). In fact, increased cognitive decline was observed in 
phase III trials in addition to serious side effects including skin cancer (Henley et al., 2014). 
More recent therapeutic efforts targeting Alzheimer’s disease have been focused on 
reducing or clearing the amyloid-β load in the brain. Several monoclonal antibodies 
including Bapineuzumab and Solanezumab have been used to target monomeric, 
oligomeric or aggregated forms of amyloid-β. While these antibodies were able to reduce 
the amyloid-β load, they failed to prevent cognitive decline in phase III clinical trials (van 
Dyck, 2018).  
The majority of Alzheimer’s disease therapeutics have failed to reduce cognitive decline in 
clinical trials for reasons that can be addressed. Secretase inhibitors were bad drug targets 
due to the additional substrates γ-secretase is known to cleave. Their inhibition therefore 
resulted in unforeseen and undesirable side effects. Likewise, while results for antibody 
therapies have been disappointing, a consensus in opinion suggests that drugs were used 
too late in the development of the disease. Molecular changes in the brain are suggested 
to have occurred decades before cognitive impairment was observed (Selkoe and Hardy, 
2016).  
Despite the number unsuccessful trials for Alzheimer’s disease therapeutics there has been 
a promising recent development for an antibody-based therapy. While phase III drug trials 
for monoclonal antibody Aducanumab were prematurely ended due to lack of significant 
results, a recent post hoc analysis has revealed that at high dosage there may be a small but 
significant reduction to cognitive decline. While the effects of this antibody are small, it may 
provide a strong proof of principle for the continued use of amyloid-β as a key therapeutic 
target.  
1.1.4 Amyloid-β production and processing 
Amyloid-β is formed through proteolytic processing of amyloid precursor protein (APP). 
APP, a type 1 transmembrane glycoprotein, is expressed ubiquitously across the central 




mRNA generates eight isoforms with sizes ranging from 695 to 770 amino acids. Of these 
the APP695 isoform is the most prevalent within the central nervous system. Translation of 
APP occurs in the endoplasmic reticulum (ER) and from there the protein exhibits complex 
post translational processing and trafficking (Kang et al., 1987; Dyrks et al., 1988; 
Weidemann et al., 1989). N-linked and O-linked glycosylation, phosphorylation and tyrosine 
sulfation modifications are made within the Golgi apparatus. It is here that much of protein 
remains, with just a small fraction being trafficked further to the plasma membrane. The 
fraction of APP present on the cell surface can be cleaved by several enzymes to release 
soluble protein fragments or can be rapidly reinternalized and trafficked into lysosomes for 
degradation (Haass et al., 1992). The proteolytic processing and trafficking of APP has been 
comprehensively reviewed by Haass et al. (2012) and Jiang et al. (2014). 
APP contains three cleavage sites that are targeted by transmembrane proteins α-, β- and 
γ-secretase. Initial cleavage can be made by either α- or β-secretase - α-secretase cleavage 
commits APP to non-amyloidogenic processing, while cleavage by β-secretase leads to 
amyloidogenic processing and the formation of amyloid-β. β-Secretase displays optimal 
activity in an acidic environment and has been suggested to be rate limiting for the 
formation of amyloid-β (Knops et al., 1995). Studies indicate that β-secretase is trafficked 
from the ER to the plasma membrane through the Golgi apparatus and endosomes. It is 
here that most APP cleavage has been suggested to take place due to the lower pH 
conditions within the acidic lumen (Vassar, 1999; Vassar, 2001). The overlapping trafficking 
of APP and β-secretase allows amyloid-β  production to occur in the ER, Golgi and 
endosomes in addition to the cell surface (Cook et al., 1997; Hartmann et al., 1997). 
Cleavage of APP by β-secretase results in the release of N-terminal soluble APPβ (sAPPβ) 
fragment while the C-terminal 99 amino acid fragment remains within the membrane 
(Figure 1.1a). The C-terminal fragment can then be cleaved by γ-secretase to release 
amyloid-β (Weidemann et al., 2002). γ-Secretase forms an amyloid-β fragment 48 or 49 
amino acids depending on the site of cleavage. The amyloid-β fragment is then cleaved in 
a stepwise manner by γ-secretase (Figure 1.1b). Due to the nature of this cleavage process 
amyloid- is produced with lengths between 37-49. Of these, the 40- and 42-residue species 





Figure 1.1, Amyloid-β protein processing. (a) Amyloid precursor protein (APP) is processed by β- and γ- secretase 
enzymes to release amyloid-β into the extracellular space. (b) The amyloid-β sequence (green) is shown with 
cleavage sites for α-, β- and γ- secretase enzymes. γ-secretase cleavage occurs in a sequential manner, removing 
two, three or four amino acid residues at a time.  
The biological roles of APP and amyloid-β have yet to be fully characterised but some 
functions have been suggested. APP has been proposed to be involved in cell-cell adhesion 
through dimerization (Soba et al., 2005) and cell-matrix adhesion through interaction with 
heparin (Clarris et al., 1997), collagen (Beher et al., 1996) and laminin (Kibbey et al., 1993). 
Additional roles have been suggested in neuronal development (Young-Pearse et al., 2007), 
signalling (Tamayev et al., 2009) and intracellular transport (Goldstein, 2012). Van Der Kant 
and Goldstein (2015) provide a summary of the current research relating to the function of 
APP. 
Amyloid-β is suggested to act as regulatory peptide, modulating synaptic activity and 
neuronal survival (Pearson and Peers, 2006). It has also been suggested that amyloid-β may 
act as a transcription factor (Bailey et al., 2011). Due to the evidence for a physiological role 
of both APP and amyloid-β, complete elimination of either protein is considered an 




1.1.5 Structures of amyloid-β 
The proteolytic processing of APP results in a range of amyloid-β peptides that vary in 
length. Once formed these peptides can exist in monomeric, oligomeric or fibrillar forms. 
Structural determination of each form is critical for understanding the molecular role of 
amyloid-β in Alzheimer’s disease.  A detailed review of the amyloid-β structures determined 
by nuclear magnetic resonance (NMR) and X-ray crystallographic (XRC) is provided by Chen 
et al. (2017), while (Viola and Klein, 2015) review the links between amyloid-β species and 
Alzheimer’s disease pathogenesis. Below these topics are covered more briefly. 
Amyloid-β monomers are soluble peptides that have been largely reported to be helical 
in nature. An NMR structure of amyloid-β 1-42 (1IYT) (Crescenzi et al., 2002) revealed the 
presence of two α-helical fragments between residues 8-25 and 27-38 (Figure 1.2). These 
helices are connected by a β-turn and are flanked by disordered N- and C-termini. Likewise, 
an NMR structure of amyloid-β 1-40 (1BA4) (Coles et al., 1998) reports the peptide to be 
helical in nature but with slight variation in the residues contributing to the helices (15-25 
and 27-36). Structures of smaller amyloid-β fragments have also been reported to adopt 
similar conformations - an NMR structure of amyloid-β 1-28 adopts a helical conformation 
(Talafous et al., 1994).  
It is important to note that the NMR structures discussed above were not determined in 
biologically relevant solvents due to the propensity of amyloid-β to aggregate at the 
concentrations required for structural investigation. Because of this, other techniques have 
been used to support NMR data. Molecular dynamic studies propose that amyloid-β  adopts 
a majority α-helical or β-sheet conformations with rapid transitions between the two (Yang 
and Teplow, 2008). The Ile41 and Ala42 residues present in amyloid-β 1-42 are suggested 
to shift the equilibrium towards a β-sheet conformation, causing an increase in propensity 





Figure 1.2, NMR structure of monomeric amyloid-β 1-42. The structure of amyloid-β (1IYT) adopts an α-helical 
conformation with a β-turn within the centre of the peptide. Molecular dynamics research has suggested that 
amyloid-β exhibits a rapid transition between -helical or -sheet conformations 
Amyloid-β oligomers are a highly diverse range of species generated from variation in the 
length, number and spatial arrangement of amyloid-β monomers. Like monomers, 
oligomers are soluble, however, due to their unstable and heterogenous nature they are 
inherently difficult to study. Crosslinking of amyloid-β peptides within oligomers has 
provided a means of covalently stabilising the oligomeric species. Methods such as PICUP 
(Bitan et al., 2003) and CHIPUP (Williams et al., 2016) allow crosslinking of peptides without 
substrate modification. Crosslinking has revealed that oligomeric species in solution can 
adopt dimers, trimers, tetramers, pentamers, hexamers and heptamers with varying degree.  
It was also revealed that amyloid-β 1-42 has a higher propensity for forming high mass 
oligomers when compared with amyloid-β 1-40. While crosslinking studies have provided 
some insight into these oligomers, it is unclear as to the impact that crosslinking has on the 
stability of species formed.  
Structural studies have yet to yield conclusive high-resolution information of oligomer 
structures. Despite limited information there is growing evidence to suggest that cyclic 
oligomeric species may play the most crucial role in Alzheimer’s disease. Lambert et al. 
(1998) first noticed cyclic oligomeric species with the use of electron microscopy. More 
recent NMR data supports the formation of cyclic pentamers and hexamers that are able to 
stack to form decamers and dodecamers (Ahmed et al. 2010).  
While the previous research on amyloid-β oligomers is substantial, full characterisation 




major challenge, not least because of the practical difficultly in dealing with the oligomers, 
but also in finding a system that accurately represents the natural environment. Further 
complexity is also present when considering that oligomers will be formed in both intra- 
and extracellular environments (Jung Lee et al., 2017).   
Amyloid fibrils are insoluble unbranched fibres formed through the stacking of amyloid-β 
monomers. This species of amyloid- can assemble into large extracellular plaques – one of 
the major pathogenic hallmarks for Alzheimer’s disease.  
Amyloid-β fibrils possess in register -sheets that run down the long axis of the fibril offering 
high stability. This stability has made structural studies easier when compared with the 
oligomeric form. To date, several structures of fibrils have been solved using NMR and cryo-
EM and their polymorphic nature has become clear (Figure 1.3). NMR structures have 
revealed fibrils of amyloid-β 1-42 can form through stacking of both monomeric (Xiao et al., 
2015) and dimeric (Colvin et al. 2016) amyloid-β units. A trimeric form has also been 
reported with amyloid-β 1-40  (Lu et al., 2013).  
Additional variation has been reported in the residues that are buried or surface exposed 
within a fibril (Schmidt et al., 2015; Colvin et al., 2016; Wälti et al., 2016; Gremer et al., 2017). 
A large contributor to this is the size of the amyloid- monomer. Amyloid-β 1-42 contains 
Ala42 which is able to form a salt bridge with Lys28 offering an explanation for the higher 
propensity of amyloid-β 1-42 to aggregate compared with amyloid-β 1-40 (Xiao et al., 2015). 
 
Figure 1.3, NMR structure of amyloid-β fibrils. (a) NMR structure of monomorphic amyloid- fibril 5KK3. Single 




form a dimer through side chain interactions and together form the stacking unit for fibril formation. Peptide 
disorder at the N-terminus (residues 1-12) are not modelled due to their highly disordered nature.      
1.1.6 Amyloid-β – peptide toxicity 
When the amyloid cascade hypothesis was published in 1992 it proposed that the primary 
cause of Alzheimer’s disease was the large aggregated plaques formed from amyloid-β 
fibrils (Hardy and Higgins, 1992). Studies in the years following have revealed the poor 
correlation between amyloid-β plaques and neuronal toxicity. Indeed, neurotoxicity of 
amyloid- was reported to be present without the formation of fibrils at all (Oda et al., 1994; 
Hsia et al., 1999; Mucke et al., 2000). More recently amyloid-β oligomers have been 
proposed as the primary mechanism by which neuronal toxicity was caused. The last two 
decades has seen this hypothesis develop and there is now considerable evidence 
implicating oligomers in neuronal toxicity both in vitro and in vivo (Walsh et al., 2002a).  
Oligomers appear to accumulate in both intracellular (Baker-Nigh et al., 2015) (Zheng et al., 
2013), and extracellular (Takeda et al., 2013) pools with movement between localisations. 
Intracellular oligomers show no preferred localisation to specific organelles (Zheng et al., 
2013), while extracellular oligomers localise to the neuronal surfaces (Gong et al., 2003) in 
what may be a cell type specific interaction (Lambert et al., 2001; Lacor et al., 2007). This 
extracellular localisation suggested the presence of a cell type specific membrane protein 
that, through interaction with amyloid- oligomers, may result in neurnal toxicity. Many 
membrane proteins are possible targets and have been reviewed by Viola and Klein, (2015) 
and Jung Lee et al. (2017). It may be that through membrane protein interaction amyloid-β 
oligomers downstream effects are mediated such as tau hyperphosphorylation (De Felice et 
al., 2007).  
 
1.2 Amyloid-degrading enzymes 
Control of amyloid-β levels is achieved through production and clearance. In Alzheimer’s 
disease this process becomes imbalanced. It has been suggested that individuals with early-
onset familial Alzheimer’s have an increase in amyloid-β production (Hatami et al., 2017). In 




a result of reduction in amyloid-β clearance (Mawuenyega et al., 2010). Understanding of 
these clearance mechanisms are therefore critical understanding of Alzheimer’s disease.  
Amyloid-β clearance mechanisms can broadly be separated into two groups - enzymatic 
and non-enzymatic. Non-enzymatic mechanisms include interstitial fluid drainage (Weller 
et al., 2000), uptake by microglial phagocytosis (Frautschy et al., 1998; Wyss-Coray et al., 
2003; Nielsen et al., 2009) and transport across the blood brain barrier (Shibata et al., 2000; 
Deane et al., 2003). The formation of insoluble plaques may also be considered a clearance 
method by acting as a sink removing more toxic oligomeric amyloid-β species (Cheng et al., 
2007; Lesné et al., 2008). 
Enzymatic clearance of amyloid-β is achieved through the protease activity of amyloid-
degrading enzymes (ADEs). These proteases function to digest amyloid-β peptides into 
smaller less-toxic species. While the majority of degradation is suggested to occur within 
the brain, clearance may also occur in other areas in which amyloid-β is localised after 
clearance from the brain. A diverse range of ADE have been discovered from several 
protease classes including metallo, serine, aspartyl, cysteine and threonine. Many of these 
proteases display activity towards multiple peptide substrates across a range of tissue 
localisations. The localisations and activities of ADE’s have been reviewed by Saido et al. 
(2012) and Nalivaeva et al. (2012). 
Amyloid-degrading metalloproteases Reference 
Neprilysin (Howell et al., 1995a) 
Neprilysin 2 (Marr and Hafez, 2014) 
Human membrane metallo-endopeptidase-like protein (Huang et al., 2008) 
Endothelin-converting enzyme I (Eckman et al., 2001) 
Endothelin-converting enzyme 2 (Eckman et al., 2003) 
Angiotensin-converting enzyme (Hemming and Selkoe, 2005) 
Insulin-degrading enzyme (Qiu et al., 1997) 
Matrix metalloproteinase 2 (Roher et al., 1994) 
Matrix metalloproteinase 9 (Backstrom et al., 1996) 




Table 1.1, Amyloid-degrading enzymes from the metalloprotease family. All proteins have demonstrated an 
ability to degrade amyloid-β in vitro, but the biological relevance of each protein has yet to be fully 
characterised.  
The best studied ADEs are members of the metalloproteases class (Table 1.1). 
Metalloproteases are the most diverse class of protease which can be separated into two 
groups based on cleavage location - exopeptidase (EC 3.4.17) and endopeptidase (EC 
3.4.24). Enzymes from this class share a conserved mechanism based around a divalent 
cation. Much of the research into the mechanism of peptide cleavage by metalloproteases 
was conducted on thermolysin (Pelmenschikov et al., 2002). The proposed water dependant 
mechanism for peptide cleavage is shown in Figure 1.4.  
 
 
Figure 1.4, Metalloprotease catalytic mechanism. Four steps are involved in the proposed mechanism for water 
dependant peptide scissile bond cleavage. The divalent metal cation is displayed as a circle with three lines 
representing the coordination sphere. (I) a water molecule coordinates the divalent cation and is stabilised through 
hydrogen bonds to a catalytic glutamate residue. (II) substrate binding occurs, and additional divalent coordination 
is provided by the oxygen of the substrate. The polarised water molecule then attacks the scissile carbonyl group 
resulting in the formation of a tetrahedral intermediate. (III) Scissile bond breakage and double proton transfer 
occurs. (IV) The resulting peptide fragments can then be released (Cerdà-Costa and Gomis-Rüth, 2014).  
Of the proteases listed in Table 1.1, four zinc metalloproteases – neprilysin, endothelin-
converting enzyme I, insulin-degrading enzyme and angiotensin-converting enzyme - have 
received the majority of attention for their actions as ADEs (Figure 1.5). Crucially each 
enzyme has in vivo evidence supporting their role in amyloid- degradation. Each of the 
four proteins displays commonality in a number of structural features, and each has a 
remarkable number of substrates that vary in sequence, size, shape and charge of substrate. 
Below each protein will be briefly described with a summary of evidence supporting their 






Figure 1.5, Crystal structures of principal ADEs. Neprilysin, endothelin-converting enzyme, insulin-degrading 
enzyme and N- and C- domains of angiotensin converting enzyme have been identified as important enzymes in 
amyloid-β regulation.  
1.2.1 Neprilysin 
Neprilysin (NEP, EC 3.4.24.11) is a transmembrane M13 zinc metalloprotease and the best 
known ADE (Iwata et al., 2001). While NEP is expressed ubiquitously, high levels have been 
identified in the kidney and intestines (Uhlén et al., 2015). After translation NEP is 
glycosylated before being transported to the plasma membrane where the large catalytic 
domain is presented into the extracellular space (Nalivaeva and Turner, 2013). Here the 
protein is known to degrade many small peptide substrates (<5 kDa) including substance P, 
angiotensin II, angiotensin I, bradykinin, enkephalins (Gafford et al., 1983; Mumford et al., 
1981), neurotensin, oxytocin (Almenoff et al., 1981; Johnson et al., 1984) and amyloid-β. 
Initial HPLC analysis of NEP confirmed the protein could degrade amyloid- in vitro and at 




analysis has provided greater resolution to the exact nature of amyloid- cleavage 
(Rogeberg et al., 2014). Presently it is clear that NEP can degrade monomeric amyloid-β 
however there remains an absence of evidence for oligomer or fibril degradation (Leissring, 
2008).  
In addition to the in vitro evidence, in vivo evidence for the key role of NEP in amyloid- 
degradation has been building over the past two decades. A study from 2002 revealed NEP 
found within the brain is localised along axons and at synapses. Varied levels of expression 
were seen in different neuronal cell types and lower neprilysin expression correlated with 
higher amyloid-β deposition. The study also suggested that ageing causes a gradual down 
regulation of ADE and therefore led to the increase in amyloid-β seen in Alzheimer’s disease 
(Fukami et al., 2002).  
Knockout mice models have also been used to demonstrate the importance of NEP in 
amyloid- regulation. NEP knockout mice display up to a two-fold increase in amyloid-β 1-
40 and 1-42 levels when compared with the wild-type in a range of brain tissues (Iwata et 
al., 2001; Farris et al., 2007). Specifically, levels of oligomeric amyloid-β have been shown to 
rise and impair cognitive function (Huang et al., 2006). Transgenic mouse studies using mice 
overexpressing the APP gene have also supported NEP’s role in amyloid-β regulation. These 
transgenic mice suffer abnormally high premature death rates (Hsiao et al., 1995; Mucke et 
al., 2000), however by crossing these mice with mice overexpressing NEP, there was a 
significant reduction in amyloid-β levels and the associated cytopathology (Leissring et al., 
2003).  
While the majority of studies strongly implicate NEP in amyloid- degradation and indicate 
a protective role for the enzyme, it should be noted there is contrasting evidence. 
Experiments using APP transgenic mice revealed NEP overexpression reduced the soluble 
monomeric amyloid- levels but oligomeric levels were unchanged with no reduction in the 
cytopathology associated with increase amyloid-β levels (Meilandt et al., 2009). The 
contrasting evidence may illustrate the complexity of the system due to the range of species 




1.2.2 Endothelin-converting enzyme I 
Endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), like NEP, is a transmembrane zinc 
metalloprotease and member of the M13 metalloprotease family. In humans, ECE-1 shares 
38% amino acid sequence similarity with NEP but exists as a disulfide linked dimer instead 
of as a monomer (Schulz et al., 2009). 
ECE-1 is expressed in four different isoforms aECE-1, bECE-1, cECE-1 and dECE-1. All 
isoforms are produced by the same gene, but variation in promoter leads to an altered N-
terminal tail sequence. The four isoforms have differing subcellular localisations, but all 
retain the same level of substrate catalysis and efficiency. aECE-1 is localised to the plasma 
membrane, dECE-1 and cECE-1 localised to the plasma membrane and intracellular 
compartments and bECE-1 is localised almost entirely intracellularly (Valdenaire et al., 1995; 
Schweizer et al., 1997; Valdenaire et al., 1999). These isoforms and their localisations have 
been reviewed by Eckman et al. (2001) and Pacheco-Quinto et al. (2013). 
ECE-1 was initially characterised for its role in converting pro-endothelin/big-ET into 
endothelins – potent vasoconstrictors. Like NEP, ECE-1 is also expressed ubiquitously across 
all vascular cells and a range of tissues nonvascular cells including the lungs, kidneys, adrenal 
gland, ovary and testis (Xu et al., 1994; Davenport et al., 1998; Korth et al., 1999). Across this 
range of tissues many substrates for ECE-1 have been identified in addition to pro-
endothelin. These include bradykinin, neurotensin, substance P and amyloid-β (Johnson et 
al., 1999; Eckman et al., 2001). Optimal catalytic activity of ECE-1 varies for different 
substrates. For big ET-1 optimal activity is achieved at neutral pH while a pH of ~5.6 is 
optimal for bradykinin, substance P and amyloid-β. The localisation and pH optima for ECE-
1 suggests that the majority of amyloid-β degradation by this enzyme is performed in the 
intracellular space (Saido and Leissring, 2012). Like NEP, this amyloid- degradation has 
been identified to be specific to the monomeric species (Leissring, 2008).  
The role of ECE-1 in Alzheimer’s disease, while less well studied than NEP, has been 
confirmed through both in vitro and in vivo degradation of amyloid-β. In vitro studies have 
revealed ECE-1 expressing cell lines have a 2-3-fold increase in extracellular amyloid-β when 
treated with metalloprotease inhibitor phosphoramidon (Eckman et al., 2001), this affect 




ECE-1 in CHO cells lacking endogenous ECE-1 expression reduced extracellular amyloid-β 
by 90% compared to a control. This amyloid-β reduction could be eliminated with 
phosphoramidon treatment. The in vitro work is supported by a transgenic mouse study 
that revealed increased brain amyloid-β levels in ECE-1 deficient mice (Eckman et al., 2003).  
1.2.3 Other notable ADEs 
Presently, there are over 20 known ADEs (Nalivaeva et al., 2014). While this is a large number 
of proteins, it is important to consider the physiological relevance of each one. A distinction 
should be made between enzymes that exhibit protease activity on amyloid-β in a test tube, 
where concentrations are greatly in excess of physiological conditions, and those that likely 
are responsible for amyloid-β degradation in a physiologically relevant system. In vivo 
evidence remains the best measure of the true relevance of an ADE. While NEP and ECE-1 
are possibly the best-known ADEs, two other enzymes have substantial evidence for their 
role in Alzheimer’s disease. 
Insulin degrading enzyme (IDE, EC 3.4.24.56) is a 110kDa endopeptidase and a member of 
the M16 zinc metalloprotease family. IDE expression is ubiquitous but expression levels are 
tissue dependant (Bondy et al., 1994). The post-translational processing and trafficking of 
the protein remain unclear but studies have revealed IDE is localised both intra- and 
extracellularly with a small fraction associating to the cell membrane (Raffaella Tundo et al., 
2012). IDE was initially characterised for its insulin degrading properties (Duckworth et al., 
1972), but has since been revealed to degrade a broad range of peptide targets including 
insulin, amylin, glucagon and amyloid-β (Shen et al., 2006). 
IDE has been identified as a major protease of amyloid-β in neuronal cell lines in vitro and 
in vivo mouse models. In vitro studies have revealed that IDE is able to digest intra- and 
extracellular amyloid- pools (Qiu et al., 1997; Qiu et al., 1998; Sudoh et al., 2002). Other 
studies present convincing evidence indicating that soluble monomeric amyloid- is readily 
digested, but that oligomeric species are not digested by IDE (Walsh et al., 2002b).  
In vivo studies on mouse IDE double knockouts reveal cerebral accumulations of amyloid- 
supporting IDE’s role in amyloid-β digestion. Membrane fractions of brain cells and intact 
primary neuronal cells from these knockout mice were determined to have a >50% decrease 




Transgenic mice overexpressing IDE show the reverse, with significant reduction in amyloid-
 levels (Leissring et al., 2003). 
Angiotensin-converting enzyme (ACE, EC 3.4.15.1) is a zinc-dependant dipeptidyl 
carboxypeptidase best known for its role in blood pressure regulation through cleavage of 
angiotensin I and bradykinin (Ignjacev-Lazich et al., 2005). Other substrates include 
enkephalins, chemotactic peptide, neurotensin and substance P (Skidgel and Erdös, 1987). 
Two isoforms of ACE are known – somatic ACE (sACE) and testicular (tACE) (Howard et al., 
1990). Both isoforms are transcribed from the same gene but while sACE is ubiquitous tACE 
is only expressed in mature testis (Igic and Behnia, 2003). The two ACE isoforms possess 
identical intracellular, transmembrane and catalytic domains (cACE) (Figure 1.6). The 
variation in isoforms stems from the additional N-terminal ACE domain (nACE) present in 
sACE but not in tACE. This additional catalytic domain has a high degree of structural 
similarity to cACE but substrate specificity is known to differ for some substrates (Natesh et 
al., 2003; Corradi et al., 2006).  
 
 
Figure 1.6, Domain organisation of somatic and testicular ACE. Both sACE and tACE possess identical cytoplasmic, 
transmembrane and cACE domains. The additional nACE domain is present in sACE has a high degree of sequence 
and structural homology to cACE. 
Evidence for the role of ACE in Alzheimer’s disease was revealed in the association between 
mutations and deletions within the ACE encoding DCP1 gene and an individual’s 




research has also flagged up the gene encoding ACE as an Alzheimer’s disease susceptibility 
gene (Bertram et al., 2007).  
In vitro evidence for sACE as a ADE has been shown by the proteins ability to significantly 
inhibit aggregation and fibril formation of synthetic amyloid-β. This capacity can be 
removed by  treatment with ACE specific inhibitor lisinopril (Hu et al., 2001). While in vivo 
studies for ACE are inconclusive (Eckman et al., 2006), the strong genetic link between ACE 
and Alzheimer’s disease means the enzyme is regarded as an important ADE, but one that 
requires greater clarification.   
1.2.4 Possible therapeutic targets of ADE benefit 
It is clear that research into ADEs is critical to gain an understanding of the landscape of 
Alzheimer’s disease as a whole. While many questions surrounding ADEs have yet to be 
addressed, current understanding has caused them to be identified as possible therapeutic 
targets for Alzheimer’s disease treatment (Nalivaeva et al., 2012; Graham et al., 2017; 
Nalivaeva and Turner, 2019). If amyloid- is a major driver of Alzheimer’s disease, and if 
accumulation of amyloid-β is due to a reduction in clearance rather than an increase in 
production, a clear direction for therapy would be to compensate for the reduced clearance 
capacity. To this end, research into the upregulation of ADE expression (Saito et al., 2005) 
or downregulation of ADE endogenous inhibitors (Jacobsen et al., 2008) has been explored 
to increasing amyloid-β degradation. The potential to use gene therapy for increased ADE 
expression has been explored in mice (Marr et al., 2003; Hong et al., 2006). Such studies 
have demonstrated gene therapy to be effective means to reduce the amyloid pathology 
associated with AD. While results appear positive, the limitations for gene therapy remain a 
large hurdle with issues of secondary toxicity, exacerbation of the immune response, low 
efficiency and high cost (Li et al., 2015). 
Another obstacle that must be addressed if ADEs are to be considered viable therapeutic 
targets is their activity on diverse populations of substrates across a broad range of tissues. 
Upregulation of ADEs would no doubt generate unwanted secondary effects, the most likely 
of which would be the alteration in blood pressure regulation. Site directed mutagenesis is 




to change specificities of ADEs for substrates and tailor these proteins for amyloid-β 
degradation (Sexton et al., 2012). 
While the therapeutic potential of ADEs remains unclear, the necessity to understand 
amyloid-β clearance mechanisms has emerged as a critical area for Alzheimer’s disease 
research as a whole. It may be through this that more effective treatment can be attained. 
1.2.5 Other functions of ADEs  
Given the large number of peptide substrates that can be degraded by ADEs, it is no surprise 
that many ADEs have been identified to have a number of other biological functions. This is 
particularly evident in two of the best known ADEs, NEP and ECE-1. Both enzymes have 
received considerable levels of interest for their roles in blood pressure regulation and 
represent promising therapeutic targets to combat cardiovascular disease. Both NEP and 
ECE-1 promote hypertension, however, each does so via different primary mechanism. To 
provide greater detail into each enzyme and a more complete view of their biological 
function the role of NEP and ECE-1 in blood pressure regulation will be considered below.  
The primary mechanism by which NEP elicits blood pressure regulation is through 
natriuretic peptide cleavage (Figure 1.7). Natriuretic peptides (NPs) are separated into three 
major classes, atrial natriuretic peptide, B-type natriuretic peptide and C-type natriuretic 
peptide (ANP, BNP and CNP). All three NPs are small (between 22-32 amino acid residues 
in length) and possess a partially conserved cyclic core. ANP and BNP are found within 
arterial myocytes in mammalian hearts where they can be readily released into the 
bloodstream. CNP is expressed in endothelial cells of vascular tissues in addition to neuronal 
cells. While NPs exhibit variation in localisation each promotes vasodilation through binding 
to plasma membrane transmembrane receptors (Zois et al., 2014).  
Receptors for NPs are expressed in a wide range of tissues. Two guanylyl cyclase receptors 
for NPs, GC-A and GC-B, are responsible for cGMP generation. Protein kinase G then 
mediates downstream effects including calcium sequestration. The third NP receptor, NPR-
C, does not possess guanylyl cyclase activity, instead it functions as a clearance receptor. 
Internalisation of NPR-C with a ligand leads to lysosomal hydrolysis of the ligand and NPR-




The role of NEP’s in NP degradation has led to it becoming a major drug target for heart 
failure. Several drugs for NEP inhibition have been developed and used to reduce 
hypertension. Currently one NEP inhibitor has been FDA approved for individuals with high 
cardiovascular disease risk. The inhibitor, sacubitril, is a pro-drug converted to sacubitrilat 
and functions as a dual inhibitor against NEP and ACE (Jhund and McMurray, 2016).  
 
Figure 1.7, The role of NEP and natriuretic peptides in blood pressure regulation. Natriuretic peptides ANP, BNP 
and CNP interact with receptors GC-A and GC-B. These receptors then mediate an intracellular response through 
protein kinase G which leads to vasodilation and natriuresis. The third natriuretic peptide receptor, NPR-C, is 
responsible for peptide clearance. The transmembrane zinc metalloprotease, NEP, degrades natriuretic peptides 
leading to vasoconstriction.   
The primary mode of blood pressure regulation for ECE-1 has been proposed to be through 
cleavage of big endothelins into endothelins (Figure 1.8). Three 21 amino acid ET isoforms 
have been characterised ET-1, ET-2 and ET-3. These ET’s interact with receptors ETA and ETB 
(Masaki et al., 1991; Haynes et al., 1995). ETA, predominantly located in vascular smooth 
muscle cells, is a G-protein coupled receptor responsive for mediating vasoconstriction. 




increasing the intracellular calcium concentration and leading to smooth muscle cell 
contraction (Miyauchi and Masaki, 1999). ETB, located in both vascular smooth muscle cells 
and endothelial cells, has a contrasting role and is responsible for release of nitric oxide, ET 
clearance and ECE-1 inhibition. All of which elicit a vasodilatory response (Luscher and 
Barton, 2000).  
 
Figure 1.8, The role of ECE-1 and endothelins in blood pressure regulation. Big endothelin’s ET-1, ET-2 and ET-3 
are processed by transmembrane zinc metalloprotease, ECE-1. The resulting peptides can then interact with 
receptors ETA and ETB. The predominant response is vasoconstriction mediated through ETA with ET clearance and 
some vasodilatory effects mediated by ETB.  
While ECE-1’s role in ET production has been the primary focus of research, ECE-1 has also 
been revealed to exhibit protease activity on natriuretic peptides (Nakayama et al., 2012). 
The physiological significance of this is not completely clear but it is likely that ECE-1, like 
NEP, has a role to play in natriuretic processing. The role of ECE-1 in blood pressure 
regulation has seen it become a drug target along with NEP and ACE. Proposed drugs are 
frequently designed as dual/triple inhibitors against two or three of the proteins  (Mellin et 





1.3 Aims of the PhD project 
The role of ADE’s in amyloid-β degradation is critical for brain homeostasis with imbalances 
strongly linked to Alzheimer’s disease. While the potential to use ADEs as a therapeutic 
target has received some research attention, they have not been characterised in-depth. 
Further research into ADE’s will provide a further base of knowledge of the processes 
underlying Alzheimer’s disease and may prove to be invaluable for development of future 
therapies.  
Two ADE’s, NEP and ECE-1, represent high priority targets for greater research and 
characterisation due to their high potencies and their variation in subcellular localisation.  
This means together these proteins are highly efficient at degrading both extracellular and 
intracellular amyloid-β. NEP and ECE-1 also possess additional functions, most notably their 
role in blood pressure regulation. These additional functions further contribute to their 
priority for characterisation as any scientific advancements will have benefits across a 
number of research fields. 
The specific aim of the Ph.D. project detailed in the following chapters was to characterise 
NEP and ECE-1 using a variety of biophysical techniques. Of these the primary method of 
characterisation would be through X-ray crystallography. Determination of high-resolution 
ADE structures, in both substrate-free and substrate-bound forms, would provide the basis 
for understanding how these proteins function and can fulfil the range of roles through 




2 Chapter 2 – Structural biology and  




2.1 Structural biology and X-ray crystallography  
Life in its cellular and non-cellular forms is created from an immense number of 
macromolecules, each with a specific function and unique network of interactions. The field 
of structural biology investigates these fundamental macromolecules through the lens of 
structure. It is through structural determination that one can infer function and how these 
functions are mechanistically fulfilled. Moreover, characterisation of the individual 
macromolecules provides a means to understand the architecture of cells and multicellular 
organisms thus providing a clear foundation for many other biological sciences.   
The bulk of structural biology research focusses on determination of protein macromolecule 
structures with a lesser focus on DNA/RNA. The most obvious issue with studying proteins 
is their size, commonly ranging from 1-20 nm in length with their covalently bound atoms 
1-2 Å apart. The wavelength of radiation is approximately equal to its resolving power – the 
distance between two points that can be separated. Visible light (350-700 nm), even with 
the use of sophisticated microscopes, can only separate two particles approximately 500 nm 
making it ill-suited for the determination of atomic coordinates. 
There are many techniques in the toolbox of a structural biologist including: mass 
spectrometry, small-angle X-ray scattering, circular dichroism, isothermal titration 
calorimetry and fluorescence resonance energy transfer. These can provide insights into the 
size, shape, fold and dynamics of a protein. However, if the primary aim of study is focused 
on determination of the precise atomic coordinates within macromolecules then one of 
three technique should be utilised. These are X-ray crystallography (XRC), nuclear magnetic 
resonance (NMR) spectroscopy and cryo-electron microscopy (cryo-EM). 
XRC represents the ‘gold standard’ for structural determination. Since the first reported 
protein structure in 1958 (Kendrew et al., 1958), XRC has been responsible for the dramatic 
rise in protein structure determination. To date, the technique has been used to determine 
over 130,000 structures, accounting for 90% of the total structures deposited into the 
Protein Data Bank (PDB). The importance of XRC in the development of structural biology 
cannot be overstated.  
X-rays have wavelengths between 10 - 0.01 nm, which is similar to the distances between 




X-rays are focused on protein crystals, which contain a regular organisation of atoms, to 
produce X-ray diffraction. The amplitude of the diffracted X-rays can be determined from 
the recorded intensity of diffracted spots. This, in addition to the phase information, which 
can be estimated using a number of different methods, is used to  determine precise atomic 
coordinates (Blow, 2004). Currently XRC represents a rapid and reliable method that is 
limited only by the requirement for proteins to be able to crystallise.  
The second technique, NMR, accounts for approximately 8% of protein structures deposited 
in the PDB. The technique exposes nuclei to an external electromagnetic field which can be 
absorbed and emitted to produce a spectrum. Through analysis of this spectrum, 
information on atom composition and atom local environment can be gained. Whilst NMR 
has no requirement for protein crystals, it is limited by the size of protein that can be 
determined. Structures are commonly between 5-25kDa, but the upper limit is 
approximately 35kDa (Yu, 1999).   
The third technique, cryo-EM, has seen a large increase in popularity in recent years, now 
contributing 2% of the total protein structures in the PDB. This technique measures the 
scattering of electrons produced by mono dispersed proteins randomly orientated on a grid. 
The scattered electrons from 1000’s of protein molecules are then analysed and merged to 
recreate the protein structure. It has been suggested that we are on the cusp of a cryo-EM 
revolution. However, like NMR, cryo-EM suffers from limitations in protein size that can be 
determined. To date, the smallest protein determined is the 52-kDa streptavidin (Fan et al., 
2019), but structures are more commonly above 150kDa in size. Until recently, resolution 
has also presented a major limitation to the method but with recent advancements in 
equipment many atomic resolution structures are being reported (Renaud et al., 2018).   
Much of the work contained within this thesis is focused on the production protein for XRC. 
Once protein has been produced a routine collection of steps can then be performed in 
order to determine macromolecular structures (Figure 2.1). The remainder of this chapter 
explores the practical and theoretical aspects of these stages in XRC providing a basis for 





Figure 2.1,  From protein to structure: a flow chart of X-ray crystallography methods. The stages involved in 
determination of a macromolecular structure using X-ray crystallography. The first three stages - protein 
production, crystallisation and data collection - are experimentally performed. Once data have been collected the 
following stages are computationally performed.   
 
2.2 Crystallisation 
To determine a protein structure using XRC it is necessary to obtain protein crystals. The 
process of crystallisation requires a large quantity of protein (>1 mg) and for that protein 
to be pure. Impurities may disrupt crystallisation or may indeed crystallise themselves. It is 




Crystallisation trials are performed with the aim of identifying which, of a vast matrix of 
crystallisation conditions, can lead to crystal formation when mixed with concentrated 
protein solution. Trials can be conducted using several experimental techniques, the most 
common of which is vapour diffusion in the form of hanging or sitting drop (Figure 2.2a and 
b) (Dessau and Modis, 2011). In this method a reservoir is filled with reservoir solution and 
a crystallisation drop is created by mixing a ratio, often 1:1, of protein solution to reservoir 
solution. The reservoir and crystallisation drop are then sealed. As the crystallisation drop 
contains a lower concentration of precipitant compared with the reservoir solution, vapour 
diffusion and a net transfer of water from the crystallisation drop to the reservoir solution 
occurs. Over time, the concentration of precipitant and protein increase in the crystallisation 
drop until the protein’s solubility limit is exceeded and the drop becomes supersaturated. 
At this point protein crystals or precipitant form and the protein concentration is reduced 
allowing the solubility limit to be re-established. This process can be represented in a phase 
diagram (Figure 2.2c). 
If conditions for crystal formation are identified, even if crystals are small or diffract poorly, 
optimisation can be used to frequently improve size and diffraction quality. Optimisation of 
initial conditions through incremental adjustments of chemical components, such as salts, 
precipitants and pH can improve the quality of X-ray diffraction.  Changes to the physical 
parameters, such as temperature, volume and the method of crystallisation may also 
improve diffraction (McPherson and Gavira, 2014; McPherson and Cudney, 2014). 
It is the process of crystallisation that presents the largest hurdle in XRC. Despite the 
introduction of 1000’s of crystallisation conditions and high-throughput screening, there 
are no guaranties that a given protein will ever yield crystals. However, there are several 
methods to make a protein more conducive to crystal formation. These include, removal of 
flexible regions or domains and glycosylation sites to reduce overall flexibility and increase 
the number of stable crystal contacts (Dale et al., 2003; Chang et al., 2007). Protein 
aggregation also presents an issue during crystallisation. This is especially true of 
transmembrane proteins, where the hydrophobic nature of transmembrane regions greatly 
increases the propensity for protein aggregation. If transmembrane domains are small and 





The theory behind crystal formation is well documented (McPherson and Cudney, 2014) and 
can be separated into two stages: nucleation and growth. Nucleation is the process of 
forming an initial nucleus or crystalline solid. In this process protein molecules collide in 
orientations that form favourable contacts and become arranged in a regular crystalline 
pattern. This can only occur in protein solutions that are supersaturated or in the ‘nucleation 
zone’. The formation and disassembly of nuclei arises frequently in a supersaturated 
solution. It is only after a critical volume is reached that the nucleus becomes stable and 
continues to grow. As solid nuclei increase in size the solution then becomes less saturated 
and the ‘metastable zone’ is reach. Here the second stage of crystal formation, growth, can 
continue to occur below the nucleation zone. This process is described as heterogeneous 
nucleation. In homogeneous nucleation, the supersaturated nucleation point is not reached, 
but crystal growth can occur through the introduction of externally produced nuclei in a 
process called seeding (McPherson and Gavira, 2014).   
Crystallisation is driven by change in free energy (ΔG). Two components contribute to free 
energy, these are enthalpy (ΔH) and entropy (ΔS) (Equation 2.1). For crystallisation to occur 
the process must have a negative ΔG and therefore be energetically favourable.  
 
 
∆𝐺 =  ∆𝐻 −  𝑇∆𝑆 Equation 2.1 
 
 
ΔH is regarded as relatively insignificant as the intermolecular bonds in a protein crystal 
contribute very little energy in formation. Therefore, the major driver of protein 
crystallisation is ΔS. This may seem unlikely, as protein in solution has a higher ΔS than 
protein in a solid state, however the ΔS of the solution must also be considered. In solution, 
protein is surrounded by ordered water molecules that form a hydration layer. When a 
protein transitions from in solution to a solid state these water molecules are released and 
there is a net increase in ΔS (Rupp, 2010). It is only through crystallisation trials that an 





Figure 2.2. Protein crystallisation. (a) and (b) schematically represent the common experimental crystallisation 
experiments hanging and sitting drop vapour diffusion respectively. In these experiments a drop containing protein 
and crystallisation buffer is separate from a large reservoir of crystallisation buffer. Over time water diffuses from 
the protein containing drop into the reservoir due to the reservoir’s higher precipitant concentration.  (c) 
crystallisation diagram illustrating the path required for crystallisation of a protein. Initially the crystallisation drop 
will be undersaturated, but as vapour diffusion occurs the concentration of protein and precipitant rises until 
supersaturation is achieved. At this point crystal nucleation may occur and as crystals form protein concentration 
is reduced into a metastable zone where an equilibrium can be reached.    
 
2.3 Crystal geometry 
Crystals are 3-dimensional periodic assemblies of a homogeneous substance. In the case of 
a protein crystal, protein molecules form the identical repeating units that are periodically 
stacked to generate a complete crystal. Through studying the internal structure of different 
crystals, it has become clear that there are many ways that individual molecules can be 
organised. Information on this internal structure is critical for XRC to be used for protein 
structure determination. Two mathematical constructs – the asymmetric unit and unit cell - 




The asymmetric unit is defined as the smallest unit of a crystal structure containing all the 
molecular information that can be translated and rotated using symmetry operators to 
generate the unit cell. Other types of symmetry can exist in a unit cell in addition to rotation, 
these are inversion and reflection. However, due to the chiral nature of protein molecules 
only rotational symmetry can exist in a protein crystal unit cell.  
The unit cell is defined as the smallest unit that can produce the complete crystal lattice 
through translational operations alone. Given this property, the unit cell must be capable 
for tessellation, limiting the rotational symmetries to 0-, 2-, 3-, 4-, and 6-fold. Seven crystal 
systems exist which describe the symmetry contained within a unit cell (Table 1.1). It is this 
symmetry that places restrictions on both the axial lengths and interaxial angles of the unit 
cell which is drawn as a parallelepiped (Figure 2.3). Crystal system can be divided further 
into point groups, with each point group describing all the rotational operations that are 
experienced by the asymmetric unit within the unit cell (Rupp, 2010). 
Further complexity may be present in the unit cell where, in addition to rotation, there may 
be some translational operations present between symmetry related molecules. If 
translation is present, it is given as a function of the unit cell length and the unit cell is said 
to contain a screw axis. The notation for screw axis is given as nm, where ‘n’ indicates the 
rotation present and the translation is ‘m/n’ of the unit cell. For example, P21 has a rotation 
of 180o for a translation of half the unit cell. 
In addition to categorisation based on symmetry, unit cells can also be separated into 14 
Bravais lattice groups based on the position of lattice points. Bravais lattices are constructed 
such that the axes of a unit cell axis are positioned parallel or perpendicular to the symmetry 
axes. In most cases a primitive unit cell can be constructed where lattice points are located 
at the 8 corners of the unit cell. However, it is sometimes necessary to construct larger unit 
cells in order to adhere to the convention of axis orientation. In these cases, unit cells can 
be generated with additional lattice points present inside, on the faces and at the ends 
(Blow, 2004).  
The point group, screw axes and Bravais lattice can be combined into a space group. It is 
the space group that contains a complete description of the geometry contained within a 




chiral molecules including proteins (Rupp, 2010). During an XRC experiment, X-rays are 
passed through a crystal and it is the space group that governs the produced diffraction 
pattern. Knowledge of the space group is required before the protein structure can be 
determined. The interaction of X-ray and crystals will be explored in greater detail below. 
 
 
Figure 2.3. The unit cell. A single lattice points is shown at each edge. Axial lengths a, b and c and interaxial angles 
α, β and γ are restricted based on the symmetry operations experienced by the asymmetric unit.  
 
 
Crystal system Interaxial 
angles 
Axial lengths Point groups 
Triclinic α≠β≠γ≠90 a≠b≠c 1 
Monoclinic α=γ=90, β≠90 a≠b≠c 2 
Orthorhombic α=β=γ=90 a≠b≠c 222  
Tetragonal α=β=γ=90 a=b≠c 4, 422 
Trigonal α=β=90, γ=120 a=b≠c 3, 32 
Hexagonal α=β=90, γ=120 a=b≠c 6, 622 




Table 2.1. Crystal systems and unit cell restrictions. The seven crystal systems with the possible point groups are 
listed. Each of these crystal systems places restrictions on the unit cell interaxial angles ‘α, β and γ’ and axial 
lengths ‘a, b and c’.  
 
2.4 X-ray diffraction  
The process of diffraction occurs when electromagnetic radiation encounters an obstacle 
and is scattered in directions other than the original one. In XRC, X-rays interact with 
electrons causing them to adopt a higher energy state. Upon returning to a lower energy 
state, radiation of the same wavelength is emitted in a random direction after a phase lag 
(Brill, 1968). X-ray diffraction by a single protein molecule is incredibly weak and cannot be 
used to determine the protein structure. In contrast, the diffraction of a protein crystals is 
far stronger due to constructive interference. From the observed diffraction pattern is 
possible to determine the crystal geometry in addition to the electron density distribution 
of the unit cell. It is this information that allows determination of a protein structure.  
The theory of X-ray diffraction in 3-dimensional crystals is well documented (Rupp, 2010), 
but is it often more simply explained in 2-dimensions. Let us consider passing a parallel 
beam of monochromatic X-rays through a perpendicular 2-dimensional plane of regularly 
space atoms. The result would be that X-rays simultaneously reach each atom in the plane 
before being scattered in all directions. The majority of diffracted waves will be out of phase 
and thus cancelled out due to destructive interference. However, in some directions, 
diffracted waves from adjacent particles will vary in phase by a whole number of 
wavelengths. It is at these specific directions that constructive interference can occur. If the 
diffracted waves were recorded on a 2-dimensional detector then a regular arrangement of 
spots would be present. In XRC it is the position of spots and their intensity that can be used 
to determine the atomic structure that is responsible for the observed diffraction. 
As atomic planes increase in complexity, more than one type of regularly spaced atoms can 
be present on the 2-dimensional plane. Each atom type would contribute a component of 
the total scattering in directions that allow for constructive interference. In this case the 




will be the same wavelength but will vary in amplitude and phase to the incident waves 
(Blow, 2004).  
These same principles apply to a 3-dimensional lattice which can be thought of as a stack 
of parallel 2-dimension planes. In a lattice however, all diffracted X-rays for a given plane 
must be in phase with those from all other parallel planes for constructive interference to 
occur Bragg’s law (Bragg and Bragg, 1913) (Equation 2.2) describes the angle of incidence 
(θ) required for which X-rays of wavelength (λ) can be diffracted by parallel planes with 
spacing (d) in phase to produce constructive interference (Figure 2.4).   
 




It is clear that for a given plane constructive interference will only occur in some crystal 
orientations relative to the incident beam (angles of θ). Therefore, at a single angle of 
incidence the diffracted X-rays provide a fraction of the total reflections for a crystal. As the 
crystal is rotated in the beam, the angle of incidence changes causing different parallel 
planes to diffract waves in phase and results in different spots to become visible on a 
detector (Figure 2.5).  
Planes will intersect the unit cell at different positions and once a full dataset is collected 
information on every scattering component will be known. Each plane corresponds to a 
distinct spot or reflection and can be assigned Miller indices ‘h, k and l’ describing the 
position that the lattice plane intersects the unit cell. In some instances, the symmetry 
present within a unit cell causes planes that satisfy Bragg’s law to be absent. These are 
named systematic absences and are a result of destructive interference from symmetry 
molecules. Systematic absences can be used during indexing to improve point group 
prediction of a given protein crystal (Rupp, 2010).   
A given reflection can be described by resolution in addition to its Miller indices. A high-
resolution reflection will have a higher scattering angle but will be less intense. The higher 
angle is caused by its lower interplanar spacing, which cause higher resolution spots contain 




experiments collection of high-resolution reflections is desired to gain the most precise 
atomic coordinates possible.  
 
Figure 2.4, Bragg’s law. A diffraction spot will only be detected when Bragg’s law is satisfied for the angle of 
incidence (ɵ) the wavelength (λ) and the distance between parallel planes (d).   
  
Figure 2.5, Protein crystal X-ray diffraction. The image shows the diffraction spots that are the result of 




the centre are higher resolution reflections. White grating pattern in the image indicates the edge of each detector 
module.   
 
2.5 X-ray diffraction data collection  
The aim of data collection in XRC is to accurately determine the positions and intensities of 
reflections from planes that satisfy Bragg’s law to the highest resolution possible. In order 
to do this, there are several physical requirements: an X-ray source, a detector, a goniometer 
and finally a protein crystal.  
X-ray sources can be classed as laboratory generators or synchrotrons. Laboratory 
generators frequently use a rotating-anode that is bombarded by electrons to generate X-
rays, and whilst these generators provide intense X-ray beams, they are substantially weaker 
than synchrotrons. As such, data collection is much slower with an increased likelihood of 
detrimental radiation damage (Rupp, 2010).  
At present, the majority of XRC data is collected at a synchrotron because of the collection 
speed and the tunability of individual beamlines (Helliwell, 2017). Synchrotrons are cyclic 
particle accelerators that generate X-rays using the acceleration and curvature of electrons 
to produce electromagnetic radiation. Briefly, an electron gun generates electrons by 
feeding a high voltage through a cathode. The produced electrons are accelerated, by a 
linear accelerator, before entering a booster ring for a further increase in energy. Once at 
the required energy, electrons are fed into the large storage ring where radio frequency 
generators are used to maintain the electron energy levels. In the storage ring electrons are 
circulated through straight sections connected by bending magnets. These magnets 
produce radiation by imposing a change in the direction of circulating electrons. The 
radiation can be tailored in wavelength and transmission in an optics hutch to facilitate the 
specific experiments taking place at a given beam line. Modern synchrotrons also contain 
insertion devices: undulators and wigglers. These devices are inserted into straight sections 
of the storage ring and an alternating magnetic field results in electron oscillation that emits 
higher energy radiation (Wiedemann, 2015).  
Detectors of diffracted X-rays have developed greatly, transitioning from photographic film 




detectors. Each iteration of detector promises improved signal to noise with faster collection 
and less dead time (Dauter and Wlodawer, 2016). The latest instalment of pixel detectors, 
Dectris Eiger2 X 16M, allows for the collection of a data set in minutes. The speed of modern 
data collection frequently means that the majority of time spent on a modern beamline is 
discerning the data collection strategy to be used rather than the data collection itself. 
As previously discussed, to determine a protein crystal structure, diffraction data must be 
collected through multiple angles of the crystal. To achieve this, crystals are mounted on 
pins which, in turn, are mounted on goniometers. A goniometer functions to rotate a crystal, 
usually along a single Φ axis, during data collection. Modern goniometers exhibit many 
additional axes of rotation including the ω and κ axis as well as translational axis X, Y and Z. 
These allow for improved crystal positioning and the ability to undergo multiple rotational 
axis during data collection that limits radiation damage (Rupp, 2010). 
The precision of modern goniometers allows for rapid data collection at small rotational 
increments (~0.1o). Collection of diffraction images from these small rotations referred to as 
‘fine slicing’ which contrasts to ‘wide slicing’ where larger ~1o rotations are used. Using 
smaller rotational increments to capture the diffraction image has two main benefits. First, 
it removes the likelihood that overlapping reflections will be generated on a single image. 
Second, each reflection will be partially observed over a number of images and the total can 
be more accurately estimated while improving signal to noise (Dauter, 2017).   
Clear advancements in X-ray source, detectors and goniometer have allowed for collection 
of higher resolution data in faster times. The final physical requirement for X-ray diffraction 
is the protein crystal itself. Whilst it is not possible to technologically improve a protein 
crystal, advancements have been made in the way crystals are handled. During data 
collection the high-intensity X-rays cause radiation damage to protein crystals. In order to 
limit the damage, cryocooling can be used. Protein crystals will be flash-cooled and stored 
in liquid nitrogen (63 – 77.2 K). For data collection to proceed, crystals are transferred from 
a liquid nitrogen container into the beam path. In this position a cryostream of cooled 
nitrogen gas is flowed over the crystal. 
The process of flash-cooling, while important for limiting radiation damage, may have 




will this lead to potential disruption of unit cell stacking but it can lead to characteristic ice 
rings on collected diffraction images. These rings saturate the detector making identification 
of diffraction spots unachievable. To overcome ice formation the speed of cooling must be 
kept to a minimum to produce amorphous ice instead of crystalline ice. Cryoprotects, such 
as glycerol and poly-ethylene glycol, are also frequently used before flash-cooling to replace 
water content of crystals reducing the likelihood of crystalline ice formation.  
Aside from the physical requirements for collection several parameters must be considered 
to optimise the collection process. These include the exposure time, transmission, beam 
size, wavelength, number of images to collect and distance to the detector. It is through 
adjustments of these parameters that collection of the highest resolution data while limiting 
the radiation damage to the crystal. Modern synchrotrons have pipelines that feed test shot 
data into software such as EDNA (Incardona et al., 2009) to provide estimates for the best 
data collection strategy. 
  
2.6 Data processing  
2.6.1 Reduction 
Once X-ray diffraction data has been collected it can be processed. There are four 
components to data processing, these are spot finding and indexing, integration, scaling 
and merging.  
Spot finding and indexing provide estimates of unit cell dimensions and indications of the 
crystallographic symmetry. These processes are automated by programmes including 
MOSFLM (Battye et al., 2011), XDS (Kabsch, 2010) and DIALS (Waterman et al., 2016) and 
hence are usually referred to as autoindexing. First, spots are distinguished from 
background radiation and their position on the 2-dimensional detector is recorded. Each 
spot will be assigned Miller indices ‘h, k and l’ which describes the lattice plane that has 
generated that specific reflection. Initially autoindexing uses a primitive triclinic cell (P1) as 
all diffraction for a chiral molecule can be assigned to group. Once indexed it is possible to 
identify if higher orders of crystal symmetry are present. This is done by scoring the data on 
how well they fit different point groups and Bravais lattices based on unit cell restraints 




MOSFLM, XDS and DIALS also record the intensity of each spot in the integration process. 
Intensities can be calculated by summation or profile fitting. Summation involves adding all 
pixel values that form a given spot, while profile fitting aims to model the profile of a spot 
as a smooth curve and then calculates the area underneath. Profile fitting will also, in the 
case of fine slicing, estimated the curve by combining the values pixels over to course of 
several images where partial reflections are observed. The calculated intensity values from 
either method are then subtracted from background radiation (Powell, 2017).  
Intensities of the integrated spots will be non-uniformed. This is due to variation in a number 
of factors during data collection. These factors include X-ray beam intensity, crystal radiation 
damage, anisotropic absorption of the crystal and movement of position in the beam. As a 
result, the recorded intensities need to be adjusted or ‘scaled’ in order to account for these 
variations seen in data collection. Scaled data can then be merged by averaging the 
observed intensity of each reflection across a number of images in order to obtain a value 
that is closer to the true value of the reflection. Aimless (Evans and Murshudov, 2013) is the 
most widely used programme that can both scale and merge data.  
It is important to note that much of these data reduction processes at modern synchrotrons 
have been automated in pipelines that included xia2 dials, xia2 3dii (Winter, 2010), 
autoPROC (Fodje et al., 2014) and FastDP (Winter and McAuley, 2011), such that minutes 
after data collection results from several pipelines will be provided.  
2.6.2 Quality of data 
After merging, the quality of reflection data is assessed. Reflections are organised into bins 
or resolution shells which contain reflections within a certain resolution range. This is 
necessary as reflections at a higher resolution are weaker and must be analysed 
independently of other reflections to accurately determine a resolution cut-off. Several 
statistics are used to assess the quality of each resolution bin and the data as a whole. A 
resolution cut-off can be determined from this information and applied to the data. This 
cut-off will exclude noise from the data that can otherwise negatively affect the calculated 
electron maps. 
R-factors have been the most common measures of data quality. Rmerge (Equation 2.3) and 




Specifically, the discrepancy of each intensities (I) for a given reflection (hkl) compared with 
the mean of that reflection where ‘N’ is number of symmetry related partners. Modern 
collection techniques frequently use high multiplicity strategies because the more a 
reflection is observed the more precise the intensity estimation. This is problematic when 
using Rmerge and Rmeas given that they both increase with multiplicity and therefore provide 
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Rpim (Equation 2.5) on the other hand, describes the precision of the averaged intensity 
measurement while also taking into account the multiplicity of the data. So unlike Rmerge and 
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In addition to R-factors, there are several other measures of data quality that can be used 
to determine a data resolution cut-off. The signal to noise measure (Equation 2.6) is 
calculated for each reflection (hkl) and the average intensity over symmetry mates (Ihkl) is 




highest resolution shell as intensities remain significantly higher than the noise (Evans and 
Murshudov, 2013).  
 














A more recent statistic that is described as a better indicator of data quality is CC1/2 (Equation 
2.7).  This statistic first separates the recorded intensity measurements into separate 
resolution bins and then multiple measurements of the same reflection are randomly 
separated into two bins of equal size.  A Pearson correlation coefficient (CC) is then 
determined for agreement between the two bins of measurements (Karplus and Diederichs, 
2012; Wang et al., 2017). At low resolutions CC1/2 is close to 100%. Higher resolution bins 
will have a lower CC1/2 as the data will contain more noise. Commonly data cut-off will be 
applied at a resolution where CC1/2 falls below 30% (Evans, 2006; Karplus and Diederichs, 
2012) but there are suggestions that it should go to 10% in the outer shell (Karplus and 
Diederichs, 2015). However, there are examples where including data below the a CC1/2 of 
27% does not provide additional structural information (Evans and Murshudov, 2013).  
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To determine a resolution limit for a data set it is necessary to review multiple data quality 
statistics. There is a balance to be had when it comes to determining a resolution cut-off. It 




statistics. However, removal of weak reflections is throwing out valuable information that 
ultimately may improve the structure. These data reduction statistics, with data collection 
parameters and unit cell parameters, are usually included in any XRC reported as 
‘crystallographic data statistics’. 
 
2.7 Structural determination 
Once diffraction data are collected and have been processed in a manner that yields the 
most information, the election density equation (Equation 2.8) can then be used to 
determine the 3-dimensional distribution of electron density for all atoms [p(xyz)] within the 
unit cell. However, in order to determine electron density, it is necessary to determine the 
structure factors. 
 











The structure factors for each reflection, with a given Miller index (hkl), have both amplitude 
[F(hkl)] and phase [φ(hkl)] components. Using the Fourier transform [e-2πi(hx+kx+lz)] these 
structure factors can be converted into an electron density map. The amplitude for a given 
reflection is proportional to the square root of intensity which is measured during X-ray 
diffraction data collection. However, the phase component of the diffracted waves is lost 
during data collection and must be estimated. This absence of phase information is often 
referred to as the ‘phase problem’ (Taylor, 2003) and methods to solve a structure through 
phase estimation or otherwise are discussed below. 
2.7.1 Patterson methods 
The structure of small molecules can be determined without phase information using the 




zero. Using just the recorded intensities a Patterson map can be generated that reveals the 
interatomic distances of atoms within the unit cell which can be used to determine real 
space atomic positions. However, as the number of atoms (N) within the unit cell increases 
as does the number of peaks present on a Patterson map by N(N-1). As such, the method 
can only be used for structures where N < 50 (Cowtan, 2003). 
2.7.2 Direct methods 
Direct methods are named because phases are estimated directly from the diffraction 
pattern. Structures of small to intermediately (N<100) (Usón and Sheldrick, 1999) sized 
molecules may be solved with the absence of phase information, like via the Patterson 
method, if X-ray diffraction data is collected to a high resolution (~1.2 Å or better). High-
angle diffraction spots give information about features of the unit cell that can be used to 
reconstruct the phases via the mathematical relationship between phases and structure 
factors. This method relies on prior knowledge of electron density – electron density cannot 
be negative, and it is generally organised into spheres around atomic peaks.   
Generally, the structure factors are calculated for a set of strong reflections. Once a set of 
structure factors are known this information, due to the phase relations between structure 
factors, can be used to quickly estimate the remaining phase information and determine the 
electron density in the unit cell (Rupp, 2010).  
2.7.3 Experimental methods 
The two methods described above can be used for molecules with small to intermediate 
numbers of atoms. However, to determine a protein structure, which contains many 
thousands of atoms, experimental methods can be utilised.  
A common experimental method is multiple isomorphous replacement (MIR) (Perutz, 1956). 
This method compares the diffraction pattern produced from native crystals to crystals 
where known contents have been added to a unit cell. The added contents, commonly heavy 
metal atoms, function as scattering centres which produce a detectable change in the 
intensity of some diffraction spots. By comparing the diffraction patterns, it should be 
possible to identify if the presence of the heavy metal has led to constructive interference 
(more intense spot) or destructive interference (less intense spot). With this in mind, it is 




across the entirety of the protein crystal and should not alter the position of the other atoms 
in the unit cell.  
Comparison to just one type of heavy metal-soaked crystal results in ambiguity as to 
whether unit cell atoms lead or lag the heavy metal atoms. Often several crystals with 
different heavy atoms bound are used to resolve this uncertainty. This allows for an 
estimation of the difference in phase between the heavy metal atoms phase and the 
remaining unit cell atoms to be generated. The position of these heavy metal atoms can 
then be calculated via the Patterson method in order to calculate their respective phase. 
Once the structure factors for the heavy metal atoms have been determined it is possible to 
approximate the phase from the remaining scattered X-rays (Cowtan, 2003).  
Multiwavelength anomalous dispersion (MAD) is the second major experimental method 
used for phasing (Hendrickson, 1991). This method exploits the tuneable wavelengths of 
modern synchrotrons and the absorption edge for specific atoms. An absorption edge is 
the energy at which there is a dramatic increase in the absorption coefficient of X-rays by 
an element. As such, collecting several X-ray diffraction datasets using wavelengths around 
the absorption edge will generate different scattering patterns and the contribution from 
the anomalously scattering atom can be identified. Selenomethionine is frequently used to 
replace methionine for the purpose of MAD. Once the small number of anomalously 
scattering atoms have been identified it is then possible to estimate the phase of the 
remaining atoms like in MIR (Cowtan, 2003).   
2.7.4 Molecular replacement  
The previous methods that have been described are incredibly powerful when no structural 
information is available for a protein of interest. However, when structural information is 
known, such as when the protein of interest is similar to another protein either in function 
or sequence identity, then molecular replacement can be used. The aim of molecular 
replacement is to position a probe into the unit cell in a way that would produce 
hypothetical diffraction data identical to that of the experimental diffraction data.  
Before molecular replacement can be used it is necessary to identify the symmetry and unit 
cell dimensions that exist within your protein crystal. Estimations of these parameters can 




within an asymmetric unit must also be known and can be estimated using Matthews 
coefficient (Matthews, 1968). In addition to information regarding the crystal geometry an 
appropriate probe must also be selected. If a protein has high sequence similarity to another 
protein, then that entire protein may be used as the probe. If no close homologues are 
available, the choice of probe may require careful thought and involve using smaller 
fragments of proteins. Once an appropriate probe is selected several programmes such as 
Phaser (McCoy et al., 2007) or MOLREP (Vagin and Teplyakov, 2010) are available for 
molecular replacement.  
The process of molecular replacement can be separated into four stages: 
1. A rotational search for the probe so that it is parallel to the displaced 
molecule 
2. A translation search for the probe so that it is in the position of the 
displaced molecule.  
3. The generation of a hypothetical model of the protein of interest based 
on the search model 
4. Refinement of the model using diffraction data collected for the protein 
of interest 
A given macromolecule will have a set of intra-atomic (self-molecule) and inter-atomic 
(symmetry molecules) vectors. In general, the intra-atomic vectors will be shorter and can 
be separated from the inter-atomic vectors. A Patterson map of the intra-atomic vectors is 
used to validate the initial rotational search. When the model is rotated the intra-atomic 
vectors rotate by the same angle. It is possible to rotate the probe until the intra-atomic 
vectors present on a Patterson map align with that of the experimental data (Evans and 
McCoy, 2008). Once the correct rotational orientation has been determined, the probe can 
be translated in the unit cell. Again, the Patterson map, now with inter-atomic vectors 
included, can be used to validate when the probe is in the correct position. By separating 
these searches, the problem becomes one that is possible to solve computationally.  
In addition to Patterson methods for validation of a solution, maximum-likelihood is another 




measuring the probability that the observed diffraction would occur given the position of 
the probe in the unit cell. Like the Patterson method, first rotation of the model is assessed 
before translation. Unlike the Patterson method, errors are incorporated for both the 
experiment and model which gives more robust solutions when compared to the Patterson 
methods. (Read, 2001) 
In recent years, advancements in molecular replacement have enabled phase determination 
of large structures through the use of very small probes often with sizes in the region of ten 
amino acids. Programmes such as Fragon (Jenkins and IUCr, 2018) and Arcimboldo 
(Sammito et al., 2014) are able to achieve this using prior knowledge of the secondary 
structure features of protein macromolecules. For example, α-helices have a very distinct 
electron density shape which can be exploited to model helical peptide fragments. It is also 
possible to model β-strands however the less identifiable density limits the method. After 
initial phases are estimated, model building programmes such as Buccaneer (Cowtan, 2006) 
or ARP/wARP (Perrakis et al., 2001) can then be used to trace the main chain and complete 
the rest of the structure. These methods require high resolution data (<1.7 Å) for the 
electron density to be clear enough to model these small initial small probes.   
As well as advancements in molecular replacement programmes, the number of determined 
protein structures has led to the development in the generation of probes. Ab initio 
modelling exploits the modular nature of protein structures. If the sequence of a protein of 
interest is known but has no obvious structural homologues the protein can be separated 
into shorter segments. The secondary structure of these segments can be predicted by 
searching large databases for similar sequences. The segments can then be linked, and 
energy minimised, in order to create a three-dimensional model for the protein structure. 
Such programmes that are able to build these models include Ample (Bibby et al., 2012) and 
Phyre2 (Kelley et al., 2015).  
In addition to the methods of molecular replacement described above several molecular 
replacement pipelines, including Balbes (Long et al., 2008) and MoRDa (Vagin and Lebedev, 
2015), are also available. Molecular replacement pipelines require only a protein sequence 
and integrated diffraction data and can generate appropriate probes before attempting to 
determine the phases for the structure. The programmes and pipelines currently available 




proteins have no homologues or may undergo large conformational changes, that 
molecular replacement may present a greater problem.     
 
2.8 Refinement and validation 
Once the phases for the macromolecular structure have been estimated and an initial model 
of the structure has been constructed, model refinement can take place. This process 
involves alteration of the modelled structure with the aim to improve the agreement with 
the observed structure factors while satisfying chemical requirements for bond lengths, 
angles and atomic interactions.  
In structural refinement the calculated structure factors from the model are compared with 
the observed structure factors from the protein crystal. This can be visuallised using electron 
density maps 2Fo-Fc and Fo-Fc where ‘Fo’ refers to the observed structure factors and ‘Fc’ 
to the calculated structure factors based on the model. The Fo-Fc map or ‘difference’ map 
shows differences between the observed and calculated structure factors. Often this map 
provides insight as to whether the model needs additional atoms to account for an area of 
electron density or whether atoms need to be removed due to an absence of electron 
density. 
Real space refinement programmes such as REFMAC5 (Murshudov et al., 2011) and Phenix 
(Adams et al., 2010) use successive cycles to make adjustments to the entire structure, 
improving model agreement with observed data while balancing geometric restraints. The 
weighing of geometric restraints can be manually adjusted. It is common practice to place 
a higher weighting on these restraints when refining lower resolution data as precise atomic 
coordinates are less clear from the data.  
Manually editing the protein model with programmes such as Coot (Emsley et al., 2010) 
allows addition and repositioning of atoms to better fit into electron density. It is often 
necessary to reposition atoms in order overcome an energy minimum that would not be 
overcome in real space refinement programmes. Structural refinement is done over several 




recalculated for the new model and an improved electron density map will be generated.  
Together these can be used to make incremental improvements to the structure. 
During the refinement process it is essential to validate the structure to confirm that the 
refinement stratagy is indeed improving the model.  There are several metrics for structural 
validation. The R-factor or reliability factor (Equation 2.9) is a measure in the correlation 
between the generated crystallographic model and the experimental X-ray diffraction data 
(Rupp, 2010). In real space refinement programmes this is the correlation between 
calculated structure factors to the observed structure factors (Fcal and Fobs). R = 0 when there 
is complete agreement between the calculated and observed structure factors. R ~ 0.59 for 
a completely random arrangement of atoms within the unit cell (Karplus and Diederichs, 
2012). In practice R-factor values never reach zero as all data collected are imperfect and 









It is possible the reduce the R-factor by adding atoms into noise but this will not improve 
the quality of the model. To combat this, the statistic ‘Rfree’ is used during refinement to 
prevent model bias or overfitting into the observered data. Rfree is calculated by excluding 
a small number of reflections (frequently 1000 unique reflections or up to 5% of total unique 
reflections), evenly selected across resolution bins, from the structure calculation. The 
agreement of these reflections to the calculated model is used to provide a measure of the 
overall fit while removing bias.  
In addition to the R-factors, which describe how well the model fits the data, chemical  
restraints must also be considered throughout refinement. The geometry of atoms within 
amino acids, and amino acids within polypeptide chains, have been determined in crystal 
structures with a high degree of accuracy. The geometry of these varies only slightly in 
different protein structures. As such, this prior knowledge allows restraints to be imposed 




data where exact atomic position is not known and restraints help to predict the most likely 
position.  
Bond lengths and angles have been studied in small molecule crystal structures and 
variation is relatively low despite changes in the local environment (Engh et al., 1991). Root-
mean-square deviation (RMSD) is used as a measure of deviation between the ideal angle 
and lengths and those that are modelled. For bond lengths ~0.02 Å is considered good 
quality but above ~0.03 Å may indicate issues in the model (Wlodawer et al., 2008) and for 
bond angles < 2o is desirable (Jaskolski et al., 2007).  
Another common measure of geometry used during refinement are the Ramachandran 
restraints. These restraints are a set of dihedral angles that can be adopted for an amino 
acid given the position of the amino acid previously specified. As atoms in a peptide bond 
lie in a plane, the main chain and Cβ atoms in two adjoining residues can be described by 
two angles – Ψ and Φ (Ramachandran et al., 1963) (Figure 2.6). Only some of these angles 
are energetically possible. The effect of side chains on the allowed Ramachandran angles is 
small with the exception of amino acids glycine and proline. Glycine posesses a side chain 
consisting of a single hydrogen atom. The absence of a Cβ atom allows for a larger range of 
angles to be adopted given the flexibility of the residue. In contrast, proline has a smaller 
range of angles that can be adopted due to the side chain connecting the Cα atom and the 
nitrogen of the amino group. The rigid nature of proline residues also impacts the 
preceeding residue to again limit the number of energetically allowed angles. Based on the 
limited Ψ and Φ angles a Ramachandran plot can be constructed (Figure 2.7). It should be 
noted that Ramachandran assumes fixed bond lengths and bond angles. Sometimes the 
main chain or side chain interactions of a amino acid cause the residue to adopt angles that 
fall outside of the Ramachandran allowed region. This occurs infrequently, and depending 
on protein size may happen up to a few times across the entire structure.  
 
Several other measures should be considered during refinement including rotamer outliers 
and clashscore. After a structure is appropriately refined and validated it can be deposited 




quality of deposited structures can be quickly assessed with the ‘percentage ranks’ statistics 
associated with each structure. 
 
Figure 2.6. Ramachandran restraints. The atoms of a peptide bond exist in a plane, the remaining bonds within 
an amino acid can be described with two dihedral angles Ψ and Φ. Only some angles of Ψ and Φ are 






Figure 2.7, Ramachandran plot. The Ψ and Φ angles for a given amino acid can be plotted onto a Ramachandran 
plot. Areas of the plot will be favoured, allowed or unfavoured based on Ψ and Φ angles restraints. Amino acid 
residues glycine and proline are mapped on alternative Ramachandran plots because of their alternative flexibility 











This chapter describes the expression, purification and crystallisation of the neprilysin 
substrate-free crystal structure. The resulting substrate-free crystal structure is included as 
a published manuscript - Moss S, Subramanian V & Acharya KR (2018) High resolution crystal 
structure of substrate-free human neprilysin. J. Struct. Biol. 204, 19–25. More extensive 
background work has been described as a commentary text in addition to a more detailed 
introduction with the aim of providing greater context to the work within this thesis. A 




Neprilysin (NEP, EC 3.4.24.11) is a transmembrane zinc metalloprotease composed of 749 
amino acids spread across three domains. Short intracellular and transmembrane domains 
contain 27 and 23 amino acids respectively, while the large catalytic extracellular domain 
contains 699 amino acids (Figure 3.1).  
 
Figure 3.1. NEP domain organisation and known glycosylation sites. Glycosylation site 335 is predicted but has yet 
to be supported by experimental evidence. 
 
To date, eight inhibitor-bound NEP extracellular domain crystal structures have been 
reported (Oefner et al., 2000; Oefner et al., 2004; Sahli et al., 2005; Oefner et al., 2007; 
Glossop et al., 2011; Schiering et al., 2016). These structures have revealed the domain is 
ellipsoid in shape and composed largely of α-helices (Figure 3.2a). Structural data has also 




which has been investigated through mutagenesis experiments. Removal of these four sites 
completely eliminates NEP activity, however activity can be restored close to maximal with 
glycosylation at either N144 or N627 (Lafrance et al., 1994; Sato et al., 2012). Detailed 
structural studies have further revealed the presence of a large enclosed cavity located at 
the centre of NEP. It is inside this cavity that the catalytic site is located, and substrate 
cleavage takes place.  
The catalytic site of NEP is based around the conserved HXXEH zinc binding motif (Cerdà-
Costa and Gomis-Rüth, 2014) (Figure 3.2b). Here a zinc ion is coordinated by conserved 
residues H583 and H587 in addition to residue E646. The conserved E584 residue is 
positioned above the zinc ion and is responsible for the generation of hydroxide ions in the 
proposed catalytic mechanism. 
 
Figure 3.2, The extracellular domain of NEP. (a) cartoon illustration of NEP with four confirmed glycosylation sites 
indicated in red. (b) the catalytic site of NEP located around a zinc ion shown in cyan. Here, conserved residues 
H583 and H587, in addition to E646, coordinate the zinc ion. Conserved E584 is involved in the proposed catalytic 
mechanism.  
The eight published NEP inhibitor-bound structures have been used to characterise inhibitor 
binding. Inhibitors of NEP are peptide-like and display a similar mode of binding at the 




interactions to proximal NEP residues. The peptide-like nature of NEP inhibitors can also 
provide information on likely interactions involved in substrate binding. While much 
information has been gained from these structures, the dynamics involved in binding remain 
unclear. Does binding induce any domain or specific conformational changes, or does 
binding have a requirement for active site flexibility? These questions make determination 
of a substrate-free structure desirable. A substrate-free structure would provide information 
on the protein in an unbound state which, through comparison with the bound form, could 
reveal any movements that occur as a result of substrate or inhibitor binding. 
There is a second basis for which a substrate-free structure is desirable. To date, all 
structures of inhibitor-bound NEP have been determined in a closed conformation. In this 
form, the central cavity is occluded and inaccessible to substrates. It is unclear whether the 
observed closed conformation is induced by inhibitor binding, a symptom of crystal packing 
or the natural conformation that exists in solution. With a substrate-free structure it would 
be possible to identify if ligand-binding was responsible for the observed closed protein 
conformation. 
3.1.2 Protein expression in Pichia pastoris 
Structural investigation using X-ray crystallography requires large amounts of protein (>1 
mg) in order to screen conditions for protein crystallisation. Four major expression systems 
are available for production of recombinant proteins (Palomares et al., 2004). These are 
bacterial, yeast, insect and mammalian. It is common practice to first explore expression in 
bacterial systems due to the fast culture growth, simple culture conditions, low cost and 
high quantity of protein production. Despite the advantage’s, bacterial systems are 
frequently inappropriate for protein expression particularly those of eukaryotic origin. This 
is largely due to solubility issues or the absence of correct post-translational modifications. 
NEP is a glycosylated protein that has been shown to require glycosylation for activity. It is 
most likely that glycosylation is required during protein folding and the absence of which 
does not produce a biologically relevant protein suitable for experimental studies. Because 
of this, expression of NEP in a bacterial system is inappropriate and previously published 
crystal structures of NEP have generated the protein in yeast or insect expression systems 




Pichia pastoris is a yeast expression system commonly utilised to produce glycosylated 
mammalian proteins. The expression system is well documented and commercially available 
from Invitrogen (EasySelect Pichia Expression Kit). Protein expression in P. pastoris is 
achieved by integrating the gene of interest into the genome under control of the alcohol 
oxidase (AOX1) promoter (Ellis et al., 1985; Cregg et al., 1993). Protein expression is then 
induced when methanol is added to the growth media. Proteins expressed in P. pastoris 
benefit from a higher eukaryotic protein processing, protein folding and post-translational 
modifications. Another main benefit of protein production in P. pastoris is the produced 
protein can be secreted. The low levels of natively secreted proteins can assist in the ease 
of purification.  
P. pastoris has a large advantage over other yeast systems due to the lack of 
hyperglycosylation. Common baker’s yeast, Saccharomyces cerevisiae, adds 50-150 
mannose residues to an appropriate asparagine site (Asn-X-Ser/Thr) compared to the 8-14 
residues observed in P. pastoris (Tschopp et al., 1987; Grinna and Tschopp, 1989). The 
reduced level of glycosylation is beneficial when attempting to crystallise a protein of 
interest. In general, the presence of large flexible sugar chains on the outside of a protein 
may greatly reduce the propensity for crystallisation through reduction in the number of 






All reagents for expression and purification were sourced from Sigma-Aldrich or Fisher 
Scientific unless otherwise specified. 
3.2.1 General experimental methods 
All buffers were made in-house unless otherwise stated. The pH of buffers was determined 
using a Jenway 3510 pH meter and a Jenway pH temperature electrode. The pH for all 
buffers was measured at 18oC. Calibration of the pH meter was performed using buffer 
standards at pH 4, 7 and 10 sourced from Fisher Scientific (product numbers 10427260, 
10000642, 10774074).  
Aseptic technique was used when manipulating any microorganism to avoid contamination. 
This work was performed next to an open flame using sterile plasticware, glassware and cell 
growth media. Sterile plasticware including falcon tubes, petri-dishes and cell spreaders 
were purchased. Glassware and cell growth media were autoclaved in-house unless stated 
otherwise. Sterilisation by autoclave was performed at a minimum temperature of 121oC for 
30 minutes at 15 psi. Filter sterilisation of solutions was performed by filtering through a 
0.22 µm filter membrane (Millipore) into a sterile container next to an open flame.  
3.2.2 Buffers 
P. pastoris growth media   
Yeast Extract Peptone agar 
(YPD agar) 
1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose 
and 2% (w/v) agar 
1 M potassium phosphate 
buffer, pH 6.0 
 
132 ml of 1 M K2HPO4, 868 ml of 1 M KH2PO4 (pH 6.0, 
adjusted with phosphoric acid or KOH) 
Buffered complex medium 
containing glycerol (BMGY) 
1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer (pH 6.0), 1.34% (w/v) yeast 
nitrogen base, 4 × 10-5% (w/v) biotin and 1% (v/v) glycerol. 
Yeast nitrogen base, biotin and glycerol were filter sterilised 
and added to the other components which had been 
autoclaved. 
Buffered complex medium 
containing methanol (BMMY) 
1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer (pH 6.0), 1.34% (w/v) yeast 
nitrogen base, 4 × 10-5% (w/v) biotin and 0.5% (v/v) 




filter sterilised and added to the other components which 
had been autoclaved. 
SDS-PAGE buffers   
20x Tris-MOPS running buffer 1.2 M Trizma base, 0.6 M MOPS, 2.0% (w/v) sodium dodecyl 
sulfate. 
 
4x SDS-PAGE sample buffer 250mM Trizma base (pH 6.8, pH adjusted with HCl), 10% 
(w/v) sodium dodecyl sulfate, 0.008 % (w/v) bromophenol 
blue, 0.588 M β-mercaptoethanol, 40% (v/v)glycerol. 
Purification buffers  
Binding buffer 25 mM Trizma base, 150 mM NaCl, 2 mM MgCl2 (pH 7.5) (pH 
adjusted with HCl). 
 
Elution buffer 25 mM Trizma base, 150 mM NaCl, 2 mM MgCl2, 500 mM 
imidazole (pH 7.5) (pH adjusted with HCl). 
 
Crystallisation buffer  
JCSG-plus A12 (Molecular 
Dimensions) 
0.2 M potassium nitrate and 20% (w/v) PEG3350 
Table 3.1, Growth media and buffers required for the expression, purification and crystallisation of NEP. 
3.2.3 NEP P. pastoris clone 
A clone of P. pastoris GS115 containing a gene encoding the NEP extracellular domain 
(residues Tyr51-Trp749) was purchased from Invitrogen. The gene was integrated into the 
genome under control of the AOX1 promotor. The integrated gene also encoded an N-
terminal 6x histidine tag and signal secretion sequence that would be cleaved after protein 
secretion had occurred.   
3.2.4 Protein expression  
Expression of the P. pastoris clone was done in accordance with the Invitrogen EasySelect 
expression manual (cat. no. K1740-01). A YPD agar plate was inoculated with the glycerol 
stock. The plate was incubated for 48 hours at 30 ºC to establish colonies of the P. pastoris. 
A single colony was used to inoculate a starter culture containing 25 mL of BMGY media in 




of the overnight culture was used to inoculate a 250 mL BMGY media in a 2 L baffled flask. 
The main culture was incubated at 30 ºC and 225rpm for 24 hours. 
After 24 hours the main culture was transferred to 500 mL centrifuge tubes which were spun 
at 6000 RCF for 20 minutes at 19 ºC. The supernatant was discarded, and the cell pellet was 
resuspended in 250 mL of BMMY media for induction. Resuspended cells were transferred 
to a new 250 mL baffled flask. The culture was then incubated for 72 hours at 30 ºC 225rpm. 
Every 24-hours 2.5 mL of 50% (v/v) methanol was added to each 250 mL culture. 
After 72 hours of induction the main culture was transferred to a 500 mL centrifuge tubes 
and spun at 6000 RCF for 20 minutes at 19 ºC. The supernatant was collected, and the cell 
pellet was discarded. Solid Trizma base and NaCl were added to the supernatant to give 
final concentrations of 25mM Trizma and 150mM NaCl. The supernatant was mixed with 
magnetic stirrer for 10 minutes at room temperature. After this time the supernatant showed 
some precipitation which was removed by flowing through a 0.22 µm filter (Millipore). The 
final filter supernatant had a pH of ~7. 
3.2.5 Protein purification 
The buffer equilibrated P. pastoris supernatant was loaded onto a 5 mL HisTrap HP affinity 
column (GE Healthcare Life Sciences) at 2 mL/min pre-equilibrated with binding buffer. 
Following loading, the column was washed with binding buffer until the UV trace returned 
to baseline. A gradient elution (0 – 100 % over 30 minutes) of elution buffer at 5 mL/min 
was used to elute the bound protein. This method was later optimised to a stepwise elution. 
For this 2% elution buffer was used to wash the column until UV trace stabilised. Bound 
neprilysin was eluted using a single step of 50% elution buffer and 2 mL fractions were 
collected. 
Protein containing fractions were confirmed using SDS-PAGE gel electrophoresis. These 
fractions were concentrated to under 2 mL in a centrifuge at 4000 RCF using a 30kDa 
molecule weight cut off (Millipore) filter unit. The concentrated protein containing sample 
was then loaded at 5 mL/min onto a HiPrep 26/10 Desalting column (GE Healthcare Life 
Sciences) pre-equilibrated with binding buffer. Alternatively, a Superdex 16/60 was used, 
pre-equilibrated with binding buffer at 1.5 mL/min. Protein containing fractions were stored 




3.2.6 SDS-PAGE gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
determine purity of protein samples and approximate protein molecular weights. Poly 
acrylamide gels ‘TruPAGE Precast Gels 10%’ (Sigma-Aldrich) were used with 1x Tris-MOPS 
running buffer.  
Protein samples were added to SDS-PAGE sample buffer (1x final concentration) and were 
electrophoresed with ‘Pageruler Plus Prestained Protein Ladder’ (ThermoFisher) or ‘Protein 
Marker Broad Range 2-212 kDa’ (New England BioLabs). Electrophoresis was conducted 
using a constant 150v for 45 minutes or until the dye front reached the bottom of the gel. 
Poly acrylamide gels were stained in SimplyBlue SafeStain (ThermoFisher) and destained in 
distilled H2O.  
3.2.7 Mass spectrometry 
Purified NEP was buffer exchanged into water and made to 1 mg/mL for HPLC using a 
centrifuge filter unit with a 30kDa molecule weight cut off (Millipore). The Chip-based 
analysis was conducted using an HPLC-Chip Cube system coupled to a 6520 quadrupole 
time-of-flight (QTOF) mass spectrometer (Agilent Technologies, Santa Clara, CA) operated 
in ESI positive-ion mode. Liquid chromatography was performed using a Protein-Chip (II) 
with a 40 nL enrichment column and analytical column of 43 mm x 75 µm with Zorbax 
300SB-C8 packing material at 5 µm (G4240-63001, Agilent, Santa Clara, CA). The ChipCube 
source was operated at 365 ºC with 5 L-1 N2 drying gas, the capillary voltage set to 2100V 
and fragmentor at 400V. The source was interfaced with an Agilent 1260/1200 series HPLC 
system consisting of a 1260 Cap pump, 1200 Nano pump, 1200 Micro WPS and 1290 Infinity 
Thermostat (Agilent, Santa Clara, CA). Between 0.2 and 1 µL samples were loaded onto the 
enrichment column using the capillary pump flow with H2O + 0.1 % (v/v) formic acid at a 
flow rate of 4 µL/min. The samples were eluted onto the analytical column using the nano 
pump at a flow rate of 0.6 µL/min. Solvent A and B consisted of H2O + 0.1 % (v/v) formic 
acid and acetonitrile:H2O 90:10 with 0.1 % (v/v) formic acid. Gradient steps were as follows: 
0-4 min from 3 % B to 50 % B, 4-5 min to 100 % B, 5-11 min 100 % B, 11-12 min from 100 
% to 3 % B. Internal lock mass calibration during the run was done using one calibration 
reference mass at 1221.9906 m/z. Data processing was performed using the Masshunter 





Deglycosylation of NEP was conducted using the Endoglycosidase H (Endo H, Cat. No. 
P0702S NEB). Deglycosylation experiments were conducted in accordance with the user 
manuals under either native or denaturing conditions. 
Native: 20 µg purified NEP was combined with 2 µl Endo H (1000U) and 4 µL 10x Glycobuffer 
3 (NEB) before making up to 40 µL with H2O. The solution was incubated 37ºC for two hours 
before the sample was analysed using gel electrophoresis.  
Denaturing: 20 µg purified NEP was incubated at 100ºC for 10 minutes in 1X Glycoprotein 
denaturing buffer (NEB). After cooling, the solution was combined with 2 µL Endo H (1000U) 
and 4 µL 10x Glycobuffer 3 (NEB) before making up to 40 µL with H2O. The solution was 
incubated 37ºC for two hours before the sample was analysed using gel electrophoresis. 
3.2.9 Cleavage assay 
Fluorogenic substrate Mca-RPPGFSAFK-(Dnp) (Enzo Life Sciences) was used to confirm the 
expressed NEP protein displays protease activity. The 7-methoxycoumarin (Mca) group is 
efficiently quenched by resonance energy transfer to the 2,4-dinitrophenyl (Dnp) group. 
Peptide cleavage of an amide bond between the two groups allows fluorescence of the Mca. 
Fluorescence was assessed using a CLARIOstar high-performance microplate reader (BMG 
LABTECK). Excitation of the Mca group was achieved at 328 nm and emission was detected 
at 393nm and readings were taken at 15 second intervals for varied total durations. 
Mca-RPPGFSAFK(Dnp) was dissolved in DMSO to 1 mM and stored at -20 ºC. For the 
cleavage assay, 50 µL of purified neprilysin (varied concentrations) was added to a black 96 
well microplates (Greiner Bio-One). Mca-RPPGFSAFK(Dnp) DMSO stock was diluted to 20 
µM in purification binding buffer for NEP. 50 µL of Mca-RPPGFSAFK(Dnp) was added to the 
well, to give a final concentration of 10 µM using the CLARIOstar inbuilt injection needle. 
This provided mixing of the components. 
Assays were repeated three times where sample availability permitted. Assay data is shown 
after subtraction of baseline fluorescence using 10 µM Mca-RPPGFSAFK(Dnp). Assay figures 





Purified NEP was concentrated by centrifugation at 4000 RCF to 4 - 12 mg/mL using 
centrifuge filter unit with a 30kDa molecule weight cut off (Millipore). Concentrations were 
determined using a NanoDrop (Thermo Scientific) and the extinction coefficient of 1.57 
(A0.1%280 value) for NEP (calculated using ProtParam). A pre-crystallisation test (Hampton 
research, Cat. No. HR2-140) was used to confirm a concentration of 7.5 - 12 mg/mL was 
appropriate for crystallisation screening. 
Initially crystallisation conditions were screened using a sitting-drop vapour diffusion set up 
with 96-well screens (Molecular Dimensions). Sitting drop crystallisation screens were 
performed using a robot (Phenix, Art Robbins Instruments, USA), 96-well plates (Intelli-plate, 
Art Robbins Instruments) and ClearVue plate seals (Molecular Dimensions). 50 µL of 
crystallisation screen was used for the reservoir solution. The sitting drop was formed from 
0.18 µL of protein and 0.18 µL of reservoir solution. Plates were incubated at 18 ºC and 
checked weekly for crystal formation. 
24-well hanging drop crystallisation screens were used to optimise conditions that showed 
crystal formation in the 96-well screens. Hanging drop screens were performed with 24-well 
plates (Greiner Bio-One) with glass cover slide (Greiner Bio-One) and high-performance 
vacuum grease (Dow Corning). 500 µL of screen condition was used as the reservoir solution. 
The hanging drop was formed from 1 µL of protein and 1 µL of reservoir solution. Plates 
were incubated at 18 ºC and checked weekly for crystal formation. 
3.2.11 Synchrotron data-collection and processing 
Protein crystals were harvested using micro loops of 20 µm to 400 µm in diameter 
(MiTeGen). Looped crystals were flash-cooled in liquid nitrogen and transferred to Diamond 
Light Source (Didcot, UK) for the collection of X-ray diffraction data. Beamlines i03 and i04 
were used to collect the X-ray diffraction data and were fitted with PILATUS-6M detectors 
at the time of collection. 
Strategies for data collection were determined using three test shots at 45º degree 
increments and software package EDNA (Incardona et al., 2009). Between 3600 - 9999 
images with 0.1º of oscillation were collected for a full data collection. The raw X-ray 




scaled and merged using AIMLESS within the CCP4 suite (Evans et al., 2013;Winn et al., 2011). 
During scaling, bad images were removed and a resolution cut off was applied based on 
statistics generated from AIMLESS (Evans et al., 2013). 
Edge scans were conducted on i04 by exploiting the variable wavelength. Specifically a zinc 
metal scan was conducted between 9559-9749 eV and CHOOCH (Evans and Pettifer, 2001) 
was used to plot the anomalous-scattering factors f′′ and f′.  
3.2.12 Structure model building and refinement 
Phaser (McCoy et al., 2007) was used to perform molecular replacement using structure 
5JMY  (Schiering et al. 2016) on the merged and scaled data from AIMLESS. Structural 
solutions from Phaser were assessed using the LLG score and visual inspection of electron 
density maps. After Phaser, the structure factors and initial coordinates were refined using 
a combination of REFMAC5 (Murshudov et al., 2011) and Phenix refine (Afonine et al., 2012) 
from the Phenix suite (Adams et al., 2010). Visualisation and alteration of the protein 
structure was done using Coot (Emsley et al., 2010). Refinement of the protein structures 
was performed until successive round of refinement failed to improve R-factor statistics. 
Programmes MolProbity (Chen et al., 2010) and PDB validation (Berman et al., 2003) were 
used to assess any stearic and geometry outliers within the modelled structure. Figures were 






3.4.1 Expression and purification 
A clone of P. pastoris GS115 containing a gene encoding the extracellular domain of NEP 
(residues Tyr51-Trp749) was purchased from Invitrogen. The gene had been integrated into 
the genome under control of promoter AOX1 and contained an additional N-terminal 
histidine tag and secretion signal. A protocol for recombinant protein expression in P. 
pastoris is included in the Invitrogen EasySelect expression manual (Cat. No. K1740-01). 
Briefly, expression begins with a 25 mL overnight culture inoculated from an agar plate. The 
overnight culture is used to inoculate a 1 L expression culture in growth media (BMGY). After 
16-24 hours the expression culture is centrifuged and resuspended in the same volume of 
induction media containing 0.5% (v/v) methanol (BMMY). After every 24-hours 2.5 mL of 
50% (v/v) methanol is added to maintain the 0.5% (v/v) concentration until the supernatant 
is harvested.  
The described expression protocol provides a guideline for protein expression but through 
parameter modification protein production can be increased. Target parameters included 
cell density prior to induction, volume of induction media and methanol concentration. 
These parameters were investigated using smaller 250 mL expression cultures to optimise 
protein expression before beginning large scale expressions. The varied expression 
conditions are shown in Table 3.2. The expressed NEP contained a secretion tag, as such, 
quantity of protein expressed was determine by sampling the supernatant before and after 
induction and analysing samples with SDS-PAGE gel electrophoresis (Figure 3.3).  
Pre-induction supernatant samples contained no observable protein bands on an SDS-PAGE 
gel. The post-induction supernatant samples all contained a band present at ~100 kDa. 
While the calculated mass of the NEP extracellular domain is 81.8 kDa, the presence of 
glycosylation was expected to increase the observed molecular weight. As four N-linked 
glycosylation sites for NEP are known, and P. pastoris commonly adds 8-14 sugars per site, 
the total mass was expected to be 6 – 10 kDa larger than just the protein mass alone. The 
additional mass and the absence of protein bands in pre-induction samples strongly 




While all expression conditions contained this band corresponding to NEP, expression levels 
varied. Equally intense bands were observed in the conditions 1 and 3. Condition 2 had a 
less intense NEP band and several other bands were present that may correspond to 
degradation products. Neither changes to induction volume in conditions 4 nor 5 improved 
protein expression over standard conditions. Based on this, condition 1 was selected for 
future protein expressions.  
Condition 1  2   3 4 5 
Inoculation volume (mL) 10 40 10 10 10 
Cell growth media (BMGY) volume (mL) 250 250 250 250 250 
Cell induction media (BMMY) volume (mL) 250 250 250 500 125 
Methanol concentration (%, v/v) 0.5 0.5 1.0 0.5 0.5 
Table 3.2, NEP protein expression optimisation in P. pastoris. Five different expression conditions were screened to 
determine if variation in cell density prior to induction, volume of induction media and methanol concentration 
resulted in greater protein production. 
 
 
Figure 3.3, NEP expression optimisation in P. pastoris. Supernatant samples taken from expression cultures before 
and after induction are analysed using SDS-PAGE gel electrophoresis. A band corresponding to NEP is present at 
~100 kDa and is observed at varying levels in all conditions post induction.   
NEP expression was repeated on a larger scale and a suitable purification method was 





the first purification step was performed by loading the harvested supernatant onto a 
histidine trap affinity column (GE Healthcare). The bound protein was eluted using a 
gradient of imidazole containing elution buffer. A single protein peak corresponding to NEP 
and was eluted at approximately 15% elution buffer. This gradient elution was later switched 
to stepwise elution to reduce purification time and elution volume. The stepwise elution 
contained a wash step of 2% elution buffer followed by a protein elution step of 50% elution 
buffer (Figure 3.4).  
 
 
Figure 3.4, NEP histidine affinity trap purification. The protein containing supernatant from a P. pastoris culture 
was loaded onto a histidine affinity trap column (GE healthcare). Once loaded the column was washed with binding 
buffer followed by a wash step of 2% elution buffer. Protein elution was achieved at 50% elution buffer. A single 
peak was observed and peak containing fractions (indicated between dash lines) were pooled.    
Peak containing fractions from the histidine affinity column were observed to be light brown 
in colour, similar to that of expression growth media. While SDS-PAGE gel electrophoresis 
revealed the protein was pure after the histidine affinity column purification step (Figure 
3.7), discolouration in the fractions indicated unknown components were present. As the 
purified protein was intended for crystallisation trials, knowledge of the exact composition 
of the protein buffer was required to ensure the repeatability of future crystallisation hits. A 
second purification step was therefore performed using a HiPrep 26/10 desalting column 
(GE Healthcare) in order to buffer exchange the sample (Figure 3.5). This second purification 




(GE Healthcare) to improve purity (Figure 3.6). Both secondary purification steps were 




Figure 3.5, NEP buffer exchange purification. The pooled fractions eluted from the histidine affinity trap column 
were loaded onto a HiPrep 26/10 desalting column to remove impurities from the induction media and to buffer 
exchange the protein into binding buffer. A single peak was observed and peak containing fractions (indicated 
between dash lines) were pooled.    
 
Figure 3.6, NEP size exclusion purification. The pooled fractions eluted from the histidine affinity trap column were 
loaded onto a Superdex 16/60 size exclusion column to remove impurities from the induction media and to buffer 
exchange the protein into binding buffer. A single peak was observed and peak containing fractions (indicated 





Figure 3.7, NEP expression and purification in P. pastoris. SDS-PAGE gel electrophoresis was used to analyse 
samples taken during NEP expression. Supernatant (s/n) and cell pellet (pellet) samples were taken from the P. 
pastoris expression culture at time points: 24-hours pre-induction, 24-hours post-induction and 72-hours post 
induction. Samples of the harvested supernatant (load) and HisTrap column flow through (F/T) are also shown. The 
eluted and pooled fractions from the HisTrap and size exclusion purification steps reveal the high purity of the final 
product.  
Samples of the protein expression and purification were analysed SDS-PAGE gel 
electrophoresis to assess protein purity (Figure 3.7). It was clear from this analysis that high 
protein purity had been achieved in the final purified sample. The final purified protein was 
pooled, and the absorbance was recorded to indicate ~1 mg of protein could be purified 
from 1 L of P. pastoris culture. 
3.4.2 Liquid chromatography-mass spectrometry 
Liquid chromatography-mass spectrometry (LC-MS) was used to support SDS-PAGE analysis 
and confirmed that NEP had been successfully expressed and purified. As previously stated, 
the calculated mass of the NEP extracellular domain is 81.8 kDa however the presence four 
N-linked glycosylation sites result in a higher expected mass. This expected mass can be 
predicted as between 87.8 – 91.8 kDa given the knowledge that P. pastoris commonly adds 
8-14 sugars per site. LC-MS analysis identified a range of species between 82kDa to 97kDa 
(Figure 3.8a). Figure 3.8b shows an enlarged section of the MS spectrum where individual 
peaks are separated by a mass equal to a single monosaccharide (~164 Da). The observed 
peaks strongly suggest that the purified protein is NEP which has been expressed in a range 





94kDa which corresponds to an average estimated glycosylation of 42-73 monosaccharide 
units per protein. 
 
Figure 3.8, NEP mass spectrometry analysis. (a) deconvoluted mass spectrum of the protein glycosylation variants 
with different masses between 82 kDa to 97kDa. (b) enlarged section of the total mass spectrum. Peaks are 
separated by ~164 Da or a single sugar residue.      
3.4.3 Cleavage assay  
To confirm that the expressed and purified NEP protein was in an active and biologically 
relevant form the ability of the protein to cleave a fluorescent peptide was assessed. The 




fluorescent ‘Mca’ group that is quenched by the ‘Dnp’ group while in close proximity. Upon 
substrate cleavage release of the ‘Mca’ group allows recordable fluorescence to occur. 
An initial assay was used to confirm peptide cleavage and determine an optimal 
concentration range that NEP could be used for accurate determination of initial rates. This 
range was determined to be between 1.6-8 nM (0.131-0.655 mg in the 100 µL reaction 
volume) (Figure 3.9). More extensive characterisation of kinetic parameters (Km and Vmax) are 
presented in Chapter 5. The peptide cleavage provided strong evidence that NEP, 
recombinantly expressed in P. pastoris and in the absence of transmembrane and 
cytoplasmic domains, was appropriate for crystallisation and structural analysis.   
 
 
Figure 3.9, NEP peptide cleavage assay. Varied concentrations of NEP were incubated with 10 µM peptide substrate 
Mca-RPPGFSAFK-(Dnp). Curves are plotted with the mean value and ±SD error bars for three repeats.   
3.4.4 Deglycosylation 
The glycosylation of proteins frequently limits the generation of high-quality protein 
crystals. Increased surface flexibility, reduction in favourable crystal stacking interactions and 
the generation of heterogenous protein molecules can all be attributed to glycosylation and 
can be a detriment to crystallisation (Davis et al., 2011). For these reasons all published 




generated from protein that was expressed in a glycosylated form but was subsequently 
deglycosylated prior to crystallisation trials. 
Using a P. pastoris expression system frequently reduces the amount of protein 
glycosylation compared with similar yeast expression systems. LC-MS analysis revealed this 
was true of the expressed and purified NEP where between 42-73 monosaccharide units per 
protein. Despite the relatively low level of glycosylation, deglycosylation of NEP was 
investigated to determine its practicality for crystallisation. This investigation was conducted 
alongside crystallisation of the glycosylated form and would only be required if glycosylated 
NEP did not crystallise. 
Common glycosylation patterns in P. pastoris are well documented (Grinna and Tschopp, 
1989). The general structure begins with two N-acetyl glucosamine (NAG) residues before 
the chain branches and has a high mannose content. Endoglycosidase (Endo H) is a 
commercially available glycosidase that removes high mannose glycans by cleaving 
between the first two NAG residues (Figure 3.10). After incubation with Endo H a 
glycoprotein contains just a single NAG at each glycosylation site. 
 
Figure 3.10, Protein N-linked glycosylation in P. pastoris. Two N-acetyl glucosamine (GN) sugars are bound to the 
asparagine residue. Attached to the N-acetyl glucosamine sugars are mannose sugars (M). Here a highly mannose 
region exists where length and branching can vary greatly. The cleavage site targeted by glycosidase Endo H is 
shown.  
Deglycosylation experiments were achieved using the standard protocol and samples were 




3.11). Deglycosylation with Endo H was successful and resulted in the observation of a 
protein band at a lower molecular weight. No difference was observed for Endo H treatment 
under protein denaturing and non-denaturing conditions suggesting that the same level of 
deglycosylation had occurred in both conditions. 
 
Figure 3.11, Deglycosylation of NEP. Endo H was incubated with NEP under native and denaturing conditions to 
assess deglycosylation. A decrease in molecular weight was caused with Endo H incubation but no difference was 
observed between the native and denaturing conditions.  
Peptide cleavage of deglycosylated NEP was assessed to confirm the protein remained 
suitable for crystallography if required. Peptide cleavage was identified for deglycosylated 





Figure 3.12, Deglycosylated NEP peptide cleavage assay. The cleavage of Mca-RPPGFSAFK-(Dnp) was assessed for 
glycosylated and endo H treated deglycosylated NEP using 0.655 mg of protein in the 100 µL reaction (8 nM). Both 
treated and untreated protein displayed vary similar assay profiles. Curves are plotted with the mean value and 
±SD error bars for three repeats.   
 
3.4.5 Crystallisation 
Crystallisation of NEP had been reported previously using varied crystallisation conditions. 
As no crystal structure from a P. pastoris expression system was available, conditions for 
crystallisation were screened. Prior to high-throughput screening a Hampton research pre-
crystallisation test was used to confirm 7.5 – 12.5 mg/mL as an appropriate concentration 
to begin crystallisation experiments.  
Initially crystallisation trials were conducted on a glycosylated form of NEP. Nine high-
throughput crystallisation trials were performed using 96-condition screens commercially 
available from Molecular Dimensions (Table 3.3). All screens were incubated at 18 ºC and 
were checked weekly.  
Table 3.3, NEP crystallisation screens. A total of nine initial 96-well high throughput crystallisation screens were 
performed using the expressed and purified NEP. A total of 9 crystallisation hits were observed. 
Crystallisation was observed with the condition JCSG-plus A12 (0.2 M KNO3, 20% (v/v) PEG 
3350) after a week. Other crystallisation hits were also identified (Figure 3.13), however only 
Screen  Crystallisation hits 
JCSG-plus 4 
PACT premier  3 
SG1 - 
Structure Screen 1 - 
Structure Screen 2 - 
Morpheus 1 
MemGold  1 





condition JCSG-plus A12 was optimised as other crystallisation conditions did not form 
crystals for >4 months.  
 
 
Figure 3.13, NEP crystallisation hits. Crystallisation hits were observed in conditions (a) JCSG-plus A12, (b) JCSG-
plus C11, (c) JCSG-plus D10, (d) JCSG-plus E8, (e) MemGold B7, (f) PACT premier E4, (g) PACT premier E9, (h) PACT 
premier F5 and (i) Morpheus H2. 
X-ray diffraction data was collected using crystals formed in the JCSG-plus A12. While these 
crystals diffracted, only low resolution (less than 4.5 Å) data could be collected (Figure 3.14). 
Despite this, it was possible to confirm the crystallised protein was NEP by solving the 
collected data using molecular replacement with an inhibitor-bound NEP structure (5JMY). 
It was also possible to confirm the presence of the catalytic zinc by exposing NEP crystals 
to a fluorescence scan at Diamond Light Source. The expected K-edge for zinc is 9658.6 eV 




Optimisation of condition JCSG-plus A12 was performed in a 24-well hanging drop set up 
with the aim of generating NEP crystals that diffracted to a higher resolution. Initially 
optimisation was attempted through variation in PEG 3350 concentration (15-25 % (v/v)). 
This optimisation was unsuccessful as higher concentrations formed large amounts of 
precipitate and reduced crystal formation, and lower concentrations failed to induce protein 
crystal formation. While optimisation of PEG 3350 concentration did not yield crystals of 
higher diffraction quality, the change from a 96-well crystallisation plate to a 24-well 
crystallisation frequently generated larger crystals which in turn diffracted to a higher 
resolution (Figure 3.16).  
 
Figure 3.14, Initial crystallisation and diffraction of NEP. (a) NEP 96-well crystallisation hits from condition JCSG-
plus A12 (0.2 M KNO3, 20% (v/v) PEG 3350). (b) example screening diffraction image from NEP crystal (resolution 





Figure 3.15, Fluorescence scan of NEP. CHOOCH plot shows the anomalous signal recorded at the zinc absorption 




Figure 3.16, Optimised crystallisation and diffraction of NEP. (a) NEP 24-well crystallisation hits from condition 
JCSG-plus A12 (0.2 M KNO3, 20% (v/v) PEG 3350). (b) screening diffraction image from NEP crystal (diffraction is 
higher than 2.5 Å). 
Repeats of the 24-well crystallisation trials were performed with condition JCSG-plus A12 to 




crystallisation drops formed crystals despite containing the same buffer and batch of 
purified protein. If crystallisation did occur diffraction quality varied a large amount between 
crystals. It was also clear that diffraction quality varied greatly between different areas of the 
same crystal (Figure 3.17).  After screening over 100 crystals at Diamond Light Source less 
than 10 crystals diffracted to a resolution of 2.5 Å or better. The following published paper 
reports the highest-resolution structure for NEP that was obtained through crystal 
screening.  
 
Figure 3.17, Diffraction variation across NEP crystals. Diffraction of NEP crystals varied dramatically across the 
length of a crystal. A grid scan was used to screen small areas of and NEP crystal. The example diffraction images 
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3.5 Post-paper conclusion 
In this chapter a method for expression, purification and crystallisation of NEP has been 
established. Using the methods described, determination of the substrate-free NEP 
structure has been possible. That structure has provided important information regarding 
the active site in an unbound form. It is now clear that the active site is static in nature with 
inhibitor binding inducing only minimal movements involving three residues W693, F106 
and R110. With a substrate-free structure determined and a methodology in place for 
production of NEP crystals, it is now possible to shift focus to structurally investigate the 
substrate binding interactions of NEP. This topic will be described in Chapter 5. 
Another avenue for further investigation is in understanding the mechanism for substrate 
entrance into the central cavity of NEP. The possibility that inhibitor binding induced the 
closed conformation in NEP crystal structures can now be ruled out. With that in mind two 
possibilities remain. First, the closed form is the favourable conformation NEP adopts in the 
absence of bound substrate. Second, the closed conformation could be driven by crystal 
packing forces in the crystallisation of NEP. Chapter 4 investigates this further through the 





4 Chapter 4 – Conformations of 





4.1 Foreword  
In Chapter 3 the substrate-free crystal structure of NEP was determined to be in a closed 
conformation. To validate this structure, and investigate the conformational dynamics of 
NEP in solution, the technique of small angle X-ray scattering (SAXS) was employed. This 
short chapter is formatted as a conventional thesis chapter and covers the analysis of NEP 
using SAXS.  
 
4.2 Introduction 
4.2.1 Small angle X-ray scattering 
Small angle X-ray scattering (SAXS) is an experimental technique which provides structural 
information in the range of 1-100 nm. Compared to X-ray crystallography, SAXS is a low-
resolution technique, providing information on protein size and shape. As such, SAXS is 
regularly used to determine protein oligomeric state and, in the case of multi-protein 
assembles, spatial organisation. SAXS can also be used to validate protein structures 
determined using X-ray crystallography and exclude the possibility that observed 
conformations are a result of the local crystal packing environment. While these applications 
for SAXS are useful, its real strength lies in its power to investigate the dynamics and 
conformation changes (in solution state) that occur in proteins over time. Frequently SAXS 
is used in combination with molecular dynamics (MD) simulations to gain comprehensive 
knowledge of structural motions that are supported through experimental data (Boldon et 
al., 2015).  
4.2.2 SAXS sample preparation and data collection 
Preparation of protein samples for a SAXS experiment is relatively simple with the only 
essential requirement being that protein particles are monodisperse in solution. Other 
sample parameters can be varied, such as protein concentration, in order to provide better 
signal-to-noise ratio. Once a monodispersed protein solution has been prepared it is 
possible to begin data collection, the aim of which is to record the scattering produced 
when a monochromatic X-ray beam is passed through a protein solution or a buffer blank. 




isotropic and a rotational averaging of scattered X-rays (Figure 4.1). Once scattering data is 
collected buffer subtraction can be used to identify the scattering components contributed 
by protein particles. 
Two main methods exist to conduct SAXS data collection, these are batch mode and HPLC 
mode. In batch mode, protein and buffer samples are separately loaded into a quartz 
capillary before X-ray exposure. In HPLC mode, also called size exclusion chromatography 
SAXS (SEC-SAXS), the protein sample is passed through a size exclusion column and the 
eluted solution is continuously exposed to X-rays. Whilst HPLC mode takes substantially 
longer than batch mode, there are two benefits. First, high quality buffer subtraction can be 
attained as the contribution of buffer scattering can be assessed from the buffer exposed 
to X-rays before protein is eluted. Second, HPLC mode guaranties that protein solution will 
be monodispersed. 
 
Figure 4.1, SAXS experiment schematic. A monochromatic X-ray beam is passed through a protein sample. The 
X-ray scattering is recorded on a detector to a maximal angle of 2ɵ. Scattering data can then be reduced, and 
structural analysis performed.  
4.2.3 Data reduction and analysis  
After SAXS data has been collected indexing can commence. Here the scattering vector q 
(also referred to as s) (Equation 4.1) is calculated from the scattering angle (θ) and the 
wavelength of the X-ray beam (λ). 
𝑞 =  
4𝜋sin (𝜃)
𝜆





Scattering vectors are then assigned a scattering intensity I(q) which is composed of two 
components: particle form factors F(q) and structure factors S(q) (Equation 4.2). The form 
factors are related to the intra-particle contacts and provided information regarding the 
shape and size of the particles. Structure factors are related to interparticle attraction or 
repulsion interactions and, if particles are monodispersed, S(q) = 1. One of the most 
common issues in SAXS is that aggregation changes results in S(q) ≠ 1. This affects the 
recorded measured scattering intensity and altering approximations of form factors.  
 
𝐼(𝑞) = 𝐹(𝑞) 𝑆(𝑞) 
 
Equation 4.2 
Once values for the scattering vector and intensity have been determined, the spatial 
variations in electron density between particles and solvent, also referred to as contrast, can 
be calculated (Kikhney and Svergun, 2015). The contrast can be used to approximate several 
particle parameters including radius of gyration (Rg), maximum particle dimension (Dmax), 
molecular weight and flexibility. These values can in turn be used to determine oligomeric 
state, protein complex organisation and predict an overall low-resolution protein model or 
‘molecular envelope’.   
The first stage in data analysis is to integrate the recorded scattering vectors and intensities 
onto a 1-dimensional SAXS profile (log I(q) by q) (Figure 4.2). The 1-dimensional profile 
contains structural information on the protein molecule, with low q scattering revealing low 
resolution information while higher q scattering provides higher resolution information. In 
order to extract structural information from the SAXS profile and determine structural 
parameters including Rg, Dmax, molecular weight and flexibility the 1-dimensional profile 





Figure 4.2, 1-dimensional SAXS profile. SAXS data can be integrated and plotted onto a graph of log I(q) by q. 
Data at low q provides low resolution size information. High q data give higher resolution information about 
internal structure.   
The first of these manipulations is frequently the Guinier plot which uses low q data (q x Rg 
< 1.3) to estimate Rg (Figure 4.3a). Low q data can be described by a linear equation 
(Equation 4.3) where the gradient is Rg and the intercept is the intensity at zero scattering 
angle (I(0)). If the low q data cannot be fitted to a linear equation it is often the first indication 
that there is a problem with the sample. Commonly this occurs when the S(q) ≠ 1 because 
there is some form of attraction/aggregation making the data inappropriate for analysis.  
 
 








The second manipulation in SAXS analysis is to convert the data into real space using an 
indirect Fourier transform or the ‘pair distance distribution function’ P(r). Like the Guinier 
plot a P(r) plot (Figure 4.3b) can also estimate Rg, however Rg is calculated using all the data 
instead of just low q scattering. This provides a better estimate less affected by S(q). A P(r) 




Rg and Dmax are the best-known parameters that can be calculated from SAXS but other 
parameters including mass and particle flexibility can also be estimated. Several methods 
are used to calculate the molecular weight of a protein from SAXS data. If the initial 
scattering intensity I(0) is known then an estimate of electron number can be made from 
which molecular weight can be determined. Alternatively, the average protein density of 
1.37 g/cm3 can be used with the calculated volume to estimate molecular weight.  
Kratky analysis (Figure 4.3c) allows approximation of the flexibility in system and can be 
used to determine if a particle is globular, partially folded or unfolded. It is particularly useful 
to visualise structural changes that alter a particles compactness and or flexibility. Frequently 
a normalised Kratky plot (Figure 4.3d) provides an even more convenient way to visualise 
conformation movement/s by removing information on particle size but retaining 
information on shape. For a globular particle, there will be a peak maximum at √3 regardless 
of particle size or composition. Divergence from this indicates flexibility or asymmetry 
(Receveur-Brechot and Durand, 2012).  
 
Figure 4.3, Example SAXS data analysis and plots. (a) Guinier plot is used to approximate the Rg of a particle using 
just low q data that can be described by a linear equation. (b) P(r) plot is an indirect Fourier transform converting 
SAXS data into real space. P(r) allows estimation of Rg using all data and calculation of Dmax. (c) Kratky plot provides 




plots show changes in particle shape independent of particle size and can be a more convenient way to observe 
structural changes (Kikhney and Svergun, 2015).  
Commonly the last of manipulation of SAXS data is the generation of 3-dimensional model 
in the process of envelope reconstruction. Dammif is a well-known programme for envelope 
reconstruction and generates a random particle model from spheres. During refinement 
spheres are added and rejected until the theoretical scattering pattern is similar to the 
pattern that was experimentally observed. The programme Damaver averages different 
Dammif runs that have started from random seeds to improve the accuracy of the models 
built. While envelope reconstruction is a nice visual way to represent SAXS data, envelopes 
have issues surrounding local minima and should not be over interpreted.  
4.2.4 Neprilysin in solution 
In Chapter 3 the crystal structure of substrate-free NEP was determined in a closed 
conformation (Figure 4.4). The technique of SAXS provides a method to confirm that this 
conformation exists in solution and is not a crystallographic artifact. SAXS may also provide 
some indication of the conformational flexibility exhibited by NEP in solution. In order to 
degrade peptides, it is clear that some conformational motion is required to allow substrates 
into the active site within the central cavity. From the NEP crystal structure, it is possible to 
identify a likely mode of conformational motion between non-covalently linked regions of 
subdomains (Figure 4.4). Determination of scattering parameters Rg and Dmax will allow 
investigation into any conformational changes that occur in SAXS experiments. 
Furthermore, it may be possible to shift the equilibrium of NEP to an open or closed 





Figure 4.4, Crystal structure of human NEP extracellular domain. The extracellular domain can be separated into 
two subdomains attached by a linker region. Subdomains act to enclose a large central cavity occluded from 








All reagents for expression and purification were sourced from Sigma-Aldrich or Fisher 
Scientific unless otherwise specified. General methods were followed as described in 
Chapter 3 (3.2.1).  
4.3.1 Buffers 
  
NEP pH 5.5 SAXS buffer  25 mM MES, 150 mM NaCl, 2 mM MgCl2 (pH 5.5, pH adjusted 
with NaOH). 
 
NEP pH 7.5 SAXS buffer  
 
NEP pH 9.5 SAXS buffer 
 
NEP low-salt SAXS buffer 
 
NEP high-salt SAXS buffer 
25 mM Trizma base, 150 mM NaCl, 2 mM MgCl2 (pH 7.5, pH 
adjusted with HCl). 
25 mM CHES, 150 mM NaCl, 2 mM MgCl2 (pH 9.5, pH adjusted 
with HCl). 
25 mM Trizma base, 150 mM NaCl, 2 mM MgCl2 (pH 7.5, pH 
adjusted with HCl). 
 
25 mM Trizma base, 500 mM NaCl, 2 mM MgCl2 (pH 7.5, pH 
adjusted with HCl). 
Table 4.1, Buffers used during SAXS analysis of NEP. 
4.3.2 Data collection 
SAXS experiments were conducted at DLS on beamline B21 using a PILATUS-6M detector. 
Experiments were set up in batch or HPLC mode. 
Batch mode: Protein samples were concentrated to 30 µl and 2.5 mg/ml in SAXS buffer pH 
7.5 using a 30 kDa molecular weight cut-off concentrator (Millipore). Buffer exchange was 
required to substitute NEP into SAXS buffer pH 5.5 and SAXS buffer 9.5. This was achieved 
by adding 470 µl exchange buffer to the 30 µl sample. This was then concentrated down to 
30 µl before repeating the process three further times. The final flow-through was collected 




HPLC mode: Proteins samples were concentrated to 60 µl and 2.5 mg/ml in either NEP low-
salt SAXS buffer or NEP high-salt SAXS buffer. Samples were loaded onto a Superdex200 
column (GE Healthcare) pre-equilibrated with their respective SAXS buffer. Column flow rate 
was 0.075 mL min-1 and eluted protein was passed through an X-ray beam at 12400 eV.  
4.3.3 Data reduction and analysis 
SAXS data processing was done within the ATSAS suite using programme Primus (Franke et 
al., 2017). Guinier and P(r) plots were used for estimation of Rg and Dmax. Predicted scattering 
data for the substrate-free NEP crystal structure was conducted using Crysol (Franke et al., 
2017) and PDB entry 6GID (Moss et al., 2018). The substrate-free NEP crystal structure was 
altered using glycam (Woods Group, 2019) to add sugar residues so there were 12 
monosaccharide residues attached to each of the four glycosylation sites. This glycosylation 
was used as an approximation from the mass spectrometry data calculated in Chapter 3. Χ2 
values of the correlation between predicted and experimentally calculated data was 
determined in Crysol. Kratky plots to illustrate the correlation between predicted and 







4.4.1 Data collection and processing 
NEP was expressed and purified in accordance with the methods described in Chapter 3. 
This protein was buffer exchanged into varied pH and salt conditions to determine the effect 
on NEP conformation in a soluble environment. For pH variation, batch mode SAXS was 
conducted using NEP at 2.5 mg/mL in protein buffer solutions of pH 5.5, 7.5 and 9.5. 
Scattering data were collected, indexed and then plotted onto 1-dimensional profiles 
(Figure 4.5a, c and e) before performing a Guinier analysis to estimate Rg values (Figure 4.5b, 
4d, and 4f). All datasets displayed linear low q data which indicated that protein samples 
were appropriately monodisperse. The calculated Rg values in addition to Dmax values 





Figure 4.5, SAXS analysis for NEP at varied pH’s.  1-dimensional SAXS profiles for NEP are shown for pH 5.5 (a), 
pH 7.5 (b) and pH 9.5 (e). Guinier plots for pH 5.5 (b), pH 7.5 (d) and pH 9.5 (f) were used to analyse the linear 
region of the low q data.  
The effect of salt concentration on NEP conformation was analysed using HPLC mode SAXS. 
NEP was analysed at 2.5 mg/mL using high (500 mM NaCl) and low (150 mM NaCl) salt 
conditions. The size exclusion elution trace for high and low salt conditions is shown in 
Figure 4.6. A clear peak corresponding to NEP was observed in both size exclusion traces 
after 400 seconds. The first part of the protein peak in both purifications was not selected 
for analysis as signs of low-level aggregation were indicated with an increase to Rg value. 
Collected SAXS datasets were then plotted onto a 1-dimensional profile (Figure 4.7a and c) 
before using a Guinier analysis to estimate Rg values (Figure 4.7b and d). Again, Rg and 





Figure 4.6, NEP SEX-SAXS chromatograms. (a) Elution profile for 150mM and (b) 500mM NEP. The region of the 
elution peak analysed is maked by ②, and the area used for buffer substration ①. A red line is used to indicate 





Figure 4.7, SAXS analysis for NEP at varied salt concentrations. 1-dimensional SAXS profiles are shown for 
150mM NaCl  (a) and 500mM NaCl (c). Guinier plots for 150mM NaCl (b)  and 500mM NaCl (d) were used to 
















4.4.2 Analysis of scattering parameters 
Scattering parameters calculated from NEP SAXS data are shown in Table 4.2. In addition to 
the experimentally calculated scattering parameters, predicted scattering parameters were 
also calculated using the crystal structure of substrate-free NEP (6GID) and SAXS software 
Crysol. Using these scattering parameters, it was possible to analyse the correlation between 
experimental and predicted data.  
 
 I(0) Rg Dmax 
Batch mode    
NEP pH 5.5 0.52252 39.1 189 
NEP pH 7.5 0.40194 32.3 101.98 
NEP pH 9.5 0.33505 31.8 103.76 
HPLC mode    
NEP 150mM NaCl 0.11035 31.5 107.44 
NEP 500mM NaCl 0.09633 31.5 107.28 
Predicted    
6GID - 28.42 105.7 
Table 4.2, Calculated SAXS scattering parameters for NEP. Estimated Rg and Dmax values are given in Å.  
Figure 4.8 shows a Kratky plot of the experimental batch mode data collected for NEP at pH 
7.5 and the predicted data from the crystal structure of substrate-free NEP. A clear 
correlation can be seen between these datasets with a Χ2 value of 1.154 for q < 0.4. Particular 
focus should be placed onto the low q data (q < 0.15) which provides information regarding 
the size and shape of the protein particle. This data has a substantially lower level of noise 
and has a Χ2 value of 2.503 indicating a similar particle shape and size for both 
experimentally calculated and predicted data. 
The correlation between predicted and experimentally calculated data results in calculated 
scattering parameters which were similar with Rg values of 28.42 and 32.3 and Dmax values 
of 105.7 and 101.98 respectively (Table 4.2). While these parameters are similar there is some 




discrepancy. First, the crystal structure of substrate-free NEP is does not include 19 N-
terminal amino acid residues due to their flexibility. Because of the absence of information 
regarding these residues it was not possible to included them when calculating predicted 
scattering data for substrate-free NEP. These 19 residues would however be contributing to 
experimental scattering and likely account for some of the discrepancy in scattering 
parameters. Second, mass spectrometry data in chapter 3 revealed the glycosylation profile 
of NEP to be varied between molecules. While attempts were made to accurately model 
glycosylation onto the substrate-free NEP crystal structure, it is reasonable to assume that 
some error would be present in the predicted scattering data.  
 
 
Figure 4.8, SAXS Kratky plot for NEP. SAXS batch mode data from NEP at pH 7.5 is plotted with the predicted 
normalised scattering data from the substrate-free NEP crystal structure (6GID).  
A high degree of correlation was observed for scattering parameters calculated from SAXS 
data collected for NEP in varied buffer conditions. One exception to this was observed for 
the dataset collected at pH 5.5. This dataset had significantly higher calculated Rg and Dmax 
values. To identify the cause of this variation, Dammif was used to visualise changes to the 
protein envelope (Figure 4.9). Calculated envelopes indicated that the increased scattering 
parameters were due to a long protrusion from the protein while the core of the protein 
particle remained unchanged. This was most likely due to pH dependent protein unfolding 




It should also be noted that Dmax values appear slightly higher for SAXS data collected using 
HPLC mode. This may be a consequence of the size exclusion purification and rigid selection 
of a specific regions of the protein elution peak. The small variation may therefore 
correspond to scattering of differently glycosylated species.  
 
Figure 4.9, 3-dimensional NEP envelope models. Batch mode SAXS dataset collected for NEP at pH 7.5 (yellow) 
and pH 5.5 (cyan) are analysed and modelled using Dammif.  
 
4.5 Conclusion 
SAXS analysis was aimed to validate the crystal structures of NEP and to identify possible 
conformations that exist in solution. Validation of crystal structures was achieved through 
comparison of experimentally calculated and predicted SAXS data. The similar scattering 
parameters for this data suggests that in solution NEP adopts similar structure to that 
observed in the crystal structure. These findings also indicate that NEP does not exist in an 
open conformation with separate subdomains.  
To identify whether detectable conformational changes in NEP could be provoked, 
variations in protein buffer conditions were investigated. Despite the use of these varied 
conditions, significant changes in scattering parameters were not observed with the 
exception of NEP analysed in a pH 5.5 buffer. The changes observed in this condition, 
however, where likely due to N-terminal unfolding and not a result of subdomain 




of the closed conformation observed in the crystal structure. This seemingly stable closed 
conformation raises questions regarding the ability of substrates to enter the central protein 
cavity for degradation.  
Several hypotheses may explain the experimentally calculated SAXS data while addressing 
the necessity for conformational motion. First, subtle conformational movements may be 
present in NEP that are sufficient to allow for substrate entry but not large enough to result 
in significantly different scattering parameters. Second, a small proportion of protein may 
adopt an open conformation, but this conformation is masked by the majority of protein 
that exists in a closed conformation. Third, substrate interaction may be required for 
conformational movement and access to the active site. 
To address these questions several avenues could be explored. More subtle conformational 
movements could be investigated through the analysis of deglycosylated NEP protein. A 
deglycosylated protein should provide more precise scattering parameters for NEP and 
remove any issues of mixed glycosylation species. In a similar way, collecting SAXS data for 
an NEP protein containing just the amino acids modelled in the crystal structure (19 N-
terminal amino acid residues truncated) would remove inaccuracies when comparing 
experimentally calculated and predicted SAXS data. Likewise, the requirement of substrate 
interaction for conformational motion could be investigated through the addition of a 
peptide substrate to protein buffer during a SAXS experiment.  
Ultimately, however, it may be necessary to investigate the conformational changes using 
cryo-EM. Cryo-EM may allow determination of the exact conformational movement in NEP 
and reveal conformations of NEP that may be obscured through the averaging nature of 




5 Chapter 5 – Characterisation of 







This chapter is a continuation of the work included in Chapter 3 and describes the methods 
used to determine a peptide-bound structure of neprilysin. The resulting peptide-bound 
crystal structure is included as a published manuscript - Moss, S., Subramanian, V. and 
Acharya, K. R. (2019), Crystal structure of peptide‐bound neprilysin reveals key binding 
interactions. FEBS Lett. 594, 327-336. Like Chapter 3, more extensive background work has 
been included in addition to a more detailed introduction with the aim of providing greater 
context to the work within this thesis. 
 
5.2 Introduction 
To date, over 30 peptide substrates have been identified for neprilysin (NEP) many of which 
link the protein to cardiology and neurology (Table 5.1) (Erdös and Skidgel, 1989). Two 
classes of substrate in particular, amyloid-β and natriuretic peptides (ANP, BNP and CNP), 
have led to considerable interest in NEP, establishing it as a possible therapeutic target for 
Alzheimer’s disease and cardiovascular disease respectively (El-Amouri et al., 2008; Jhund 
and McMurray, 2016).  
Vasoactive peptides Neurological peptides Other peptides 
Adrenomedullin Amyloid-β Caspase-9 precursor 
Angiotensin 1 & 2 Cholecystokinin Gastrin 
Bradykinin Corticotropin Glucagon 
Endothelin 1, 2 & 3 Dynorphin  
Kallidin Galanin  
Natriuretic peptides (ANP, BNP, CNP) Oxytocin  
Neurokinin Melanin-concentrating hormone  
Neuropeptide Melanotropin  
Physalaemin Neurotensin  
Substance P Enkephalin  
 Peptide YY  
Table 5.1, Peptide substrates of NEP with known vasoactive or neurological functions. Substrate list based on the 




The identified substrates of NEP display large amounts of variation in charge, shape and 
sequence. Despite this variation, all substrates are uniform in their small size (< 5 kDa). This 
size specificity shown by NEP is strongly linked to the size of its central cavity (Figure 5.1). It 
is the limited volume of this cavity that permits only small peptides entry and subsequent 
cleavage (Macours et al., 2004). In addition to cavity size, the electrostatic potential of the 
cavity likely plays a role in substrate specificity. Indeed, electrostatic interactions are known 
to be a key mechanism for many binding interactions and long range attraction (Plantinga 
et al., 2008; Zhou and Pang, 2018). 
 
 
Figure 5.1, Crystal structure of substrate-free NEP (6GID). NEP contains a large central cavity with a distinct 
electrostatic potential. The active site of NEP is located within the cavity and is based around a zinc ion (cyan).  
While substrates are clearly diverse in nature and the mechanism for substrate specificity is 
not fully understood, research has revealed that NEP exhibits a preference in cleavage 
positions shared across substrates (Quay et al., 1994; Spungin-Bialik et al., 1996). That is, 
NEP commonly cleaves peptides at the amino side of hydrophobic residues. Figure 5.2 is a 
schematic representation of the NEP subsites and substrate residue positions according to 
the Schechter and Berger convention (Schechter and Berger, 1967). In the schematic the S1’ 
site has the preference for a hydrophobic residue as such the P1’ residue is commonly a 
phenylalanine, leucine, tyrosine, isoleucine or valine (Rawlings et al., 2018). In addition to 
the S1’, there is also some degree of specificity contributed by S1 site which has presence 




determined to have a substantial effect on cleavage position. The identified cleavage sites 
for well-known substrates - natriuretic peptides and amyloid-β - largely obey these 
recognised preferences (Figure 5.3). 
 
Figure 5.2, Schematic of NEP subsites and corresponding substrate residues. Subsites (S) and substrate residue 
positions (P) are labelled based on cleavage position. Numbers are non-prime in the direction of the substrate N-
terminus and prime (‘) in the direction of C-terminus. The labelling convention follows the Schechter and Berger 
convention (Schechter and Berger, 1967)  
 
 
Figure 5.3, Location of NEP cleavage sites in amyloid-β and natriuretic peptides. Cleavage site locations in amyloid-
β (Rogeberg et al., 2014) natriuretic peptides (atrial, B-type and C-type) (Potter, 2011) are indicated by arrows. 
Red arrows are used to indicate the proposed primary cleavage locations.  
Crystal structures for NEP have been published in a substrate-free and inhibitor-bound 




it possible to characterise subsites S1-S2’ and identify residues that are likely to be involved 
in substrate binding (Figure 5.5). However, the absence of a substrate-bound structure 
prevents complete understanding of the substrate binding in NEP. 
 
Figure 5.4, Zinc metalloprotease inhibitor phosphoramidon. The inhibitor is peptide like in design and the substrate 
scissile bound is mimicked by the bound between the phosphorus and nitrogen. Sections of the inhibitor are labelled 
with the subsites in NEP that form interactions.  
A substrate-bound structure would allow several of the underlying questions regarding 
substrate binding in NEP to be addressed. Firstly, the general mode of peptide binding could 
be identified. That is, the position of the peptide backbone and the interactions to NEP 
amino acids. This general mode of binding is likely to be highly similar for all substrates of 
NEP, a feature that has been demonstrated in other zinc metalloproteases (Shen et al., 2006; 






Figure 5.5, NEP active site with bound phosphoramidon. NEP active site residues (blue) and zinc ion (cyan) are 
shown with phosphoramidon (yellow). Phosphoramidon mimics a substrate and the corresponding substrate 
positions are labelled according to the Schechter and Berger convention. 
 
The position of the peptide backbone would also confirm the orientation of peptides within 
the active site. While inhibitor binding strongly suggests cleavage occurs in the N- and C-
terminal orientation shown in Figure 5.2, it is possible that cleavage may occur with the 
peptide flipped in the opposite direction. Some evidence for this, based on mass 
spectrometry experiments, is present in the zinc metalloprotease angiotensin-converting 
enzyme (Larmuth et al., 2014). 
Secondly, a substrate bound structure would allow for comparative investigation into the 
possible changes in peptide binding interactions that are generated from variation in 
substrate side chain residues. These could, in turn, be related to the observed preferences 
for residues in the P1 and P1’ positions. 
Thirdly, it would be possible to identify to what extent interactions between substrates and 
the NEP cavity occur in locations proximal to the active site. As current inhibitors occupy 
just the S1-S2’ sites, a substrate-bound structure would reveal if there are binding 
interactions proximal to these sites which may have critical roles in substrate binding or 
positioning. While there is no experimental evidence to suggest proximal interactions are 
required, computation docking for NEP with natriuretic peptides has been conducted 
(Pankow et al., 2009) and suggests that proximal residues including R222 and D377 may 
play a role in binding the peptide (Figure 5.6). It is equally possible that the majority of 
peptide binding interactions are contributed by the active site alone and that portions of 
substrate not directly bound to the active site have limited interactions with the cavity wall 
thus exhibiting a large amount of flexibility.  
Finally, it has also been suggested that larger NEP substrates may not be entirely enclosed 
by the cavity and some degree of protrusion may be present. Structures in complex with 





Figure 5.6, NEP cavity surface with phosphoramidon bound. Phosphoramidon interacts (yellow) with a shallow 
binding pocket formed of subsites S1-S2’ located around the zinc ion (cyan). In a substrate-bound structure a larger 
amount of the NEP cavity would be occupied. The interactions that take place in this cavity between substrate and 
NEP are unknown but docking studies have suggested Arg222 and Asp377 may have a role in substrate interaction 





5.3 Materials and Methods 
All reagents for expression and purification were sourced from Sigma-Aldrich or Fisher 
Scientific unless otherwise specified. General methods were followed as described in 
Chapter 3 (3.2.1).  
5.3.1 Plasmid construction and transfection  
cDNA encoding full length human NEP in cloning vector pMD18-T Simple was purchased 
from Sinobiology. A polymerase chain reaction (PCR) was used to, amplify the extracellular 
domain of NEP (Thr49 - Trp749), add a 6x histidine tag and add restriction enzyme sites 
KpnI (5’) and NotI (3’). The PCR reaction was set up in accordance with the NEB Q5 hot start 
polymerase manual. Specific component and parameter details are given in Table 5.2 and 
Table 5.3.  
Component Reaction Volumes Final Concentration 
5X Q5 Reaction Buffer 10 µL 1X 
10 mM dNTPs 1 µL 200 µM 
10 µM Forward Primer 2.5 µL 0.5 µM 
10 µM Reverse Primer 2.5 µL 0.5 µM 
1 ng/µL Template DNA 1 µL 0.02 ng/µL 
Q5 Hot Start HF DNA Polymerase 0.5 µL 0.02 U/µL 
Nuclease-Free Water to 50 µL   
Table 5.2, PCR reaction components used  to generate the histidine tagged NEP (Thr49 - Trp749). 
Stage Temperature Time 
Initial Denaturation 98 °C 30 seconds 
35 Cycles 98 °C 10 seconds 
58 °C 20 seconds 
72 °C 90 seconds 
Final Extension 72 °C 2 minutes 
Hold 4 °C   
Table 5.3, PCR reaction parameters  used to generate the histidine tagged NEP (Thr49 - Trp749).  
The amplified PCR product and vector pPICzαA were digested with restriction enzymes KpnI 




product was then ligated into pPICzαA downstream of a secretion tag with T4 ligase (NEB) 
(Table 5.5). 
 
Component Reaction Volumes 
Restriction Enzyme 1 µL (10U) per 
enzyme 
DNA 1 µg 
10X NEBuffer 5 µL (1X) 
Nuclease-free water to 50 μL 
Incubation Time 1 hour 
Incubation Temperature 37 oC 
 Table 5.4, Standard  reaction parameters for a restriction digest.  
Component Reaction Volumes 
T4 DNA Ligase Buffer (10X) 2 μL 
Vector DNA (3 kb) 50 ng  
Insert DNA (2.2 kb) 110 ng  
T4 DNA Ligase 1 μL 
Nuclease-free water to 20 μL 
Incubation Time 16 hours 
Incubation Temperature 16 oC 
 Table 5.5, Ligation reaction parameters used to generate histidine tagged NEP pPICzαA.  
Mutation of NEP residue 584 from glutamate to aspartate or glutamine (E584Q or E584D) 
was performed using PCR site-directed mutagenesis (NEB Q5). Specific component and 
parameter details are given in Table 5.6 and Table 5.7. Mutagenesis was confirmed using 
DNA sequencing. A full list of primer sequences used to generate the NEP E584D and E584Q 





Q5 Hot Start High-Fidelity 2X Master Mix 12.5 µL 1X 
10 µM Forward Primer 1.25 µL 0.5 µM 
10 µM Reverse Primer 1.25 µL 0.5 µM 




Nuclease-Free Water 9 µL   
Table 5.6, PCR reaction components used to generate NEP E584D and E584Q pPICzαA.  
 
 
Stage Temperature Time 
Initial Denaturation 98 °C 30 seconds 
25 Cycles 98 °C 10 seconds 
63 °C 20 seconds 
72 °C 90 seconds 
Final Extension 72 °C 2 minutes 
Hold 4 °C   
Table 5.7, PCR reaction parameters used to generate NEP E584D and E584Q pPICzαA.  
Primer DNA sequence 
Sequencing primer 1 GCCAGGGTTTTCCCAGTCACGAC 
Sequencing primer 2 CAGCTGAAAAAGCTATTGCACAACTGAATTC 
Sequencing primer 3 GAGCGGATAACAATTTCACACAGG 




Amplification Rev (3’ NotI) GCTTGCGGCCGCTCACCAAACCCGGCACTTC 
E584Q mutagenesis Fwd GACTAGGACACGACATCACCCATGGC 
E584Q mutagenesis Rev TGACCATGCCGATGCCCC 
E584D mutagenesis Fwd CAACATAGGACACCAAATCACCCATGGCTTCG 
E584D mutagenesis Rev ACCATGCCGATGCCCCCA 
Table 5.8, Primer DNA sequences for generation of NEP mutants. All primers used to generate and confirm the 
DNA sequence of NEP E584D pPICzαA and NEP E584Q pPICzαA are listed. 
The mutant NEP pPICzαA constructs were transformed into TOP10 Chemically Competent 
E. coli cells (ThermoFisher) for plasmid replication. Transformation was performed by 
incubating 20 µL TOP10 cells on ice with 1 µL of 1 ng/µL NEP E584D pPICzαA or NEP E584Q 
pPICzαA DNA for 10 minutes. Cells were transferred to a water bath at 42oC for 45 seconds 
before incubating on ice for a further two minutes. 100 µL of LB was added to the cells and 




onto an LB agar plate containing 100 µg/mL ampicillin. LB agar plates were incubated 
overnight at 37oC.  
5 mL of LB ampicillin (100 µg/mL) media was inoculated with transformed TOP10 colonies. 
5 mL cultures were grown overnight at 37oC and 200rpm. Cultures were harvested by 
centrifugation at 3000 RCF for 10 minutes. DNA was harvested from TOP10 cells using 
Wizard® Plus SV Minipreps DNA Purification Systems (Promega).  
NEP E584D pPICzαA or NEP E584Q pPICzαA DNA was linearised with restriction enzyme SacI 
(NEB) using the protocol described in Table 5.4. DNA was then integrated into the genome 
of Pichia pastoris GS115 using electroporation in accordance with the Invitrogen EasySelect 
manual (cat. no. K1740-01). Transformed cells were then plated onto a YPD plate containing 
100 μg/mL zeocin for colony selection. 
5.3.2 Protein expression and purification 
Expression of recombinant NEP and NEP E584D extracellular domains from the P. pastoris 
GS115 was performed in accordance with the Invitrogen EasySelect manual. The protocol 
used was identical to that described in Chapter 3. For small-scale test expressions the 
standard protocol was used but the culture volume and induction time were scaled down 
to 25 mL and 24-hours.   
5.3.3 Metal removal and replacement  
Metal removal was attempted using chelating agents EDTA and 1,10 phenanthroline. NEP 
at 50 nM was buffer equilibrated into 25 mM Trizma base, 150 mM NaCl and 75mM EDTA 
or 1,10 phenanthroline (pH 7.5, pH adjusted with HCl) using a centrifuge filter unit with a 
30kDa molecule weight cut-off (Millipore). NEP was incubated for 24-hours at 19°C before 
buffer equilibration into binding buffer (25 mM Trizma base, 150 mM NaCl, 2 mM MgCl2 
(pH 7.5, pH adjusted with HCl)).  
For metal replacement NEP at 50 nM was buffer equilibrated into 25 mM Trizma base, 150 
mM NaCl and 2 mM CoCl2 or NiCl2 (pH 7.5, pH adjusted with HCl). NEP was incubated for 




5.3.4 Enzyme assay 
The activity of NEP and NEP E584D mutant were assessed by measuring cleavage of the 
fluorogenic peptide Mca-RPPGFSAFK-(Dnp) (Enzo Life Sciences). Protein was diluted to 
varied concentrations in binding buffer. 50 µL of diluted protein was added to a black 96 
well microplate (cat. no. 655076, Greiner Bio-One). 50 µL of between 50 – 3.125 μM Mca-
RPPGFSAFK-(Dnp), dissolved in binding buffer with 10% (v/v) DMSO, was added to a black 
96 well microplate (Greiner Bio-One) to initiate the reaction.  
Each fluorescence assay was performed in triplicate and fluorescence was recorded at 
20 second intervals for at least 35 minutes on a CLARIOstar high-performance microplate 
reader (BMG LABTECK). Excitation was achieved at 328 nm and emission was detected at 
393 nm.  
Values for initial rates were determined in relative fluorescence units (RFU) using a line of 
best fit through data points up to 200 seconds. Where more than one substrate 
concentration was used, initial rate data was plotted, and a non-linear regression was used 
to estimate Km and Vmax values. RFU values were converted to µM using the conversion ‘1 
µM = 2103 RFU’ which was calculated using a standard curve of product fluorescence versus 
product concentration.  
5.3.5 Circular dichroism  
The secondary structure composition of NEP and NEP E584D mutant was analysed using 
circular dichroism. Protein samples of NEP and NEP E584D mutant were diluted to 2.725 µM 
and 2.6 µM respectively before analysis.  Data were collected in triplicate using a 1 mm 
quartz cuvette and a Chirascan circular dichroism spectrometer at 20ºC. The wavelength 
scanning range was between 200-300 nm with a 1 nm step size, monochromator bandwidth 
of 3 nm and sample time-per-point of 3 seconds.  
5.3.6 Crystallisation 
Sacubitril-bound wild-type NEP - Protein crystallisation was performed by adding 1 µL of 
50 mM sacubitril dissolved in 100% DMSO to 300 µL NEP at 0.75 mg/mL in binding buffer. 
The solution was incubated for 1 hour at 19°C before concentrating it to 30 µL using a 
centrifuge filter unit with a 30kDa molecule weight cut off (Millipore). The concentrated 




PEG3350 (Molecular Dimensions, England). 2 µL of the mixed solution was manually 
dispensed into 24-well (Molecular Dimensions, England) plates for crystallisation 
experiments using hanging drop vapour diffusion. Plates were stored at 18 ºC and crystals 
formed within a month. Crystals used for data collection were mounted in a loop and flash-
cooled for storage in liquid nitrogen without cryoprotectant. 
Peptide-bound wild-type NEP and NEP E584D - Protein crystallisation was performed by 
adding 4 µL NEP at 8-10 mg/mL to 1 µL of substrate dissolved in binding buffer. Substrates 
were Aβ fragments 1-40, 10-16, 35-42, 1-16, bradykinin (GenScript) and Mca-RPPGFSAFK-
(Dnp) (Enzo Life Sciences). Substrate concentrations were varied to be between 6 – 34-fold 
excess of NEP in the final solution.  
The protein solution was mixed 1:1 with crystallisation buffer 0.2 M KNO3 and 20% (w/v) 
PEG3350 (Molecular Dimensions, England). The mixed solution was manually dispensed into 
24-well (Molecular Dimensions, England) or 96-well (Intelli-Plate Art Robbins Instruments) 
plates for crystallisation experiments using hanging or sitting drop vapour diffusion. Plates 
were stored at 18 ºC and crystals formed within a month. Crystals used for data collection 
were mounted in a loop and flash-cooled for storage in liquid nitrogen without 
cryoprotectant. 
Published peptide-bound NEP E584D CNP structure - Protein crystallisation was 
performed using sitting drop vapour diffusion. NEP E584D (8 mg/mL) was dispensed with a 
Phoenix crystallisation robot (Art Robbins Instruments) into an Intelli-Plate 96 (cat. no. 102-
0001-03, Art Robbins Instruments) at a ratio of 0.2 µL: 0.2 µL protein to crystallisation buffer. 
Crystallisation buffer for the peptide-free structure was 0.16 M potassium nitrate, 0.04M 
sodium bromide, 0.02 M bis-tris propane and 20% (w/v) PEG 3350. Crystallisation plates 
were incubated at 18 °C and crystals formed within two months.  
Attempts to co-crystallize NEP E584D with peptide were unsuccessful. Instead the peptide-
bound structure was achieved through soaking. Crystals for soaking were generated using 
crystallisation buffer 0.16 M KNO3, 0.04 M NaI and 20% (w/v) PEG 3350. Again, crystallisation 
plates were incubated at 18 °C and crystals formed within two months. Once formed 0.2 µl 
of 9.1 mM C-type natriuretic peptide was added to the crystallisation drops and incubated 




the amino acid sequence ‘GLSKGCFGLKLDRIGSMSGLGC’ and was sourced from (GenScript). 
All crystals used for data collection were flash-cooled in liquid nitrogen for storage without 
the use of cryoprotectant.  
5.3.7 X-ray data collection and refinement 
X-ray diffraction data collection for the NEP E584D substrate-free and peptide-bound 
structures was performed on Diamond Light Source (Didcot, Oxford UK) beamlines I04 
(mx17212-37) and I04 (mx17212-46) respectively. At the time of collection both beam lines 
were fitted with Eiger2 X 16M detectors. 
X-ray diffraction data were indexed and integrated using DIALS (Waterman et al., 2016). 
Data were scaled and merged using AIMLESS (Evans and Murshudov, 2013; Winn et al., 
2011) where resolution cut offs were applied. The structures were solved by molecular 
replacement using Phaser (McCoy et al., 2007) and substrate-free neprilysin (6GID) (Moss et 
al., 2018). Programmes Refmac5 (Murshudov et al., 2011) and Coot (Emsley et al., 2010) were 
used for refinement of the structures. 
Validation of the structures was achieved using programmes MolProbity (Chen et al., 2010) 
and PDB validation (Berman et al., 2003). All structural images and superpositions were 
generated in CCP4mg (McNicholas et al., 2011).  
5.4 Results 
5.4.1 Inhibitor-binding 
Prior to substrate binding investigations, cocrystallisation of NEP was attempted with the 
inhibitor sacubitril. As a crystal structure was already available for NEP in complex with 
sacubitril, the cocrystallisation experiment was used to confirm that the previously 
determined crystallisation conditions (Chapter 3) were appropriate for cocrystal generation. 
It also provided an indication of the substrate concentration required for cocrystallisation.  
Cocrystals of NEP and sacubitril were formed using the previously determined crystallisation 
conditions without any observable morphological differences to crystals formed in the 
absence of sacubitril. X-ray diffraction data for these crystals were collected to determine if 
inhibitor was bound. The highest resolution dataset was solved in space group P3221 to a 




The determined structure displayed a high degree of similarity to the published substrate-
free (6GID) and sacubitril-bound NEP (5JMY) with RMSD’s for the 696 residues of 0.380 Å 
and 0.363 Å respectively. It was possible to model the sacubitril molecule into electron 
density proximal to the catalytic zinc ion (Figure 5.7a). A superposition of the published 
sacubitril-bound NEP structure (5JMY) and the structure presented here indicates the almost 
identical positions of inhibitor and active site residues (Figure 5.7b). The only notable 
difference in the two crystal structures was that 5JMY was crystallised in the orthorhombic 
space group P212121 and not P3221 as reported here.  
As sacubitril binding in NEP has been reported in detail for the 5JMY structure (Schiering et 
al., 2016), further analysis is not given here. However, the presented unpublished structure 
confirmed that the crystallisation conditions and crystallisation protocol were appropriate 








 Sacubitril-bound NEP 
Beamline I03, DLS 
Wavelength (Å) 0.9763 
  
Crystallographic statistics  
Space group P3221 
Unit cell dimensions  
a,b,c (Å) 107.93, 107.93, 112.53 
α, β, γ (°) 90.00, 90.00, 120.00 
Resolution range (Å) 71.90-2.50 (2.60-2.50) 
R merge 0.254 (5.417) 
CC1/2 0.999 (0.539) 




Completeness (%) 100.0 (100.0) 
No. observed reflections 1044509 (117321) 
No. unique reflections 26709 (2989) 
Multiplicity 39.1 (39.3) 
  
Refinement statistics  
Rwork /Rfree (%) 0.240/0.277 
R.m.s deviations  
Bond lengths (Å) 0.004 
Bond angles (°) 1.183 
Ramachandran statistics  
Favoured (%) 98 
Allowed (%) 2 
Outliers (%) 0 
Wilson B-factor (Å2) 39.9 
Average B-factors (Å2)  












Values in parentheses are for highest-resolution shell. 






Figure 5.7, NEP active site with bound inhibitor sacubitril. (a) 2Fc-Fo electron density map (contoured to 1σ) 
supported the placement of sacubitril. (b) superposition of published sacubitril-bound NEP structure (5JMY, pink 
and green) and unpublished structural data presented in this chapter (blue and yellow).  
5.4.2 Peptide-binding 
Given that cocrystallisation of NEP with an inhibitor was possible and density for the bound 
inhibitor in the active site was clear, cocrystallisation with several substrates was performed. 
These substrates included bradykinin, fluorescent Mca-RPPGFSAFK-(Dnp) peptide and 
amyloid-β fragments 1-40, 10-16, 1-16 and 35-42. Different amyloid-β fragments were used 




and cleave amyloid-β at several locations, smaller fragments were used to limit the number 
of possible binding positions that could be observed in a crystal structure.  
NEP cocrystals were grown in the presence of substrates and displayed the same crystal 
morphology as crystals grown in the absence of substrate. As described in Chapter 3, crystals 
exhibited variation in diffraction quality within different areas of the same crystal and 
between different crystals. Given this range in diffraction quality many cocrystals were 
screened with only a small number better than 3 Å in resolution. In general, lower resolution 
data was far less likely to have strong density corresponding to a bound ligand.  While high-
resolution datasets were more likely to have stronger density for a bound ligand, they 
frequently did not.  
Due to the variation seen in resolution and peptide binding, a large number of datasets 
from NEP cocrystals were collected. These datasets were solved using molecular 
replacement and refined using a single refmac5 run. This fast processing protocol was used 
to quickly determine if structures contained unmodelled electron density corresponding to 
bound peptide. Four structures have been included to illustrate the commonly observed 
electron density proximal to the zinc ion in a position that would be occupied by bound 
peptide (Figure 5.8).  
The majority of solved structures had a small amount of electron density above the zinc no 
larger than a water molecule (Figure 5.8a). Other structures contained slightly elongated 
electron density, but the density was ambiguous and ‘not peptide-like’ in shape (Figure 
5.8b). In these cases, it is likely that different molecules were bound to the zinc across the 
NEP molecules that make up a crystal. The electron density is therefore an average of these 
different molecules gives rise to the ambiguous observed density.  
The determined structures from two of the highest resolution datasets collected (1.9 Å and 
2.1 Å) were identified to have large areas of unmodelled electron density (Figure 5.8a and 
b). It seems likely that higher resolution data is required to observed clear electron density 
corresponding to bound peptide. In these two higher resolution structures the electron 
density proximal to the zinc ion shared a common peptide-like shape. To better understand 
the identity of this electron density a superposition of the structure was made with 




structure and the fact it overlapped with the observed electron density in the P1’ and P2’ 
positions supported the hypothesis that the density corresponded to a bound peptide.  
Using the superimposed phosphoramidon structure as a template, an alanine dipeptide 
fragment was modelled into the electron density (Figure 5.9b). The modelled peptide 
provided a convincing description of the observed electron density, however the peptide 
could be positioned with the C- or N-terminus towards the zinc ion. Figure 5.9b shows the 
C-terminus orientation as the density fit was moderately better.  
From the electron density it was clear that there was no continuation in peptide past the P1’ 
and P2’ positions. This observation suggested peptide cleavage had occurred and the 
bound peptide was likely to be a small dipeptide fragment. This observation was not 
unexpected given that the NEP protein used for crystallisation had been confirmed to 
possess protease activity. Peptide cleavage did however represent a major issue in 
observing peptide binding interactions. With this in mind the possibility to remove protease 





Figure 5.8, Unmodelled electron density in wild-type NEP active site. NEP crystals formed in the presence of peptide 
substrates. (a) amyloid-β fragment 35-42, (b) amyloid-β fragment 1-16, (c) bradykinin and (d) fluorescent Mca-





Figure 5.9, Modelled electron density in wild-type NEP active site. (a) Phosphoramidon-bound NEP structure 
(1DMT) is superimposed onto the determined structure and the position of the bound phosphoramidon is shown 
(green). (b) di-alanine peptide (yellow) is modelled into the electron density using the phosphoramidon coordinates 
as a template. The electron density correlates well to a bound peptide and it is clear that no continuation in the 
peptide chain is present past the cleavage site (dashed box). Fc-Fo and 2Fc-Fo electron density maps are contoured 
\t 1 and 3σ respectively. 
5.4.3 NEP metal removal and replacement  
The proposed mechanism for zinc metalloprotease enzymes is centred around the zinc ion 
and the removal of this ion has been shown to eliminate protease activity (Holmquist and 
Vallee, 1974). Zinc removal from metalloproteases has been performed using chelating 
agents including phenanthroline and EDTA (Bünning and Riordan, 1985). It has also been 
shown that the zinc ion can be removed through mutation of a zinc binding residue. Such 
a method has been used on the zinc metalloprotease insulin-degrading enzyme (IDE) where 
mutagenesis of a conserved histidine residue in the HEXXH motif was used to generate IDE 
protein absent of the zinc ion. While the mutation removed protease activity, the protein 
retained the secondary structure and insulin binding capacity (Gehm et al., 1993). 
Subsequent X-ray crystallography research into IDE has resulted in structures of several 
substrate-bound structures of IDE absent of a zinc ion (Shen et al., 2006). The success of 
metal removal in IDE indicated such a method would be a good target for use with NEP.  
For NEP, metal removal was initially attempted using chelating agents and not mutagenesis. 
The major benefit of this being that the same wild-type protein could be used, and new 
mutant protein did not have to be expressed. For metal removal NEP protein was incubated 




removed using buffer exchange. A cleavage assay, as described in Chapter 3, was then 
performed on NEP samples (Figure 5.10 and Figure 5.11). From the assay it was clear that 
treatment with chelating agents was unsuccessful in removing NEP protease activity. While 
some variation was seen in the initial rate of reaction, substantial peptide cleavage was still 
present after each treatment. It is unclear why protease activity was retained; it is possible 
that the zinc ion was very stably bound in NEP preventing its removal.  
While metal removal was unsuccessful, the possibility to replace the zinc ion with an 
alternative metal was explored. Metal substitution has been shown to alter activity in other 
zinc metalloproteases (Holmquist and Vallee, 1974; Bünning and Riordan, 1985). Nickel and 
cobalt were selected for metal replacement in NEP. In model zinc metalloprotease 
thermolysin, cobalt substitution resulted in an increase in activity while nickel replacement 
resulted in a <2% activity. NEP zinc replacement was performed by incubating NEP with an 
excess of nickel and cobalt in order to outcompete zinc. Excess metal was then removed 
using buffer exchange. Like treatment with chelating agents, metal replacement also yielded 
NEP with retained protease activity (Figure 5.10). Again, some variation was seen in the initial 
rates (Figure 5.11) however, as protease activity was still present, neither metal removal nor 
replacement was appropriate for production of inactive NEP that could be used for substrate 
cocrystallisation.  
 
Figure 5.10, NEP peptide cleavage assay post zinc removal or replacement treatments. NEP was incubated with 
75mM chelating agents phenanthroline or EDTA, or 2mM metals cobalt or nickel. The treated NEP at 3.125 nM 




RPPGFSAFK-(Dnp) to assess peptide cleavage. Some variation was observed in cleavage between NEP samples 
however all samples still retained protease activity. Curves are plotted with the mean value and ±SD error bars for 
three repeats.   
 
 
Figure 5.11, NEP peptide cleavage initial rates after zinc removal or replacement treatments. Initial rates were 
calculated from a single 50 µM substrate concentration. Mean values and ±SD error bars are plotted for three 
repeats.   
5.4.4 NEP glutamate 584 mutagenesis  
Removal of protease activity in zinc metalloproteases has also been demonstrated through 
mutagenesis. As previously stated, it is possible to mutate one of the conserved histidine 
residues in the HEXXH motif to prevent zinc binding and therefore remove protease activity. 
While this method has been shown to inactive zinc metalloproteases and prevent substrate 
cleavage, the absence of the zinc ion likely has the undesirable effect of altering substrate 
binding. For this reason, an alternative target for mutagenesis, the conserved glutamate in 
the HEXXH motif, was used. The glutamate is involved in hydroxide generation during 
proteolysis, but the residue has limited effect on substrate binding in other zinc 
metalloproteases.  
Glutamate mutations E584D and E584Q were selected with the aim to conserving the amino 
acid characteristics. To generate mutant NEP E584D and E584Q it was necessary to first use 




pastoris for protein expression. An overview of the cloning method is shown in Figure 5.12. 
Briefly, PCR was used to amplify the DNA sequence corresponding to extracellular domain 
from the full-length NEP gene. During amplification restriction sites KpnI (5’) and NotI (3’) 
were added in addition to a 6x histidine tag (5’) (Figure 5.13a). The resulting amplification 
product and vector pPICzαA were double digested with KpnI and NotI before being ligated 
together. The ligation product was transformed into TOP10 E. coli cells before growth on a 
zeocin LB plate to select colonies containing NEP pPICzαA. A single colony was used for 
DNA production and the harvested DNA was digested to confirm the presence of the NEP 
gene within the vector (Figure 5.13b).  
The NEP pPICzαA construct was then targeted for site directed mutagenesis using PCR and 
converting glutamate 584 to an aspartate or glutamine. The resulting PCR products were 
sequenced to confirm successful point mutations had been achieved and that no other 
mutations had resulted from the PCR. The mutant NEP E584D pPICzαA and NEP E584Q 
pPICzαA constructs were then linearised using restriction enzyme SacI before 
transformation and DNA integration into P. pastoris using electrophoresis. Transformed P. 






Figure 5.12, Cloning plan for generation of active site mutant NEP. pPICzαA vectors are shown with the extracellular 






Figure 5.13, Generation of NEP pPICzαA. (a) DNA product from a PCR reaction using full length NEP pMD18-T 
simple as the DNA template and primers Amplification 1 Fwd and Rev. The resulting product was 2152bp and 
contained the extracellular domain of NEP with a 5’ KpnI site, 6x histidine tag and a 3’ NotI site. (b) Ligation product 
of NEP and pPICzαA cut with NotI or NotI and KpnI (digestion incomplete).  
5.4.5 Mutant NEP expression in P. pastoris 
P. pastoris clones transformed with NEP E584D pPICzαA or NEP E584Q pPICzαA were 
screened for protein expression. Often colonies can grow on a YPD zeocin plate without 
DNA integration due to transient expression of the transformed pPICzαA vector. Because of 
this, multiple clones were screened to identify a clone with the integrated construct and 
high levels of protein expression.  
Only two P. pastoris clones grew on a YPD plate containing zeocin after NEP E584D pPICzαA 
transformation. Both clones were used for small-scale protein expressions to assess if either 
expressed NEP E584D protein. Post-induction supernatant samples were analysed and both 
clones 1 and 2 contained a band ~110 kDa observed on an SDS-PAGE gel and a western 
blot (Figure 5.14). As discussed in Chapter 3, while the mass of NEP is 81.8 kDa the predicted 
weight with glycosylation is expected to be higher. This in addition to the positive western 
blot result confirmed the band corresponded to NEP E584D. 
SDS-PAGE analysis of the supernatant sample from P. pastoris clone 2 revealed several 




signal on the corresponding western blot (Figure 5.14b) suggested that these additional 
protein bands correlated to NEP E584D degradation products. As these degradation 
products were not present in clone 1 it is this clone that was used for large-scale protein 
expression. 
 
Figure 5.14, Small-scale NEP E584D expression. (a) SDS-PAGE gel electrophoresis analysis of post-induction 
supernatant samples from two P. pastoris clones expressing NEP E584D. (b) Western blot analysis of the same 
samples loaded onto the SDS-PAGE gel electrophoresis using a histidine tag antibody.   
Large-scale protein expression and purification was performed using clone 1 in an identical 
way to wild-type NEP as described in Chapter 3. The histidine affinity purification and size 
exclusion purification are shown in Figure 5.15 and Figure 5.16. SDS-PAGE gel 
electrophoresis was used to confirm pure protein had been obtained after purification 
(Figure 5.17). The quantity of the purified protein was assessed and like wild-type NEP, 






Figure 5.15, NEP E584D histidine affinity trap purification. 500 mL of protein containing supernatant from a P. 
pastoris culture was loaded onto a histidine affinity trap column (GE healthcare). Once loaded the column was 
washed with binding buffer followed by a wash step of 2% elution buffer. Protein elution was achieved at 50% 
elution buffer. A single peak was observed and peak containing fractions (indicated between dash lines) were 
pooled.    
 
Figure 5.16, NEP E584D size exclusion purification. The pooled fractions eluted from the histidine affinity trap 
column were loaded onto a Superdex 16/60 size exclusion column to remove impurities from the induction media 
and to buffer exchange the protein into binding buffer. A single peak was observed and peak containing fractions 






Figure 5.17, P. pastoris NEP E584D expression and purification. SDS-PAGE electrophoresis was used to analyse 
samples taken during NEP E584D expression. Supernatant pre- and post-induction samples were taken from the 
P. pastoris expression culture at 24-hours pre-induction and 72-hours post induction. Samples of the HisTrap 
column flow through (F/T) are also shown. The eluted and pooled fractions from the HisTrap and size exclusion 
purification steps reveal the high purity of the final product.  
Far more colonies were present on a YPD plate containing zeocin, after NEP E584Q pPICzαA 
transformation. 11 of these clones were screened for protein expression on a small-scale.  
Post-induction supernatant samples from the 11 clones were analysed with SDS-PAGE gel 
electrophoresis and western blot. The SDS-PAGE analysis revealed all clones contained 
several protein bands (Figure 5.18a), however only clones 8 and 10 had an observable band 
on the western blot at ~110 kDa corresponding to NEP E584Q (Figure 5.18b). Both of these 
colonies were tested for large-scale protein expression.  
Large-scale expression of clones 8 and 10 were performed and the expressed protein was 
purified using the same method for wild-type NEP and NEP E584D. SDS-PAGE 
electrophoresis was used to confirm pure protein had been obtained after purification 
(Figure 5.19a and b). While pure protein had been produced from clones 8 and 10, the 
quantity was much lower compared to expression of wild-type NEP and NEP E584D mutant 
(<0.5 mg). For this reason, kinetic and crystallisation work was performed using NEP E584D 








Figure 5.18, Small-scale NEP E584Q expression. (a) SDS-PAGE gel electrophoresis analysis of post-induction 
supernatant samples from 11 P. pastoris clones expressing NEP E584D. (b) Western blot analysis of the same 
samples loaded onto the SDS-PAGE gel electrophoresis.   
 
Figure 5.19, NEP E584Q expression and purification from clones 8 and 10. SDS-PAGE electrophoresis was used to 
analyse samples taken during NEP E584Q expressions. Supernatant pre- and post-induction samples were taken 
from the P. pastoris (a) clone 8 and (b) clone 10 expression cultures at 24-hours pre-induction and 72-hours post 
induction. The eluted and pooled fractions from the HisTrap and size exclusion purification steps reveal the high 
purity of the final product in both clones. 
5.4.6 Protease activity of wild-type and E584D mutant NEP  
Protease activity of the purified NEP E584D mutant protein was assessed using the cleavage 
assay as described in Chapter 3. Initial enzymatic rate was calculated for five substrate 
concentrations. A non-linear regression was then used to describe the experimental data 









calculated from a standard curve of product fluorescence versus product concentration 
(Figure 5.21). Estimates the calculated kinetic parameters Km and Vmax for wild-type and 
mutant E584D NEP are shown in Table 5.10.  
The Km and Vmax for wild-type NEP were 38.14 µM and 0.0118 nmol/s respectively. The 
kinetic data for NEP E584D mutant revealed a complete absence of protease activity. It 
should be noted that low level activity undetectable over the assay durations may remain 
but based on the kinetic data collected NEP E584D was considered appropriate for substrate 




Figure 5.20, Protease activity of wild-type and mutant E584D NEP.  Initial rates of activity using 0.256 mg of protein 
in a 100 µL reaction volume (3.125 nM) were assessed at substrate Mca-RPPGFSAFK-(Dnp) concentrations of 50, 
25, 12.5, 6.25 and 3.125 µM. Initial rate values were calculated from three repeats and the mean values is  plotted 






Figure 5.21, Standard curve of product fluorescence versus product concentration for Mca-RPPGFSAFK-(Dnp). 
Substrate concentrations were 50, 25, 12.5, 6.25 and 3.125 µM and maximal fluorescence at each concentration 
was recorded. A line of best fit was used to determine the relationship between substrate concentration and RFU 
(1 µM = 2103 RFU). For the 100 µL reaction volume a ratio of 0.1 nmoles = 2103 RFU was calculated. Maximal 
fluorescence at each substrate concentration was repeated three times with the mean and ±SD error bars shown 






 Wild-type NEP NEP E584D mutant 
Vmax (nmol/s) 0.0118 (0.0097 – 0.0153) - 
Km (µM) 38.14 (26.00 – 59.45) - 
Table 5.10, Kinetic parameters for wild-type NEP and NEP E584D. Approximations for Vmax and Km were calculated 
from a non-linear regression in Graph Pad Prism using the data from Figure 5.20. 95% confidence limits are shown 
in parentheses. Absence of Vmax and Km values for NEP E584D are due to no calculatable activity. Activity was 
determined using 0.256 mg of NEP or NEP E584D in a 100 µL reaction volume (3.125 nM).  
5.4.7 Crystallisation and optimisation of NEP E584D 
Crystallisation of NEP E584D mutant was initially performed using the same crystallisation 
condition used for wild-type NEP (JCSG-plus A12, 0.2 M KNO3, 20% (v/v) PEG 3350). Slight 




crystallisation or generating crystal that consistently diffracted to higher resolution. 
Variation was done by screening 80% (v/v) of condition JCSG A12 with 20% (v/v) JCSG-plus 
or PACT premier. Many of the new crystallisation conditions generated crystals. 
Cocrystallisation and soaking experiments were performed with new conditions using NEP 
E584D with substrates including C-type natriuretic peptide, B-type natriuretic peptide, 
bradykinin, fluorescent Mca-RPPGFSAFK-(Dnp) peptide and amyloid-β fragments 1-40, 10-
16, 1-16 and 35-42. The following published manuscript reports the highest-resolution 
structure with the best peptide-bound density for NEP E584D mutant obtained through 
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5.6 Post-paper conclusions 
In this chapter the process of determining the first peptide-bound structure of NEP has been 
presented. Initial attempts to crystallise wild-type NEP with substrate were unsuccessful 
most likely as a result of substrate cleavage. To overcome the issues surrounding substrate 
cleavage a mutant NEP E584D protein was generated. Through circular dichroism and X-ray 
crystallography it was possible to confirm that this the structure of NEP E584D was highly 
similar to wild-type NEP and therefore a suitable model to study peptide-binding 
interactions.  
Using the mutant protein, a peptide-bound structure of NEP E584D was determined in 
complex with C-type natriuretic peptide (CNP). This structure revealed the mode of peptide 
binding for CNP and by extension the likely mode of peptide binding for all substrate. Three 
key residues Asp 542, Ala 543 and Arg 717 were the main contributors to backbone peptide 
binding. Comparisons to other zinc metalloproteases revealed the conserved identity of 
these residues and the interactions they make.  
While it was possible to model the backbone of CNP there was limited information available 
on the side chains of the peptide. This may be a result of several factors, but a likely 
explanation is that across a protein crystal, individual protein molecules will be binding the 
CNP at different positions. As such, the side chain density would be a mix of the residues 
that occupy the subsites. Another obvious limitation with the structure was the resolution. 
With higher resolution data it may be possible to gain a better indication of side chain 
identity. Higher resolution data would also provide greater certainty for peptide interactions 
to areas of the cavity proximal the active site. In the attached manuscript a potential exosite 
was discussed however at 2.6 Å there is some uncertainty in the density for this site.  
Attempts were made to collect high resolution data from a peptide-bound crystal however 
two issues limited this. The first was the low frequency at which NEP crystals diffracted to 
high-resolution, an issue discussed in Chapter 3. The second was the low frequency at which 
crystals either soaked or cocrystallised with substrate showed strong electron density for a 
bound substrate. Indeed, several datasets for NEP crystals grown or soaked with substrate 
were collected to a higher resolution but binding of the peptide was not observed in the 




6 Chapter 6 – Construction, expression 
and purification of endothelin-






This chapter describes the methods used to express and purify endothelin-converting 
enzyme I with the intention to use the produced protein for structural and functional 
characterisation. This results chapter is formatted as a conventional thesis chapter and is not 
based around a published manuscript.   
6.2 Introduction 
6.2.1 ECE-1 current structural perspectives  
Endothelin-converting enzyme I (ECE-1, EC 3.4.24.71) is a transmembrane zinc 
metalloprotease. Four isoforms of ECE-1 have been reported - aECE-1, bECE-1, cECE-1 and 
dECE-1. All isoforms are transcribed from the same gene, however utilisation of different 
promoters leads to variation in N-terminal size. This variation is minor with the smallest 
isoform, cECE-1, 754 amino acids in length, while the largest isoform, bECE-1, is 770 amino 
acids in length. Research has revealed that it is this N-terminal sequence that determines 
protein localisation. aECE-1 is localised to the plasma membrane, both dECE-1 and cECE-1 
are localised to the plasma membrane and intracellular compartments, and bECE-1 is 
localised almost exclusively intracellularly (Valdenaire et al., 1995; Schweizer et al., 1997; 
Valdenaire et al., 1999).  
 
Figure 6.1, ECE-1 domain organisation. ECE-1 is composed of three domains with 8 predicted N-linked 
glycosylation sites within the extracellular domain (ExPASy).  
ECE-1 is composed of three structural domains. For bECE-1, short intracellular and 
transmembrane domains contain 68 and 21 amino acids respectively, while the large 
catalytic extracellular domain contains 681 amino acids (Figure 6.1). Human ECE-1 forms a 
dimer through the formation of a disulfide bond between the Cys428 residue of two 




for ECE-1 activity (Korth et al., 1997). In humans, ECE-1 shares 38% sequence identity with 
neprilysin (NEP) (Figure 6.2). This figure increases to 53% when considering the extracellular 
domain alone. Because of this high sequence homology, it is unsurprising that the enzymes 
have similar roles and specificity. Like NEP, ECE-1 can degrade a wide variety of small 
peptide substrates that are uniformly < 5 kDa in size (Johnson et al., 1999). While both 
enzymes have overlapping substrate specificities, they exhibit different cleavage efficiencies. 
This is most notable in the minimal activity ECE-1 displays for small peptides (< 7 residues) 
(Johnson et al., 1999).   
ECE-1 was initially characterised for its role in conversion of big endothelins to vasoactive 
endothelins. The production of endothelin-1, a potent vasoconstrictor, has resulted in 
considerable interest in ECE-1 for its role in blood pressure regulation and cardiovascular 
disease. As such, ECE-1, like NEP, has been targeted for selective inhibition (Doggrell, 2004). 
The role of ECE-1 in cardiovascular disease is not limited to its protease activity on big 
endothelins. Several other vasoactive substrates including natriuretic peptides and 
bradykinin, can also be degraded by ECE-1 thus providing a further link to blood pressure 
regulation and cardiovascular disease. It should be noted, however, that unlike the role of 
ECE-1 in big endothelin degradation, the evidence for protease activity on these substrates 
in vivo is unclear and the physiological relevance has yet to be confirmed (Hartopo et al., 





Figure 6.2, Sequence alignment for bECE-1 and NEP. The alignment covers all domains of the two proteins with 
the level of conservation indicated by the intensity of blue. Alignments were conducted using Clustal Omega and 
are presented in Jalview.  
In more recent years ECE-1 has also been implicated in amyloid-β degradation (Eckman et 
al., 2001; Eckman et al., 2003). Now regarded as one of the most potent amyloid-degrading 
enzymes, ECE-1 has been identified as one of the few enzymes that, through gene knockout, 
can elicit elevated amyloid-β levels in transgenic mice (Eckman et al., 2003). The subcellular 
localisation of ECE-1 isoforms allows both intracellular and extracellular pools of amyloid-β 
to be targeted for degradation. This differs from the plasma membrane localised NEP which 
has been suggested to mainly target extracellular pools. The different localisations of ECE-
1 and NEP likely gives rise to the variation in observed optimal pH’s. While NEP has an 
optimal activity range of between pH 7-7.5 (Mumford et al., 1981), ECE-1 displays optimal 




their differences in pH optima, similar levels of activity between have been recorded over a 
range of substrates (Johnson and Ahn, 2000). 
To date, a single structure of the ECE-1 structure has been reported. This crystal structure, 
containing just the extracellular domain has been determined in an inhibitor-bound state 
(Schulz et al., 2009). The structure is highly similar to NEP with the domain adopting an 
ellipsoid shape which can be divided into two lobes connected by a small linker (Figure 
6.3a).  These lobes act to enclose a large central cavity which contains the active site. The 
finite volume of this central cavity, like within NEP, has been suggested to be the reason 
that substrates are limited to <5 kDa.  
 
Figure 6.3, Crystal structure of the extracellular domain of ECE-1 (3DWB). (a) ribbon illustration of ECE-1. 
Subdomains are coloured yellow and orange with the linker region coloured brown. (b) the catalytic site of ECE-1 
located around a zinc ion shown in cyan. Here, conserved residues His607 and His611, in addition to Glu667, 
coordinate the zinc ion. Conserved Glu608 is involved in the proposed catalytic mechanism. 
The active site of ECE-1 is based around the conserved HEXXH motif shared by many other 
zinc metalloproteases. In ECE-1 the residues involved in zinc binding are His607, His611 and 
Glu667. The conserved Glu608 is positioned above the zinc and is required for the proposed 
catalytic mechanism. Partial characterisation of the active site has been achieved from the 
inhibitor-bound structure (Schulz et al., 2009) in addition to site directed mutagenesis 
studies (Johnson et al., 2002; Schulz et al., 2009). The S1 subsite has very little effect on 




ECE-1 specificity is conferred by the S1’ subsite which exhibits a strong preference for large 
hydrophobic P1’ residues (Rawlings et al., 2018). The S1’ subsite in ECE-1 varies from NEP in 
just a single residue where Val603 replaces NEP’s Met579. While just a single substitution is 
present there is a substantial increase to the S1’ pocket size.  
Considerable information has been gained from the reported inhibitor-bound structure, 
however, characterisation of substrate binding in ECE-1 has yet to be addressed.  Like the 
work on NEP described in previous chapters, substrate-free and substrate-bound structures 
of ECE-1 would address several of the underlying questions regarding how substrate 
binding is achieved and provide greater insights into substrate specificity.  
In order to undertake structural and functional characterisation of ECE-1 it is first necessary 
to establish a method by which the protein can be produced. A method for ECE-1 expression 
and crystallisations has already been reported (Schulz et al., 2009) and could be used as an 
initial guideline to determine substrate-free and substrate-bound structures of ECE-1, 
however, there are several points that need to be noted. First, the inhibitor-bound structure 
was determined using protein expressed in a bacterial expression system where no 
mechanisms for glycosylation are present. The protein expressed in this system formed 
inclusion bodies, likely due to the simplistic protein processing pathway in bacteria. Because 
of this, protein had to be refolded after expression. The high sequence similarity between 
ECE-1 and NEP, in conjunction with the high structural similarity between the reported ECE-
1 and NEP structures, provides substantial validation to this method of ECE-1 production. 
Despite this, the absence of information relating to protein glycosylation should be noted, 
particularly as there was an absence of kinetic data in the published paper.  
The second point to note is that the reported inhibitor-bound structure of ECE-1 is in a 
monomeric state due to point mutation C428S preventing dimer formation. There were 
attempts to crystallise the wild-type ECE-1, but these were unsuccessful, hence the 
necessitated for the mutation C428S. 
While it would no doubt be preferential to investigate substrate binding in a glycosylated 
and dimeric ECE-1 protein complex, the reported bacterial expression system and 
crystallisation protocol provide an attractive starting point. It would, however, be necessary 




protease activity is confirmed, structural characterisation could begin. If the protein cannot 
be refolded or if activity is absent, then alternative expression systems, including yeast and 
mammalian, could be trialled. If a suitable system is found, active protein could then be used 
for structural characterisation of substrate binding interactions in ECE-1. 
6.3 Materials and Methods 
All reagents for expression and purification were sourced from Sigma-Aldrich or Fisher 
Scientific unless otherwise specified. General methods were followed as described in 
Chapter 3 (3.2.1).  
6.3.1 Buffers 
E. coli   
Lysogeny broth (LB) / 
Lysogeny broth agar  
0.5% (w/v) yeast extract, 1% (w/v) peptone and 1% (w/v) 
NaCl (for LB agar 1% (w/v) agar was added)  
Inclusion body 
solubilisation solution 
100 mM Trizma base, 8 M Urea, 10 mM β-
mercaptoethanol, 10 mM dithiothreitol (DTT), 1 mM 
glutathione (GSH), 0.1 mM glutathione disulfide (GSSG) 
and 1 mM glycine (pH 10, adjusted with NaOH) 
 
Inclusion body wash buffer 
1 
50 mM Trizma base, 20 mM ethylenediaminetetraacetic 
acid (EDTA) and 2% (v/v) triton X-100 (pH 7.2, pH adjusted 
with HCl) 
Inclusion body wash buffer 
2 
50 mM Trizma base and 20 mM EDTA (pH 7.2, pH adjusted 
with HCl) 
E. coli binding buffer 1 50 mM Trizma base (pH 8, pH adjusted with HCl)  
E. coli elution buffer 1 50 mM Trizma base and 1 M NaCl (pH 8, pH adjusted with 
HCl) 
 
E. coli binding buffer 2 50 mM Trizma base and 150 mM NaCl (pH 8, pH adjusted 
with HCl) 
 
E. coli elution buffer 2 50 mM Trizma base, 150 mM NaCl and 500 mM imidazole 
(pH 8, pH adjusted with HCl) 
 




Yeast Extract Peptone agar 
(YPD agar) 
1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) 
dextrose and 2% (w/v) agar 
 
1 M potassium phosphate 
buffer, pH 6.0 
 
132 mL of 1 M K2HPO4, 868 mL of 1 M KH2PO4 (pH 6.0 
adjusted with phosphoric acid or KOH) 
Buffered complex medium 
containing glycerol 
(BMGY) 
1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer (pH 6.0), 1.34% (w/v) yeast 
nitrogen base, 4 × 10-5% (w/v) biotin and 1% (v/v) glycerol. 
1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium 
phosphate buffer (pH 6.0), 1.34% (w/v) yeast nitrogen base, 4 × 
10-5% (w/v) biotin and 1% (v/v) glycerol. Yeast nitrogen base, 
biotin and glycerol were filter sterilised and added to the other 
components which had been autoclaved. 
Buffered complex medium 
containing methanol 
(BMMY) 
1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer (pH 6.0), 1.34% (w/v) yeast 
nitrogen base, 4 × 10-5% (w/v) biotin and 0.5% (v/v) 
methanol. 1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer (pH 6.0), 1.34% (w/v) yeast nitrogen 
base, 4 × 10-5% (w/v) biotin and 1% (v/v) glycerol. Yeast nitrogen 
base, biotin and methanol were filter sterilised and added to the 
other components which had been autoclaved. 
 
P. pastoris binding buffer 50 mM Trizma base and 150 mM NaCl (pH 8, pH adjusted 
with HCl) 
P. pastoris elution buffer 50 mM Trizma base, 150 mM NaCl and 500 mM imidazole-
HCl (pH 8, pH adjusted with HCl) 
HEK 293T   
Dulbecco's Modified Eagle 
Medium (DMEM) 
Sigma-Aldrich (D5796-500ML) 












Phosphate buffered saline 
solution (PBS) 
Sigma-Aldrich (D8537-500ML) 
HEK binding buffer 50 mM Trizma base and 150 mM NaCl (pH 8, pH adjusted 
with HCl) 
HEK elution buffer 50 mM Trizma base, 150 mM NaCl and 500 mM imidazole 
(pH 8, pH adjusted with HCl) 
SDS-PAGE buffers   
20x Tris-MOPS running 
buffer 
1.2 M Trizma base, 0.6 M MOPS, 2.0% (w/v) sodium 
dodecyl sulfate 
 
4x SDS-PAGE sample 
buffer 
250 mM Trizma base, 10% (w/v) sodium dodecyl sulfate, 
0.008% (w/v) bromophenol blue, 0.588M β-
mercaptoethanol, 40% (v/v) glycerol (pH 6.8, pH adjusted 
with HCl) 
Other buffers  
Enzyme assay buffer 25 mM Bis-Tris-HCl, 150 mM NaCl, 2 mM MgCl2 (pH 6, pH 
adjusted with HCl) 
 
Table 6.1, Buffers and growth media used for ECE-1 protein expression trials.  
6.3.2 Insoluble ECE-1 expression in E. coli   
cDNA for the extracellular domain of human ECE-1 (Q90-W770) was purchased from 
Imagene. The cDNA contained point mutation C428S which has been shown to prevent 
homodimer formation. The ECE-1 gene was cloned into a pET22b vector and transformed 
into Rosetta Gami B DE3 (RGB) cells (Novagen) by Dr Mohd Akif from the Acharya lab. 
Glycerol stocks of the clone were stored at -80°C.  
The ECE-1 RGB cell glycerol stock was used to inoculate an LB agar plate containing 100 




which was incubated for 48 hours at 37°C to establish colonies. A single colony was used to 
inoculate a starter culture containing 25 mL of LB broth with 100 µg/mL ampicillin, 25 µg/mL 
chloramphenicol, 50 µg/mL kanamycin and 10 µg/mL tetracycline in a 250 mL flask. The 
starter culture was incubated overnight at 37°C and 225rpm. 10 mL of the overnight culture 
was used to inoculate two main cultures in 2 L flasks containing 750 mL LB broth with 100 
µg/mL ampicillin and 25 µg/mL chloramphenicol. These main cultures were incubated at 
37°C 225rpm until reaching an OD600 ≈ 0.6. The cultures were then induced using IPTG at a 
final concentration of 2 mM. Main cultures were incubated overnight at 30°C 225rpm. 
Cultures were transferred to 500 mL centrifuge tubes which were spun at 6000 RCF for 20 
minutes at 19°C. The supernatant was discarded, and the cell pellet was used for purification 
immediately or was flash froze in liquid nitrogen for storage at -80°C. 
The ECE-1 RGB cell pellet was resuspended in E. coli binding buffer 1 with 1 µL benzonase. 
The resuspended pellet was then passed through a cell disruptor (Constant Systems) pre-
cooled to 4°C and washed with purification E. coli binding buffer 1. Lysed cells were 
centrifuged at 47750 RCF for 15 minutes. The supernatant was discarded, and pellet was 
resuspended in Inclusion body wash buffer 1. The resuspended solution was centrifuged at 
47750 RCF for 15 minutes. The supernatant was discarded, and pellet was resuspended in 
Inclusion body wash buffer 2. The resuspended solution was centrifuged at 47750 RCF for 15 
minutes. The supernatant was discarded and the inclusion body containing pellet was 
solubilised in inclusion body solubilisation solution at 0.1 g/mL and stirred at room 
temperature for 1-hour. Insoluble matter was separated by centrifugation at 47750 RCF for 
15 minutes. The solubilised fraction was diluted to an OD280 of 5 in inclusion body 
solubilisation solution and used in a refolding screen. 
For the refolding screen 50 µL of solublised sample was added to 950 µL of refolding 
conditions (Table 6.2) and incubated at 4°C. After 24 hours samples were assessed using 
SDS-PAGE. Large-scale refolding was achieved using 450 mL of refolding buffer 13 (Table 
6.2) and 50 mL of solubilised inclusion body. Refolding was performed for 24 hours at 4°C 
after which the protein solution was loaded at 5 mL/min onto a 5 mL HiTrap anion exchange 
column (GE Healthcare) pre-eqilibrated with E. coli binding buffer 1. Protein elution was 





Table 6.2, ECE-1 in-house protein refolding screen. 16 conditions with varied pH and chemical components were 
used to refold ECE-1 protein from inclusion bodies.  
6.3.3 Soluble ECE-1 expression in E. coli  
Human ECE-1 C428S pET22b cDNA was provided by Dr Mohd Akif. This cDNA was used as 
a template for a polymerase chain reaction (PCR) in which the entire vector was amplified 
using primers listed in Table 6.3. PCR reaction components and parameters are detailed in 
Table 6.4 and Table 6.5. This PCR reaction added a 5’ 6x histidine tag upstream of the ECE-
1 gene for western blot analysis and ease of protein purification.  
 















5X Q5 Reaction Buffer 10 µL 1X 
10 mM dNTPs 1 µL 200 µM 
10 µM Forward Primer 2.5 µL 0.5 µM 
10 µM Reverse Primer 2.5 µL 0.5 µM 
1 ng/µL Template DNA 1 µL 0.02 ng/µL 
Q5 Hot Start High-Fidelity DNA 
Polymerase 
0.5 µL 0.02 U/µL 
Nuclease-Free Water 32.5 µL   
Table 6.4,  Standard PCR reaction components.  
 
Stage Temperature Time 
Initial Denaturation 98 °C 30 seconds 
35 Cycles 98 °C 10 seconds 
60 °C 20 seconds 
72 °C 4 minutes 
Final Extension 72 °C 10 minutes 
Hold 4 °C   
Table 6.5, PCR reaction parameters  used  to generate histidine tagged ECE-1 C428S pET22b. 
The amplified histidine tagged ECE-1 C428S pET22b was transformed into RGB cells. 
Transformation was performed by incubating 20 µL RGB cells on ice with 1 µL of 1 ng/µL 
DNA for 10 minutes. Cells were transferred to a water bath at 42oC for 45 seconds before 
incubating on ice for a further two minutes. 100 µL of LB was added to the cells and cells 
were incubated at 37oC for 45 minutes at 200 rpm. 100 µL cell solution was then plated onto 
an LB agar plate containing 100 µg/mL ampicillin, 25 µg/mL chloramphenicol, 50 µg/mL 
kanamycin, 10 µg/mL tetracycline. LB agar plates were incubated overnight at 37oC. 
A starter culture containing 25 mL of LB broth with 100 µg/mL ampicillin, 25 µg/mL 
chloramphenicol, 50 µg/mL kanamycin and 10 µg/mL tetracycline in a 250 mL flask was 




and 225rpm. 1 mL of the overnight culture was used to inoculate test expression cultures in 
250 mL flasks containing 75 mL LB broth with 100 µg/mL ampicillin and 25 µg/mL 
chloramphenicol. These main cultures were incubated at 37°C 225rpm until reaching an 
OD600 ≈ 0.6. The cultures were then induced using IPTG at a final concentration of 2 mM. 
Induction times and temperatures were varied to determine an appropriate condition for 
soluble protein expression. Samples of the test expressions were analysed with SDS-PAGE 
and western blot.  
Once an appropriate condition for soluble ECE-1 expression was determined large-scale 
protein expressions were performed. A starter culture containing 25 mL of LB broth with 100 
µg/mL ampicillin, 25 µg/mL chloramphenicol, 50 µg/mL kanamycin and 10 µg/mL 
tetracycline in a 250 mL flask was inoculated with a single ECE-1 C428S pET22b RGB colony 
and incubated overnight at 37°C and 225rpm. 10 mL of the overnight culture was used to 
inoculate two main cultures in 2 L flasks containing 750 mL LB broth. These main cultures 
were incubated at 37°C 225rpm until reaching an OD600 ≈ 0.6. Induction was achieved using 
IPTG at a final concentration of 2 mM. A 3-hour induction at 16°C was selected for soluble 
protein expression. After this induction period, cells were harvested from expression cultures 
by centrifugation for 20 minutes at 5000 RCF. The supernatant was discarded, and cell pellet 
was resuspended in E. coli binding buffer 2 (20 mL per g of cell pellet) with 1 µL benzonase. 
The resuspended pellet was then passed through a cell disruptor (Constant Systems) pre-
cooled to 4°C and washed with E. coli binding buffer 2. 
The soluble and insoluble cell lysate fractions were separated by centrifugation for 30 
minutes at 47750 RCF. The supernatant was collected and filtered through a 0.22 µm syringe 
filter (Millipore). Filtered supernatant was loaded at 5 mL/min onto a 5 mL histidine affinity 
column (GE Healthcare) pre-equilibrated with E. coli binding buffer 2. Protein elution was 
achieved using a gradient of E. coli elution buffer 2 over 40 mL. Samples were taken from 
fractions with slightly elevated UV absorbances and analysed with SDS-PAGE and western 
blot. 
6.3.4 ECE-1 expression in Pichia pastoris 
Human ECE-1 C428S cDNA with a 5’ histidine tag was amplified using PCR from the 




a 5’ EcoRI site and a 3’ NotI site to the ECE-1 gene for cloning purposes (Table 6.6). The PCR 
reaction components and parameters are detailed in Table 6.6 and Table 6.7. 
The amplified product and vector pPICzαA were digested with restriction enzymes EcoRI 
and NotI (NEB) (Table 6.8). Digested DNA was then ligated with T4 ligase (NEB) to form ECE-
1 C428S pPICzαA (Table 6.9). 
 
Primer DNA sequence 
Amplification forward CCGCCGGAATTCCATCACCACCATCATCACGGAGG  
Amplification reverse GCTTGCGGCCGCTTACCAGACTTCGCACTTGTGAGGCG  
Table 6.6, Primer DNA sequences used to generate histidine tagged ECE-1 C428S for ligation into pPICzαA. 
 
Stage Temperature Time 
Initial Denaturation 98 °C 30 seconds 
35 Cycles 98 °C 10 seconds 
60 °C 20 seconds 
72 °C 90 seconds 
Final Extension 72 °C 10 minutes 
Hold 4 °C   
Table 6.7, PCR reaction parameters  used  to generate histidine tagged ECE-1 C428S for ligation into pPICzαA. 
 
Component Reaction Volumes 
Restriction Enzyme 1 µL (10U) per 
enzyme 
DNA 1 µg 
10X NEBuffer 5 µL (1X) 
Nuclease-free water to 50 μL 
Incubation Time 1 hour 
Incubation Temperature 37 oC 





Component Reaction Volumes 
T4 DNA Ligase Buffer (10X) 2 μL 
Vector DNA (3 kb) 50 ng  
Insert DNA (2.2 kb) 110 ng  
T4 DNA Ligase 1 μL 
Nuclease-free water to 20 μL 
Incubation Time 16 hours  
Incubation Temperature 16 oC 
 Table 6.9, Ligation reaction parameters used to generate histidine tagged ECE-1  C428S pPICzαA.  
The ECE-1 C428S pPICzαA construct was transformed into TOP10 Chemically Competent E. 
coli cells (ThermoFisher) for plasmid replication (protocol detailed in 5.3.1). DNA was 
harvested from TOP10 cells using Wizard® Plus SV Minipreps DNA Purification Systems 
(Promega). DNA was linearised with restriction enzyme PmeI (NEB) using standard 
parameters (Table 6.8) and integrated into the genome of P. pastoris GS115 using 
electroporation in accordance with the Invitrogen EasySelect manual (cat. no. K1740-01). 
Transformed cells were then plated onto a YPD agar plate containing 100 µg/mL zeocin for 
colony selection. 
Protein expression using transformed P. pastoris clones was done in accordance with the 
Invitrogen EasySelect expression manual (cat. no. K1740-01). A single colony was used to 
inoculate a starter culture containing 25 mL of BMGY media in a 250 mL baffled flask. The 
starter culture was incubated overnight at 30ºC 225rpm. 10 mL of the overnight culture was 
used to inoculate a 250 mL BMGY media in a 2 L baffled flask. The main culture was 
incubated at 30ºC and 225rpm for 24 hours1.  
After 24 hours the main culture was transferred to 500 mL centrifuge tubes which were 
centrifuged at 6000 RCF for 20 minutes at 19 ºC. The supernatant was discarded, and the 
cell pellet was resuspended in 250 mL of BMMY media for induction. Resuspended cells 
were transferred to a new 250 mL baffled flask. The culture was then incubated for 24 hours 
at 30 ºC 225rpm. 
 




After 24 hours of induction, the main culture was transferred to a 500 mL centrifuge tubes 
and spun at 6000 RCF for 20 minutes at 19 ºC. The supernatant was collected, and the cell 
pellet was discarded. Solid Trizma base and NaCl were added to the supernatant to give 
final concentrations of 25mM Trizma and 150mM NaCl. The supernatant was mixed with 
magnetic stirrer for 10 minutes at room temperature. After this time, the supernatant 
showed some precipitation which was removed by flowing through a 0.22 µm filter 
(Millipore). The final filter supernatant had a pH of ~7. 
The buffer equilibrated P. pastoris supernatant was loaded onto a 5 mL HisTrap HP affinity 
column (GE Healthcare Life Sciences) at 2 mL/min pre-equilibrated with P. pastoris binding 
buffer. Following loading, the column was washed with P. pastoris binding buffer until the 
UV trace returned to baseline. Protein elution was performed at 5 mL/min in a stepwise 
manner. 2% P. pastoris elution buffer was used to wash the column until UV trace stabilised. 
Bound protein was eluted using 50% P. pastoris elution buffer and 2 mL fractions were 
collected. 
Protein containing fractions were confirmed using SDS-PAGE gel electrophoresis. These 
fractions were concentrated to under 2 mL in a centrifuge at 4000 RCF using a 30kDa 
molecule weight cutoff filter unit (Millipore) The concentrated protein containing sample 
was then loaded at 1.5 mL/min onto a Superdex 16/60 pre-equilibrated with P. pastoris 
binding buffer.  
6.3.5 ECE-1 expression in human embryonic kidney cells 
The human ECE-1 C428S gene was amplified using PCR from the previously created ECE-1 
C428S pPICzαA. Primers for this PCR reaction were designed to add a 5’ KpnI site and a 3’ 
PmeI site to the ECE-1 gene for cloning purposes (Table 6.10). The PCR reaction components 
and parameters are detailed in Table 6.6 and Table 6.11. The amplified product and vector 
pOPINTTGneo were digested with restriction enzymes KpnI and PmeI (NEB) using the 
reaction parameters described in Table 6.8. Digested DNA was then ligated with T4 ligase 
(NEB) to form ECE-1 C428S pOPINTTGneo using reaction parameters detailed in Table 6.12.  
Primer DNA sequence 
Amplification forward GTAGCTGAAACCGGGCACCATCATCACCACCATCATCACGG 




Table 6.10, Primer DNA sequences used to generate histidine tagged ECE-1 C428S for ligation into 
pOPINTTGneo. 
 
Stage Temperature Time 
Initial Denaturation 98 °C 30 seconds 
35 Cycles 98 °C 10 seconds 
58 °C 20 seconds 
72 °C 90 seconds 
Final Extension 72 °C 10 minutes 
Hold 4 °C   
Table 6.11, PCR reaction parameters used to generate histidine tagged ECE-1 C428S for ligation into 
pOPINTTGneo. 
The ECE-1 C428S pOPINTTGneo construct was transformed into TOP10 Chemically 
Competent E. coli cells (ThermoFisher) for plasmid replication (protocol detailed in 5.3.1). 
DNA was harvested from TOP10 cells using Wizard® Plus SV Minipreps DNA Purification 
Systems (Promega). DNA then transformed into HEK 293T cells. A small-scale expression in 
a 24-well plate was used to determine the best transformation protocol for the highest 
protein expression. 
 
Component Reaction Volumes 
T4 DNA Ligase Buffer (10X) 2 μL 
Vector DNA (3 kb) 50 ng  
Insert DNA (2.2 kb) 35 ng  
T4 DNA Ligase 1 μL 
Nuclease-free water to 20 μL 
Incubation Time 16 hours 
Incubation Temperature 16 oC 
 Table 6.12, Ligation reaction parameters used to generate histidine tagged ECE-1 C428S pOPINTTGneo.  
HEK 293T cells were revived from cryogenic storage with a 2-3 minute thaw in a 37°C water 
bath. 1 mL of thawed cells was added to 9 mL complete growth medium (pre-warmed to 




supernatant and replacing with 15 mL complete growth medium (pre-warmed to 37°C). The 
cell suspension was then transferred to a T75 flask and incubated at 37°C in a 5% CO2 
humidified incubator. Cells were passaged when cultures reached between 70 - 90% 
confluence.  
20 - 24 hours before transfection HEK 293T cells were dissociated from a T175 flask and 
diluted to between 1 - 2 x 105 viable cells/mL. Cells were then transferred as 500 µL aliquots 
to separate wells of a 24-well plate. Cultures were incubated at 37°C in a 5% CO2 humidified 
atmosphere until between 40-80% confluent. 1-4 hours before preparing transfection 
complexes cell growth medium was replaced with 500 µL reduced serum media. 
To create transfection complexes 100 µL aliquots of serum free medium were made. To each 
aliquot 20 - 40 µL of 100 ng/µL DNA and 2 - 16 µL of 1 µg/µL PEI was added.  Aliquots were 
mixed using a vortexer for 20-30 seconds and incubated at room temperature for up to 10 
minutes to allow complex formation. Transfection complexes were added dropwise to each 
500 µL culture and incubated at 37°C in a 5% CO2 humidified atmosphere. Cell supernatant 
was harvested 24 hours after transfection. 
Once appropriate transfection conditions had been determined, large-scale transfections 
were performed in an expanded surface (2125 cm2) roller bottles (Cellmaster, Greiner Bio-
One). Roller bottles were inoculated from cells grown in a T175 flask at >90% confluency. 
Cells were removed from the T175 flask by first removing cell growth media. Cells were then 
washed with 10 mL PBS before adding 5 mL of trypsin solution to dissociate attached cells. 
The resuspended cells in 5 mL trypsin solution was then added to 20 mL DMEM containing 
10% (v/v) FBS (Dulbecco’s Modified Eagle Medium, ThermoFisher Scientific, 41965039) 
which was then added to 225 mL DMEM containing 10% (v/v) FBS (pre-warmed to 37 °C) in 
the roller bottle. Roller bottles were incubated at 37°C in a 5% CO2 whilst rotating at 0.5 
rpm. 
After 24 hours, growth media was removed and replaced with 200 mL of DMEM containing 
2% (v/v) FBS. To this, the transfection solution – 2 mg of ECE-1 C428S pOPINTTGneo in 50 
mL of DMEM containing 2% (v/v) FBS – was added to the roller bottle. A further incubation 
was then performed at 37°C in a 5% CO2 whilst rotating at 0.5 rpm. Cell supernatant was 




The 250 mL of cell media was removed from roller bottles and centrifuged at 4000 RCF for 
30 minutes. Cell media was then filtered through a 0.22 µm syringe filter (Millipore) before 
loading at 5 mL/min onto a HisTrap HP affinity column (GE Healthcare) pre-equilibrated in 
HEK binding buffer. Protein elution was achieved using a gradient (0 - 100%) of HEK elution 
buffer over 40 mL. Eluted fractions were then analysed using SDS-PAGE and western blot. 
ECE-1 containing fractions were concentrated and pooled before loading at 1.5 mL/min 
onto a Superdex 16/60 size exclusion column pre-equilibrated in HEK binding buffer.  
6.3.6 Cleavage assay 
The protease activity of ECE-1 C428S was assessed by measuring cleavage of the fluorogenic 
peptide Mca-RPPGFSAFK-(Dnp) (Enzo Life Sciences). Protein was diluted to varied 
concentrations in Enzyme assay buffer. 50 µL of diluted protein was added to a black 96 well 
microplate (cat. no. 655076, Greiner Bio-One). 50 µL of Mca-RPPGFSAFK-(Dnp), between 50 
- 3.125 μM dissolved in Enzyme binding buffer with 10% (v/v) DMSO, was added to a black 
96 well microplate (Greiner Bio-One) to initiate the reaction.  
Each fluorescence assay was performed in triplicate where samples allowed and 
fluorescence was recorded at 20 second intervals on a CLARIOstar high-performance 
microplate reader (BMG LABTECK). Excitation was achieved at 328 nm and emission was 
detected at 393 nm. Values for initial rates were determined in relative fluorescence units 
(RFU) using a line of best fit through linear data points up to 200 seconds.  
 
6.4 Results 
6.4.1 Insoluble ECE-1 expression in E. coli 
Initial protein expression and refolding protocols followed the methods described in Schulz 
et al. (2009), which had been used to determine the structure of the ECE-1 extracellular 
domain in an inhibitor-bound state. A Rosetta-gami B (RGB) clone containing the 
extracellular domain of human ECE-1 (Q90-W770) C428S in vector PET22b was created by 
the Dr Mohd Akif from the Acharya lab (Figure 6.4). A key benefit of the cell line was the 





Figure 6.4, Cloning methods conducted for generation ECE-1 C428S pET22b.  Cloning was performed by Dr Mohd 
Akif. 
The protein expression protocol followed a 30°C growth and induction temperature. Protein 
formed during induction was found within insoluble inclusion bodies in the cell lysate. 
Inclusion bodies were separated from the rest of the cell mass and SDS-PAGE analysis 
confirmed the presence of an ~80 kDa protein corresponding to ECE-1 (Figure 6.5). SDS-
PAGE analysis also revealed the presence of several other molecular weight bands in the 
insoluble sample, most notably at ~30 and ~45 kDa. From this analysis, it was possible to 
confirm that ECE-1 expression in RGB cells could yield large quantities of protein, however 





Figure 6.5, ECE-1 expression in RGB cells. Pre- and post- induction cell lysate and the insoluble fraction of the post-
induction cell lysate was analysed using SDS-PAGE gel electrophoresis.  The band corresponding to ECE-1 is marked 
with an arrow.     
Information regarding protein refolding was not included in the protocol described in 
Schulz et al. (2009). Instead, an in-house refolding screen was performed to determine a 
condition in which ECE-1 from inclusion bodies could form soluble and correctly folded 
protein. 16 conditions were screened, and protein samples incubated in those conditions 
were analysed by SDS-PAGE (Figure 6.6). Six refolding conditions contained protein that was 
soluble after a 24-hour incubation. Other refolding conditions contained large amounts of 
precipitated protein. Protein samples from these six conditions were then assessed for their 
peptide cleavage using the assay described in Chapter 3 and 5. 
 
Figure 6.6, ECE-1 after incubated in refolding conditions. ECE-1 expressed in inclusion bodies was solubilised before 






to assess which conditions resulted in soluble ECE-1 protein. The bands corresponding to ECE-1 is marked with an 
arrow.     
Full kinetic characterisation for each ECE-1 refolded samples was not performed. Instead, a 
single substrate concentration used for each protein sample. While full characterisation 
would have been preferential, it was not required to provide insights into the efficiency of 
protein refolding. It has been reported that ECE-1 should possess a 10-fold greater efficiency 
for substrate Mca-RPPGFSAFK-(Dnp) compared to NEP (Johnson and Ahn, 2000).  Therefore, 
the assay was used to provide a rudimental estimate as to whether refolding had been 
successful in refolding ECE-1. It is also important to note the assays were conducted using 
varied protein concentrations. The rationale behind this was to allow accurate measurement 
of initial rate. In the case of the refolded ECE-1 samples, far higher protein concentrations 
were required compared to control NEP samples to provide detectable fluorescence.  
Two of the six conditions assayed displayed some level of peptide cleavage, however the 
recorded initial rate was substantially lower than that observed for NEP despite the far 
greater protein concentrations (Figure 6.7). The greatest initial rate value of the refolded 
samples was detected in ECE-1 incubated in refolding condition 13. The refolding protocol 
for this condition was repeated on a larger scale and refolded protein was used to determine 
the suitability of the sample for protein purification. Refolded protein was purified using 
anion exchange in accordance with the protocol described in (Schulz et al., 2009). A gradient 
of NaCl containing buffer was used to elute the protein in a stepwise manner and several 





Figure 6.7,  Peptide cleavage assay for ECE-1 after refolding. (a) Peptide cleavage was assessed for 5 µM ECE-1 
refolded in conditions 8 and 13 at a single substrate concentration of 10 µM. NEP was used as a positive control at 
4 nM. Substrate cleavage by NEP was repeated three times with the mean and ±SD error bars shown above. For 
ECE-1 samples, substrate cleavage was repeated twice with both repeats shown above.  (b) Initial rates calculated 
from the peptide cleavage assays.  For NEP, the mean and ±SD error bars are shown from the initial rates calculate 
from three repeats. For ECE-1, the initial rate is shown as the mean of two repeats.  
Eluted protein fractions corresponding to peaks were analysed using SDS-PAGE (Figure 6.9) 
to reveal all eluted peaks contained a band corresponding to ECE-1 (~80 kDa). The most 
likely explanation for this was that protein in the refolding buffer was present in a range of 
partially folded protein molecules. These differently folded species had different surface 
exposed regions and therefore bound with varied affinity to the anion exchange column. 
Refolding was repeated and attempted for longer time periods however similar results were 
observed.  
The generation of heterogenous species was highly detrimental to protein yield and was 
inappropriate for protein crystallisation. It may have been possible, through screening more 
conditions and incubation times, to improve the suitability of refolded protein for structural 
characterisation. However, initial results for protein refolding did not indicate that it was an 






Figure 6.8, Anion exchange purification of refolded ECE-1. 500 mL of protein refolded in refolding condition 13 was 
loaded onto an anion exchange column (GE healthcare). Once loaded the column was used with E. coli loading 
buffer 1 until the UV trace returned to baseline. Protein elution was achieved using 10% step increases in E. coli 
elution buffer 1. A total of eight peaks were observed after step increases in elution buffer. Fractions of these peaks 
were analysed with SDS-PAGE. 
 
Figure 6.9, ECE-1 anion exchange protein containing fractions. Sample were taken from eight peak containing 
fractions from the anion exchange purification and analysed with SDS-PAGE electrophoresis. All samples contained 
a protein band at ~80 kDa corresponding to ECE-1 which is marked with an arrow.   
For soluble ECE-1 expression three expression systems were selected and tested in parallel. 
The first system, P. pastoris, was an obvious choice based on the previous success seen in 
NEP expression. The second system, human embryonic kidney 293T cells, was selected for 
its mammalian post-translational machinery. Finally, in addition to the two new expression 
systems, the RGB expression system was revisited to determine if it was possible to express 





6.4.2 Soluble ECE-1 expression in E. coli  
Expression of ECE-1 in RGB E. coli cells was revisited to determine if soluble protein could 
be formed. The protocol described in Schulz et al. (2009) used a 30°C growth and induction 
temperature to generate ECE-1 that formed inclusion bodies. At high temperatures such as 
this has been reported to greatly increase the likelihood of inclusion body formation due to 
the increased rate of protein production in conjunction with the limited capacity of protein 
folding pathways (Singh et al., 2010). To determine if it was possible to produce soluble 
protein in RGB cells, several expression conditions with varied induction times and 
temperatures were assessed. Prior to this expression screening the initial DNA construct was 
altered such that the ECE-1 gene contained a 5’ 6x histidine tag. This tag allowed western 
blot analysis using poly histidine antibodies and had the added benefit of improving 
purification efficiency. A whole plasmid PCR reaction was used to generate the final 6x 
histidine tag containing construct (Figure 6.10). This final vector was analysed with an 
agarose gel (Figure 6.11), sequenced and transformed into RGB cells for expression. 
 
Figure 6.10, Cloning plan to modify the pET22b ECE-1 C428S construct by adding a 5’ 6x histidine tag. The tag 





Figure 6.11, Generation of ECE-1 pET22b C428S with a 5’ 6x histidine tag. The PCR amplification product was 
analysed using agarose gel electrophoresis revealing a single band is present at ~7.5 kDa (marked with an arrow). 
The band for the template DNA is has been included as a size reference.  
Six expression protocols were tested for soluble ECE-1 expression (Table 6.13). Samples of 
the soluble and insoluble supernatant and cell lysate fractions were collected before and 
after induction for each expression condition. These samples were then analysed with SDS-
PAGE and western blot (Figure 6.12).  
Analysis of induction temperatures revealed that a large amount of protein formed inclusion 
bodies when induction was performed at 37°C or 20°C for 20 hours (Figure 6.12b). In these 
conditions a large band at ~80 kDa corresponded to the extracellular domain of ECE-1, 
however, several other lower molecule weight bands were also present on the western blots. 
These additional bands likely correspond to degradation products of ECE-1 which occurred 
to a greater extent with increased temperature and induction length.  
A single induction condition - ‘3 hours at 16°C’ - contained a band corresponding to ECE-1 
in the soluble cell lysate sample (Figure 6.12b). This condition emerged as the most 
promising of all conditions for generating soluble ECE-1 protein. A second protein band at 
~45 kDa was also present in this sample and likely corresponded to degradation product. 
Based on the results observed in the trial expressions the ‘3 hours at 16 °C’ condition was 
chosen for large-scale protein production. The soluble cell lysate from a large-scale 
expression was loaded onto a histidine trap affinity column for purification (Figure 6.13). 




were then analysed using SDS-PAGE. From this analysis it was clear that while ECE-1 protein 
was present in the loaded sample (Figure 6.14b), it could not be identified in the column 
eluate. Despite repeated expression and purification, the same outcome was observed. As 
only low level ECE-1 was present in the loaded sample it is likely that the sample became 
too dilute and could not be detected in the eluate.   
 




2 Cell lysate soluble 
3 Cell lysate Insoluble 
4 
Post-induction 
3hrs at 4°C 
S/N 
5 Cell lysate soluble 
6 Cell lysate Insoluble 
7 
Post-induction 
20hrs at 4°C 
S/N 
8 Cell lysate soluble 
9 Cell lysate Insoluble 
10 
Post-induction 
3hrs at 16°C 
S/N 
11 Cell lysate soluble 
12 Cell lysate Insoluble 
13 
Post-induction 
20hrs at 16°C 
S/N 
14 Cell lysate soluble 
15 Cell lysate Insoluble 
16 
Post-induction 
3hrs at 37°C 
S/N 
17 Cell lysate soluble 
18 Cell lysate Insoluble 
19 
Post-induction 
20hrs at 37°C 
S/N 
20 Cell lysate soluble 
21 Cell lysate Insoluble 
Table 6.13, Protein expression trials for the production soluble ECE-1 in E. coli. Conditions varied in temperature 
and induction time and samples were taken of the supernatant, and soluble and insoluble cell lysate fractions. 






Figure 6.12, Soluble ECE-1 expression trials in E. coli RGB cells. (a) SDS-PAGE analysis of ECE-1 supernatant and 
soluble and insoluble cell lysate samples. (b) western blot analysis of ECE-1 supernatant and soluble and insoluble 
cell lysate samples. Sample identities are shown in Table 6.13 and bands corresponding the ECE-1 are marked with 




Figure 6.13, Histidine affinity trap purification of soluble ECE-1. ECE-1 was expressed in RGB cells using a 3-hour 






healthcare). Protein elution was achieved using a gradient of elution buffer over 40 mL. Over the course of the 
gradient elution there was an absence of clear peaks in the UV trace. Four samples were taken from fractions with 
slightly elevated UV absorbances. These samples were then analysed with SDS-PAGE and western blot.    
 
Figure 6.14, Soluble ECE-1 expression and purification in E. coli RGB cells. (a) SDS-PAGE and (b) western blot 
analysis of soluble and insoluble cell ECE-1 cell lysate post-induction and histidine affinity trap fractions from 
Figure 6.13. Bands corresponding to ECE-1 are marked with an arrow.  
While soluble protein was present from western blot analysis, the quantity of protein was 
too low for purification and assessment of peptide cleavage. It was also unlikely that 
optimisation or scaling up of the protocol would have allowed the production of quantities 
required for structural work. These results, in combination with the inclusion body protein 
expression described in Schulz et al. (2009), strongly suggests a bacterial expression system 
is inappropriate for soluble ECE-1 expression.  
6.4.3 ECE-1 expression in P. pastoris  
For ECE-1 expression in P. pastoris it was necessary to remove the ECE-1 C428S gene from 
pET22b and ligate it into the yeast specific vector pPICzαA vector (Figure 6.15). Two PCR 
reactions were used to amplify ECE-1 C428S from the pET22b adding a 5’ 6x histidine tag, 
5’ EcoRI site and a 3’ NotI site. The PCR product was then ligated into the vector pPICzαA 





genome for secreted protein expression. After integration of pPICzαA ECE-1 C428S into P. 
pastoris, clones where screened for protein expression.  
 
Figure 6.15, Cloning plan to generate ECE-1 C428S pPICzαA. The ECE-1 C428S gene was extracted from pET22b 





Figure 6.16, Production of ECE-1 C428S pPICzαA. (a) DNA product from a PCR amplifying ECE-1 C428S from 
pET22b and adding a 5’ 6x histidine tag. (b) DNA product from a second PCR adding a 5’EcoRI site for ligation 
into pPICzαA. (c) pPICzαA vector.  
19 P. pastoris clones were selected for small-scale protein expression experiments. As 
protein was expressed with a secretion tag only post-induction supernatant samples were 
analysed for ECE-1 expression. Samples were analysed using western blot to determine if 
ECE-1 was expressed and which clones had the highest expression levels (Figure 6.17). 
Translated ECE-1 protein has a mass of ~80 kDa. However due to previous observations of 
mass increase in NEP (Chapter 3), it was expected that ECE-1 could exhibit similar behaviour 
due to glycosylation. Several clones contained a visible protein band on the western blot at 
~100 kDa corresponding to ECE-1. Two clones, 7 and 11, had far higher levels of protein 





Figure 6.17, small-scale ECE-1 C428S P. pastoris expression cultures. 19 post-induction supernatant samples from 
P. pastoris clones were screened using western blot analysis to determine which clones had the highest level of 
ECE-1 C428S protein expression. Bands corresponding to ECE-1 expression are marked with arrows.    
The protocol for large-scale ECE-1 expression in P. pastoris was initially performed in an 
identical way to that of NEP expression. However, western blot analysis of post-induction 
samples revealed a lower induction time of 24 hours was required as longer induction times 
resulted in substantial protein degradation (Figure 6.18).  
 
Figure 6.18, Large-scale ECE-1 C428S expression in P. pastoris clone. Supernatant samples were taken pre-
induction and post-induction at 24 and 96 hours and analysed using a western blot. A band corresponding to ECE-
1 was present in the 24 hours post-induction sample and is marked with an arrow.  
The protocol for large-scale ECE-1 expression was then repeated but with a reduced 24-
hour induction period. Post-induction supernatant harvested and loaded onto a histidine 







elution step. A single elution peak was observed (Figure 6.19) and peak containing fractions 
were pooled and concentrated before loading onto a superdex size exclusion column. A 
protein peak eluted from the size exclusion column at 75-85ml. The same peak was 
observed during NEP purification, however the peak corresponding to ECE-1 was 
substantially lower in absorbance (Figure 6.20). Samples were taken throughout the 




Figure 6.19, P. pastoris expressed ECE-1 C428S histidine affinity trap purification. 500 mL of protein containing 
supernatant from a P. pastoris culture was loaded onto a histidine affinity trap column (GE healthcare). Once 
loaded the column was washed with binding buffer followed by a wash step of 2% elution buffer. Protein elution 
was achieved at 50% elution buffer. A single peak was observed and peak containing fractions (indicated 
between dash lines) were pooled.    
 
Figure 6.20, P. pastoris expressed ECE-1 C428S size exclusion purification. The pooled fractions eluted from the 




the induction media and to buffer exchange the protein into binding buffer. The peak containing fractions (indicated 




Figure 6.21, P. pastoris ECE-1 C428S expression and purification. (a) SDS-PAGE and (b) western blot analysis of 
supernatant pre- and post-induction samples taken from the P. pastoris expression culture just before induction 
and 24-hours post induction. Samples of the histidine affinity column flow through (F/T) are also shown. The eluted 
and pooled fractions after purification steps reveal the high purity of the final product (mark with arrows). Smearing 
of the final sample can be attributed to protein glycosylation.   
Protein expression in the supernatant of P. pastoris was clearly observed from the western 
blot. While a small level of protein did not bind to the histidine column and was observed 
in the flow through, the majority of protein appear to bind to the column. The histidine trap 
did provide purification of ECE-1 and it was the only major protein band present in the 
eluted sample (Figure 6.21). The protein band corresponding the ECE-1 displayed a high 
level of smearing both in the SDS-PAGE and western blots. The most likely cause of which 
was glycosylation of the protein. After the second purification step the sample was observed 
to contain the same ~100 kDa protein band but with reduced smearing. This is likely a 
consequence of removing some high glycosylation species.  The absorbance of the final 





This purified sample was then used to for a cleavage assay. Full kinetic characterisation for 
the ECE-1 sample was not performed. While full characterisation would have been 
preferential, assessment of a single concentration was used to provide insights into whether 
P. pastoris was an appropriate expression system. Assays were conducted at a single 
substrate concentration and the initial rate for that concentration is shown in Figure 6.22.  
Substrate cleavage was confirmed for ECE-1 expressed in P. pastoris. The initial rate for the 
single ECE-1 concentration was observed to be similar to that of the NEP control. However, 
it should be noted that the protein sample of ECE-1 and NEP were assayed at 83.2 nM and 
6.25 nM respectively. While initial rate was lower than that observed for NEP, taking into 
account the protein concentration, the rate was substantially higher than that previously 
determined for ECE-1 expressed in E. coli RGB cells and refolded.  
 
 
Figure 6.22, Peptide cleavage assay for ECE-1 expressed in P. pastoris. (a) Peptide cleavage was assessed at a single 
substrate concentration (6.25 nM for NEP and 83.2 nM for ECE-1). Substrate Mca-RPPGFSAFK-(Dnp) was used at 
10 µM final concentration. Substrate cleavage by NEP and ECE-1 was repeated three times with the mean and ±SD 
error bars shown above. (b) Initial rates of cleavage for protein samples at the single concentration. The mean and 





6.4.4 ECE-1 expression in human embryonic kidney cells  
For ECE-1 expression in HEK 293T cells it was necessary to remove the ECE-1 C428S gene 
from pPICzαA and ligate it into the mammalian vector pOPINTTGneo vector (Figure 6.23). 
A PCR reaction was used to amplify ECE-1 C428S from the pPICzαA adding a 5’ KpnI site 
and a 3’ PmeI site. The PCR product was then ligated into the vector pOPINTTGneo (Figure 
6.24). This specific vector allowed transient and secreted protein expression in mammalian 
cells. 
 
Figure 6.23, Cloning plan to generate ECE-1 C428S pOPINTTGneo. The ECE-1 C428S gene was extracted from 





Figure 6.24, Production of ECE-1 C428S pOPINTTGneo. Agarose gel electrophoresis analysis of the (a) DNA 
product from a PCR amplifying ECE-1 C428S from pPICzαA and (b) pOPINTTGneo vector double digested to 
remove an unrelated placeholder gene.  
The final pOPINTTGneo ECE-1 C428S construct was transformed into HEK 293T cells and a 
small-scale expression trial was used to determine the best transformation protocol for 
protein expression through variation in DNA and polyethylenimine (PEI) concentrations 
(Table 6.14). 24-hours after transformation the supernatant from small-scale expression 
trials were analysed with SDS-PAGE and western blot (Figure 6.25). As previously stated, the 
translated ECE-1 protein is ~80 kDa but with glycosylation this figure is expected to be 
larger. ECE-1 expressed in P. pastoris was observed to be ~100 kDa due to glycosylation 
(Figure 6.21). In HEK 293T cells the level of glycosylation was expected to be of a similar 
level (Croset et al., 2012). All supernatant samples displayed a band at ~130 kDa on the 
western blot corresponding to ECE-1. Of transduction conditions the greatest ECE-1 band 
intensity was observed in conditions 1 and 3.  
Condition DNA PEI DNA:PEI 
1 4µg 4µg 1:1 
2 2µg 4µg 1:2 
3 4µg 8µg 1:2 
4 2µg 6µg 1:3 
5 4µg 12µg 1:3 
Table 6.14, Transfection ratios for protein expression trials of ECE-1 C428S in HEK 293T cells. DNA and PEI 






Figure 6.25, Small-scale trials of ECE-1 C428S expression in HEK 293T cells. (a) SDS-PAGE and (b) western blot 
analysis of cell supernatant 24-hours after induction. An untransformed control is shown with the five different 
transformation conditions listed in Table 6.14. Bands corresponding to ECE-1 were present in the western blot 
and are marked with an arrow. 
Large-scale expressions were performed using the scaled up the transformation condition 
1 in a 2 m2 roller bottle. Transformed cells were incubated for four days, after which the 
protein containing supernatant was extracted and protein purification was conducted. 
Protein purification was performed first with a histidine strap affinity column. Supernatant 
was filtered and loaded onto the histidine trap column and eluted using a gradient of 
imidazole containing buffer (Figure 6.26).  
 
Figure 6.26, HEK 293T large-scale ECE-1 histidine affinity trap purification. 500 mL of protein containing cell 
supernatant from a HEK 293T culture was loaded onto a histidine affinity trap column (GE healthcare). Protein 





sharp peak was observed. Eight fractions were collected across the peak and were analysed with SDS-PAGE and 
western blot.  
A single peak was observed during elution and fractions from that peak were analysed by 
SDS-PAGE and western blot (Figure 6.27). It was clear that only fractions corresponding to 
the second half of the peak contained ECE-1 protein as indicated from the western blot. The 
presence of other protein bands in addition to the band corresponding to ECE-1 indicated 
that further purification was required.  
 
Figure 6.27, Protein containing fractions from a histidine affinity purification of ECE-1 C428S expression in HEK 
293T cells. (a) SDS-PAGE and (b) western blot analysis loaded supernatant, flow through (F/T) and eight fractions 
collected within the eluted peak. Fractions 3-7 contained a band at ~130 kDa corresponding to ECE-1 which is 
mark with an arrow. 
Protein containing fractions 3-7 were pooled and loaded onto a superdex size exclusion 
column for further purification. This had the additional benefit of removing any imidazole 
in the protein sample. Four peaks were present in the size exclusion elution profile (Figure 
6.28). Fractions from these peaks were pooled and analysed using SDS-PAGE and western 
blot to reveal that peak three contained ECE-1 (Figure 6.29). Given the overlap between the 
elution of peak 3 and peaks 2 and 4 the final pooled peak 3 protein sample contained several 
weaker bands in addition to ECE-1. This made estimation of the quantity of purified protein 







Figure 6.28, Size exclusion purification of ECE-1 C428S expressed in HEK 293T cells. The pooled fractions (3-7) 
eluted from the histidine affinity trap column were loaded onto a Superdex 16/60 size exclusion column to remove 
impurities from the induction media and to buffer exchange the protein into binding buffer. Four peaks were 
observed and peak containing fractions (indicated between dash lines) were pooled and analysed with SDS-PAGE 
and western blot. 
 
Figure 6.29, Protein containing fractions from a size exclusion purification of ECE-1 C428S expression in HEK 293T 
cells. (a) SDS-PAGE and (b) western blot analysis loaded protein sample for the histidine affinity purification and 
pooled fractions from the four eluted peaks. Fraction 3 contained a band at ~130 kDa corresponding to ECE-1 
which is marked with arrows. 
The pooled protein from peak 3 was then used to for a substrate cleavage assay. Assays 
were conducted at a single substrate concentration and the initial rate for that concentration 
is shown in Figure 6.30. Substrate cleavage was confirmed for ECE-1 expressed in HEK 293T 
cells. The initial rate for the single ECE-1 concentration was observed to be similar to that of 
the NEP control. However, the initial rate determined for the single ECE-1 concentration was 
far lower than that of the NEP. It should also be noted that the protein sample of ECE-1 and 







Figure 6.30, Peptide cleavage assay for ECE-1 expressed in  HEK 293T cells. (a) Peptide cleavage was assessed at a 
single substrate concentration (6.25 nM for NEP and 833 nM for ECE-1). Substrate Mca-RPPGFSAFK-(Dnp) was 
used at 10 µM final concentration. Substrate cleavage by NEP and ECE-1 was repeated three times with the mean 
and ±SD error bars shown above. (b) Initial rates of cleavage for protein samples at the single concentration. The 
mean and ±SD error bars are shown for the initial rates calculate from three repeats. 
 
6.5 Conclusions 
The initial aim for the work on ECE-1 was to establish an expression system in which active 
protein could be expressed and used for structural characterisation. Schulz et al. (2009) 
demonstrated that ECE-1 could be generated in a bacterial expression and refolded for use 
in structural studies. This method was investigated at the start of this chapter with the aim 
of replicating ECE-1 production and providing evidence that the protocol was suitable for 
production of active protein despite the absence of glycosylation.  
The method of ECE-1 expression described by Schulz et al. (2009) did not include 
information regarding the refolding process, instead a refolding screen was used to 
determine a suitable condition. While some refolding conditions produced soluble protein 
that was able to cleavage peptide substrate, the observed cleavage was extremely low. 
Additionally, the purification of refolded samples indicated that refolding had generated a 




Indeed, attempts were made to express soluble ECE-1 protein in E. coli RGB cells, but it was 
clear only small quantities of protein were produced that could not be purified.  
Additional expression systems were attempted with the aim of generating soluble ECE-1. A 
clear place to start, based on the success of NEP, was the yeast expression system P. pastoris. 
This expression system offered more sophisticated post-translational processing including 
protein glycosylation. 19 transformed clones of P. pastoris were screen for ECE-1 expression 
and the clone with the highest level of ECE-1 expression was selected for large-scale protein 
production. Expressed ECE-1 was purified by histidine trap affinity chromatography with a 
further size exclusion chromatography step to yield pure protein. This pure protein was then 
analysed using the fluorescent assay to measure initial rate data.  
While initial rate was only determined for a single ECE-1 concentration it was used to 
provide a measure of the efficiency of the expression system in producing active protein. It 
also provided a means of comparing the different protein expression systems tested. The 
observed initial rate for ECE-1 expressed P. pastoris was lower than that of the NEP control 
but was far higher than that determined for the ECE-1 express in E. coli and then refolded.  
In addition to P. pastoris, a mammalian expression system in the form of human embryonic 
kidney 293T cells was performed for ECE-1 expression. Screening transformation protocols 
for HEK 293T cells allowed selection of an optimal protocol for protein expression. ECE-1 
expressed in HEK 293T cells could be purified by histidine trap affinity chromatography with 
a further size exclusion chromatography step. The final product analysed by SDS-PAGE and 
western blot contained a band for ECE-1 but also several other bands corresponding to 
protein impurities. Despite this, the final protein sample was analysed using the fluorescent 
assay to measure initial cleavage rate data. Again, a single protein concentration of the ECE-
1 sample was assayed, and peptide cleavage was detected. The initial rate data was lower 
than that of the NEP control in additional to ECE-1 produced in P. pastoris. Initial rate values 
for expressed ECE-1 are summarised in Table 6.15. 
 








ECE-1 P. pastoris 83.20  133.63 1.58 
ECE-1 HEK 293T 833.00 45.91  7.00 
NEP control 6.25  155.95 5.56 
Table 6.15, ECE-1 peptide cleavage assay initial rate data. Table summarises the initial rate data from Figures 
6.22 and 6.30. 
While characterisation of peptide cleavage for ECE-1 was simplistic, and a direct comparison 
cannot be made due to the variation in protein concentration, the calculated initial rate data 
does suggest P. pastoris may be a better system for production of active ECE-1 (Table 6.15). 
It should however be noted that the presence of impurities in the purified ECE-1 sample 
from HEK293T cells may affect the initial rate data. 
The expression trials discussed above have revealed that soluble ECE-1 could be expressed 
in both P. pastoris and HEK 293T expression systems and that protein produced possessed 
protease activity as demonstrated in the peptide cleavage assay. While protein could be 
expressed, there was a major limitation in that both expression systems generated a low 
level of protein. Yields of ~0.2 mg/L for both expression systems were of an insufficient 
quantity to begin structural characterisation.  
Time limitations in the project prevented further work on ECE-1, however, from the work 
conducted P. pastoris emerged as the most promising expression system for several reasons. 
First, the protein expressed in P. pastoris could be purified with relative ease to yield a highly 
pure final sample. Second, the highest initial rate peptide cleavage was recorded for ECE-1 
expressed in this system. Third, while expression levels of ~0.2 mg/L were insufficient to 
begin structural characterisation, with greater time it would be possible to revisit the P. 
pastoris transformation and screen more clones with the aim of identifying a clone with 
greater expression levels.  
While time restrictions prevented structural characterisation of ECE-1, information regarding 
substrate binding in ECE-1 can be gained from the previously reported ECE-1 
phosphoramidon-bound structure. Below a small section is included to comment on the 
current structural understanding of ECE-1 specificity. This brief section provides the 




ECE-1 extracellular domain in conjunction with NEP structures discussed in Chapters 3 and 
5.  
6.5.1 ECE-1 structural analysis  
The extracellular domains of ECE-1 and NEP are highly similar with an RMSD of 1.4 Å (Figure 
6.31). Indeed, one of the most highly conserved regions of the protein is the active site 
(residues that form the S1-S2’ sites). A comparison between the active site of 
phosphoramidon-bound ECE-1 (3DWB) and NEP (1DMT) reveals the almost identical 
position of both the inhibitor and the surrounding residues (Figure 6.32). Because of this 
almost identical binding interaction, it should be unsurprising that ECE-1 and NEP have 
similar catalytic efficiencies for many substrates (Johnson and Ahn, 2000) and share a 
preference for cleavage at the amino side of a hydrophobic residue located in the S1’ site 
(Rawlings et al., 2018). 
 
Figure 6.31, Ribbon representation of ECE-1 and NEP superposition. The extracellular domain of ECE-1 (orange) 
and NEP (blue) display a high degree of structural similarity with an RMSD of 1.424 (calculated using the Align 
function in Pymol).  
Given the high level of conservation in active site residues and the similarity in 
phosphoramidon binding (Figure 6.32) it is likely that many of the substrate binding 




hold true for ECE-1. That is, the major drivers of substrate backbone interactions in the S1-
S2’ sites for ECE-1 are likely contributed by residues Asp566, Ala567 and Arg738.  
The interactions within the active site for ECE-1 and NEP are almost identical and account 
for the similarities seem in preferred substrate cleavage position. It seems unlikely, however, 
given this similarity, that it is the active site residues alone that account for the distinct 
specificities between ECE-1 and NEP when considering substrate identity. This discrepancy 
is most drastic when considering small (<7 residue) peptides for which ECE-1, unlike NEP, 
has very low affinity for  (Johnson et al., 1999).  
 
Figure 6.32, Active site binding of inhibitor phosphoramidon in NEP and ECE-1. Active site residues in (a) NEP 
and (b) ECE-1 are shown with bound phosphoramidon (shown in cyan and pink respectively) with zinc ion shown 
in grey.  
Substrate specificity can be considered to be the culmination of steric restraints and 
electrostatic/hydrophobic interactions (Náray‐Szabó, 1993). Given the high degree of 
similarity in cavity size and active site spatial organisation for ECE-1 and NEP, it is unlikely 
that steric restraints can account for the distinct specificity between the two proteins. It is 
therefore likely that electrostatic or hydrophobic interactions plays a critical role.  
Analysis of the surface electrostatic potential of ECE-1 and NEP internal cavities has revealed 
their distinct nature (Figure 6.33). Such electrostatic organisation has been suggested to be 
a major contributor to long-range positioning of substrates in other proteins (Zhang et al., 




attraction of substrates due to the differences in the observed electrostatic potentials. It is 
also likely that the varied identity of residues lining the cavity in ECE-1 and NEP, which 
contribute to the observed different electrostatic potentials, interact with substrates upon 
binding. It may be these interactions, proximal to the active site, which account for the 
distinct substrate specificity.  
The concept of proximal interactions has been discussed in Chapter 5 with the possible 
identification of an exosite in NEP. Proximal interactions in ECE-1 would offer an explanation 
for ECE-1’s low cleavage efficiency of small peptides. Small peptides may be of insufficient 
length to interact with key residues in the ECE-1 cavity. It is clear that further structural 
characterisation of ECE-1 is required, however, the points discussed above suggests residues 
proximal to the active site in ECE-1 and NEP have importance in protein-peptide binding 






Figure 6.33, Ribbon representation of ECE-1 and NEP with electrostatic potentials of internal cavity surfaces. Both 
(a) ECE-1 and (b) NEP contain large central cavities with distinct electrostatic potentials (calculated with APBS). 









7.1 Summary  
Alzheimer’s disease presents an immense hurdle for science in the 21st century. Whilst the 
last two decades have seen substantial progress made in the field of Alzheimer’s research, 
it has further revealed the complex nature of the disease. It is clear that a greater 
understanding of the underlying processes of Alzheimer’s disease are required before 
therapies can be developed that significantly reduce or halt disease progression. 
The current understanding of Alzheimer’s disease firmly points towards the peptide 
amyloid-β as a major contributor to disease progression. Because of this, the regulation of 
amyloid-β is a critical area of Alzheimer’s disease research. Amyloid-degrading enzymes 
(ADEs) are known to be key drivers of amyloid-β degradation and research into these 
enzymes builds upon the knowledge of the underlying mechanisms of Alzheimer’s disease.  
To date, over 30 proteins have been identified as possible ADEs. These proteins exhibit 
different potencies, localisations and many display additional roles. The proteins that were 
studied and described in this thesis, neprilysin (NEP) and endothelin converting enzyme I 
(ECE-1), are highly potent ADEs but also have an additional function in blood pressure 
regulation. The involvement of NEP and ECE-1 in amyloid-β degradation and blood pressure 
regulation makes them high-value therapeutic targets for Alzheimer’s disease  and 
cardiovascular disease.  
The aim of this Ph.D. research was to provide structural and functional characterisation of 
NEP and ECE-1. Through this characterisation the mechanism of NEP and ECE-1 in peptide 
degradation could be further revealed and their potential as therapeutic targets could be 
realised. The discussion below is organised into sections based on the protein studied. 
7.1.1 Neprilysin 
While NEP is the best-known ADE (Iwata et al. 2001), the majority of structural and functional 
characterisation has been focused on its role in blood pressure regulation. Inhibition of NEP 
is desirable in patients with high-blood pressure, and a number of crystal structures have 
been reported for NEP with inhibitors bound. These structures have served as valuable 
starting points for functional characterisation, revealing the overall protein fold and the 




Despite the number of inhibitor-bound structures reported, at the start of this project a 
substrate-free form had yet to be determined. With any protein, determination of the native 
or substrate-free structure provides an insight into its unbound state. This unbound state is 
critical to identify conformational movements that may result from ligand binding. These 
conformational movements can be large domain movements or can be conformational 
changes in specific amino acid residues. It is often these movements that are key to the 
molecular mechanism underlying a protein’s function. 
Chapter 3 details the processes used to determine the first substrate-free NEP structure 
(Figure 7.1). This structure revealed the protein conformation and position of active site 
residues in the absence of peptide substrate. Previous inhibitor-bound structures of NEP 
have determined that the protein adopts a closed conformation where the central cavity is 
occluded and inaccessible to substrates. The substrate-free NEP structure was also revealed 
to adopt a similar closed conformation indicating that inhibitor binding was not required 
for the protein to adopt this closed form. Through comparisons to inhibitor-bound 
structures it was also possible to identify the highly similar positions occupied by active site 
residues. This observation suggests the active site is static in nature and does not display 
major conformational movements upon ligand binding.  
The conformation of substrate-free NEP raised question regarding how substrates access 
the active site and whether the observed closed conformation was an artefact of the crystal 
environment or a true picture of its natural state. To address this important question in NEP 
and to validate the closed structure observed in the crystal structure, small-angle X-ray 
scattering technique was used. Experimentally calculated scattering parameters Rg and Dmax 
were compared to predicted scattering parameters from the NEP crystal structure. These 
scattering parameters were highly similar and indicated that in solution NEP adopts a similar 
conformation to the one observed in the crystal structure. Indeed, attempts were made to 
elicit conformational flexibility of subdomains using varation in buffer conditions, however, 






Figure 7.1, Crystal structure of the extracellular domain of NEP in a substrate-free form (6GID). The protein contains 
a large central cavity where the active site is located based around a zinc ion (cyan). 
Further crystallographic research presented in Chapter 5 detailed the methods used to 
determine the first peptide-bound structure of NEP. In order to obtain such a structure, 
removal of catalytic activity was required to prevent NEP degrading peptides during the 
incubation period required for crystallisation.  
Catalytic inactivation for crystallisation had been successfully used in other zinc 
metalloproteases including insulin-degrading enzyme (Manolopoulou et al., 2007). Our 
results with NEP have revealed that mutation of the conserved glutamate in the active site 
motif HExxH removed detectable protease activity. Similar results have been reported for 
the model zinc metalloprotease thermolysin (Vazeux et al., 1996) for which detailed 
characterisation of the catalytic mechanism has been achieved. The conserved active site 
motif and similar response to glutamate mutation provides further evidence that NEP 
utilises a catalytic mechanism analogous to thermolysin.  
Using circular dichroism and X-ray crystallography it was possible to confirm that mutant 
NEP was near-identical in structure to wild-type NEP and was suitable model to study 
peptide-binding interactions. This protein was then used to determine the first peptide-
bound structure of NEP in complex with vasoactive peptide CNP. Structural analysis revealed 




Such residues have previously been shown to be critical to inhibitor binding in NEP. Indeed, 
comparison with other zinc metalloproteases has further illustrated the similar function and 
importance of these residues in peptide binding.   
Substantial steps towards comprehensive characterisation of NEP have been achieved from 
the work reported in this thesis. There are however a number of points that should be 
addressed and several avenues for further research. First, characterisation of peptide side 
chain binding. One of the major limitations of the NEP peptide-bound structure included in 
Chapter 5 was the inability to model side chain residues for the substrate. This was likely a 
result of active site residues binding to different regions of the peptide resulting in mixed 
side chain occupancy in the calculated electron density. To address this, it may be possible 
to use smaller substrates (3-4 amino acids) to reduce the likelihood of alternative binding 
conformations.  
Second is the investigation into substrate-protein binding interactions proximal to the active 
site. For this, structures with longer substrates bound would provide information regarding 
proximal interactions that may be present within the cavity of NEP. Limited success has been 
achieved so far with large substrate binding so it may be necessary to remove the zinc ion 
to remove any low-level activity that remains in the NEP E584D mutant. 
Finally, conformational fexibility in NEP is a clear area for future research. While further SAXS 
analysis may provide additional insights into subdomain motion, it may be necessary recruit 
higher resolution techniques, such as cryo-EM, to determine the exact nature of 
conformational movement in NEP. Such research may help provide comprehensive 
characterisation of NEP and indicate why the enzyme exhibits specificity exclusively for 
smaller substrates.  
7.1.2 ECE-1 
ECE-1 is another highly potent ADE (Leissring, 2016), but has received little structural and 
functional characterisation. To date, a single crystal structure of ECE-1 has been published 
in an inhibitor-bound form (Figure 7.2) (Schulz et al., 2009). The protein used to determine 
this structure was expressed in E. coli, required refolding, and included point mutation C428S 
to prevent dimerization. No kinetic characterisation had been conducted for this protein so 




the structure is validated by the high structural homology to NEP and serves as a good 
starting point for ECE-1 characterisation. 
Chapter 6 outlines the research conducted on ECE-1. Similar to NEP, characterisation of ECE-
1 first required the development of a method for protein expression and purification. Initial 
expression trials were performed using the protocol described in (Schulz et al., 2009). 
However, limited information regarding the method of protein refolding prevented the 
successful replication of this protocol and the production of correctly folded protein was 
not achieved. 
Additional fungal and mammalian expression systems were used to assess the optimal 
method for protein expression and purification. While soluble protein was generated in both 
expression systems, the ECE-1 yield was low. Despite this, the results included in Chapter 6 
suggest that the P. pastoris expression system was the most appropriate for ECE-1 
expression and, given more time, it may be possible to improve protein yield. Without the 
required quantity of protein required for crystallisation trials the work on ECE-1 did not 
progress into structural determination. Despite this, structural analysis was possible through 
comparison of the available ECE-1 structure with the NEP peptide-bound structure detailed 
in Chapter 5. 
Future research into ECE-1 could follow the same narrative of NEP. Determination of 
peptide-bound structures would provide information regarding how specificity is achieved. 
Likewise, research into the conformational flexibility in ECE-1 could be achieved through 
SAXS or cryo-EM analysis. Such methods, if used on dimeric ECE-1, would also provide 






Figure 7.2, Crystal structure of the extracellular domain of ECE-1 in an inhibitor-bound form (3DWB). The protein 
contains a large central cavity where the active site is located based around a zinc ion (cyan). 
 
7.2 Concluding remarks 
The field of Alzheimer’s disease research is one that encompasses a variety of scientific 
disciplines, principally neuroscience, biochemistry and pharmacology. The increased focus 
placed on Alzheimer’s disease, particularly over the last twenty years, has led to a vast 
collection of literature surrounding the field. To date, some 181,116 articles have been 
published (Dong et al., 2019), covering a broad range of topics including technological 
advances in disease diagnosis, identification of genetic risk factors and molecular 
biomarkers associated with disease initiation and progression, protein networks involved in 
possible molecular mechanisms, while also including interdisciplinary investigations such as 
the role of inflammation in disease progression. 
While this information has helped to identify individuals with higher risk of developing 
Alzheimer’s disease, and provide disease preventing lifestyle guidelines (Barnard et al., 
2014), current research has yet to yield therapeutic agents capable of halting or significantly 
reducing disease progression. A major limitation to this is the absence of a concrete 




Presently a large quantity of evidence, discussed throughout the introduction of this thesis, 
firmly points to the peptide amyloid-β as playing a critical role in disease initiation and 
progression. Indeed, the recent positive clinical trial results for amyloid-β antibody therapy 
– aducanumab – has reinforced the importance of amyloid-β in Alzheimer’s disease 
research.  
If therapies targeting amyloid-β can yield reductions in disease progression, it is clear that 
a significant focus should be placed on mechanisms governing amyloid-β regulation. Of 
these mechanisms ADE’s represent key means of amyloid-β regulation, and, while a strong 
foundation of knowledge has been accumulated full characterisation of these proteins has 
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